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Abstract 
This thesis describes the establishment and initial findings of the Children with Down 
Syndrome Study, a birth cohort of children with DS.  The Children with Down Syndrome 
Study was set up in order to characterise the haematology of neonates with Down syndrome 
and specifically to test the hypothesis that that this differed in this population.  The study was 
carried out with the support of the Down Syndrome Association and the Down Syndrome 
Medical Interest Group, and through consultation with clinicians and families.  Following a 
pilot study in the Yorkshire region it was established in over 60 hospitals across the north of 
England.   
The Children with Down Syndrome Study is the largest birth cohort of children with Down 
syndrome established to date, and this is the largest reported analysis of the haematology of 
neonates with Down syndrome.  The results confirm that neonates with Down syndrome have 
a distinct haematological profile.  Means and ranges for haematological parameters 
throughout the neonatal period are provided.  The effects of gestational age, birth weight, 
postnatal age and the venepuncture to processing interval on the neonatal full blood count 
were examined, and this is the first report of factors that influence the haematological 
parameters in neonates with Down syndrome.   
In order to analyse the blood cell morphology a new approach to morphology was developed 
and validated.  Morphological review of samples from neonates with Down syndrome 
demonstrated that blasts were common.  Comparison with automated findings showed that 
manual review of a film is indicated to look for evidence of transient myeloproliferative 
disorder. 
This is also the largest longitudinal study of haematological parameters of children with Down 
syndrome beyond the neonatal period.  The results showed that parameters changed 
between birth and 1 year, with most being stable thereafter.  However, it appears that 
children with Down syndrome continue to have a distinct morphological profile.   
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 Chapter 1 Introduction  
1.1 Purpose 
The first recognizable description of Down syndrome (DS) occurs in 1886 in a case report by 
John Langdon Down who recognised phenotypic similarities within a subset of 
institutionalised adults (Down, 1866).  Over the subsequent years features seen as part of the 
DS phenotype were increasingly well defined, although at the same time it became evident 
that there was very marked heterogeneity within DS.  More than eighty years after  the report 
by Langdon Down, LeJeune described the causal association between a third chromosome 
21 and the DS phenotype (LeJeune, Turpin and Gautier, 1959), which results from non-
disjunction in ~95%; translocation in ~4%; or chromosomal mosaicism in ~ 1% (Nicolaidis and 
Petersen, 1998).   
Importantly, although children with DS may have myriad health problems, medical 
understanding - and consequently management - of these is based on a surprisingly small 
evidence base.  It is well recognised that children with DS are at increased risk of developing 
serious haematological disease such as acute leukaemia (Krivit and Good, 1957; Hasle, 
Clemmensen and Mikkelsen, 2000; Yang, Rasmussen and Friedman, 2002; Hill et al, 2003; 
Agarwal et al, 2005), and children with DS are therefore over-represented in paediatric 
haematology wards and clinics.  However, more subtle abnormalities of the full blood count 
are also fairly frequent, and yet there is little published data on these, making it difficult to 
respond to requests for advice on management with any degree of confidence.   
The central hypothesis underpinning this work is the supposition that the haematological 
profile of neonates with DS is distinct and that if studied systematically in as near a population 
based cohort as possible then it will be possible to characterise this profile.  Further, it may 
then be possible to determine variables affecting the haematology of this specific population.   
As well as the numerical parameters obtained from automated analysis, information about 
blood cells can be provided by morphological analysis of a blood film.  If the numerical 
parameters are distinct in DS then it is likely that the morphological appearances in DS may 
also be distinct.  Moreover, morphological analysis may yield additional information which is 
important clinically. 
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1.2 Aims  
The primary aims of this work are: 
1. To describe the neonatal haematological ranges for children with DS with reference to 
the standard haematological parameters typically measured as part of full blood count 
analysis; 
2. To examine factors that may be associated with variations in the neonatal 
haematological profile of children with DS; 
3. To describe the features of neonatal blood cell morphology in children with DS; 
4. To describe the haematological parameters in children with DS beyond the neonatal 
stage. 
The secondary aims, which are related to but not directly part of this thesis, are:  
1. To set up a study of children with DS which is capable of collecting information and 
biological samples from birth onwards; 
2. To set the study up so that information about all aspects of health is collected and so that 
other studies may be nested within it; 
3. To encourage collaborations with experts in different areas in order to maximise the 
potential of the study to investigate other areas of importance relevant to DS. 
The Children with Down Syndrome Study (CDSS; www.cdss.org.uk) was set up specifically to 
address these aims.  The CDSS is a collaborative project involving clinicians, scientists, 
families and other interested groups following a cohort of children with Down syndrome from 
birth onwards in order to develop a resource from which a robust evidence base might be 
developed to enable clinicians, and indeed the whole multi-disciplinary team, to provide the 
best care possible for children with DS – in the field of haematology and across all aspects of 
health. 
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 Chapter 2 Critical assessment of the literature 
2.1 Introduction 
This chapter reviews the medical literature on neonatal haematology, considering first DS 
neonates, and then the wider population of non-DS neonates.  Literature searches were 
conducted using PubMed search engines (www.ncbi.nlm.nih.gov/pubmed), citation searches, 
cross-referencing of papers and standard clinical text books.  
To find relevant literature on the haematology of DS neonates the following terms were used 
in a PubMed search engine:  
 haematology AND Down syndrome;  
 acute leukaemia AND Down syndrome;  
 acute myeloid leukaemia AND Down syndrome;  
 acute lymphoblastic leukaemia AND Down Syndrome;  
 transient myeloproliferative disorder AND Down syndrome; 
 blood film AND Down syndrome; 
 blood cell morphology AND Down syndrome.   
In addition from the start of the research period weekly reports from PubMed of any paper 
with Down syndrome in the abstract, title or as a keyword were reviewed.   
To find relevant literature on the haematology of the wider neonatal population the following 
terms were used in a PubMed search engine:  
 reference range AND white cell count;  
 reference range AND platelet;  
 reference range AND red cell count;  
 erythrocyte indices; 
 blood cell morphology AND microscopy; 
 platelet morphology AND microscopy. 
Again, during the research period weekly reports from PubMed of any paper with any of the 
above terms in the abstract, title or as a keyword were reviewed.   
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2.2 The haematology of neonates with Down syndrome 
Children with DS are susceptible to a spectrum of haematological abnormalities ranging from 
asymptomatic changes of the full blood count to an increased incidence of acute leukaemia – 
changes which may even be apparent in utero.   
2.2.1 Benign haematological changes  
The published reports of haematological indices in neonates with DS are shown in Table 2-1, 
and of children with DS beyond the neonatal stage in Table 2-2.  It can be seen that much of 
the literature is based on anecdotal case reports or small series and it is perhaps surprising 
that only one prospective study of the haematology of DS neonates has been reported, and 
this is small – only including 25 neonates (Kivivuori, Rajantie and Siimes, 1996).   Similarly, 
although the need for DS specific haematological reference ranges has long been recognised 
(Starc, 1992; Kivivuori, Rajantie and Siimes, 1996), none have been reported.  
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Table 2-1. Published reports of haematological indices in neonates with Down syndrome. 
 
Reference Age range Number of cases with 
DS 
Type of study Parameters studied   
Behrman et al, 
1966  
Neonates 3 sibs (all with DS) 
Reports of 2 
Case report; 
One followed up 
for 3 years 
 
HB, HCT, MCHC, WBC, PLT  
Blood cell morphology 
 
Lappalainen et 
al, 1972 
Neonates  874  referred for 
medical treatment 
14 had DS 
17 extra DS cases 
added 
 
Retrospective 
review  
 
HB, HCT,  
Prothrombin level 
Kohne et al,  
1975 
Neonates 11  Prospective 
Cross-sectional 
6 month follow up 
in 3 cases 
 
HCT 
HbA1, HbA2, HbF 
 
Thüring et al, 
1979 
Neonates 70  Retrospective 
Cross-sectional 
 
HB, HCT 
Miller et al,  
1983 
Neonates  61  
Counts available in 
51 
Retrospective 
review; 
 
HCT, WBC, PLT 
Widness et al, 
1994 
Umbilical 
cord blood  
18 
36 controls 
Prospective 
 
erythropoietin,  
HCT in 10/18 with DS 
 
Hord et al, 
1995 
Neonates 31 
40 controls 
 
Cross-sectional  PLT 
Kivivuori et al, 
1996 
Neonates  25  Prospective 
1 year follow up 
HB, HCT, MCV, WBC, PLT 
Erythropoietin 
 
Henry et al,  
2006 
Neonates 266  
Results for 158 
Retrospective HB, HCT, NRBC, WBC, 
neutrophils, PLT 
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Table 2-2. Published reports of haematological indices in children with Down syndrome. 
 
Reference Age range Number of cases with 
DS 
Type of study Parameters studied   
Ridler et al,  
1959 
 
2-15 months 8 Longitudinal WBC 
 
Roizen et al,  
1983 
2-6 years 18 
18 controls 
Prospective, 
Cross-sectional 
2 year follow up 
HCT, MCV, thyroid function  
serum folate, red cell folate 
WBC in 14/18 with DS 
HB electrophoresis in 3/18 
with DS 
reticulocytes in 2/18 with DS 
 
Akin et al, 
1988 
Children 7 Not specified HCT, HC, MCV, WBC 
Starc et al,  
1991 
3 months – 7 
years 
63 
196 controls without 
cardiac disease 
111controls with 
cardiac disease 
Retrospective 
review 
 
HB, HCT, RCC, MCV, MCH, 
MCHC 
     
Bartelik et al, 
1995 
3 months -
10 years 
 
62 Cross-sectional 
 
MCV, HCT, serum iron, ferritin 
WBC 
David et al,  
1996 
2-15 years 50 
68 controls 
Cross-sectional 
 
HB, HCT, RCC, MCH, MCHC, 
RDW, MCV, WBC, PLT, MPV, 
serum folate, red cell folate, 
vitamin B12 
haptoglobin, red cell creatine 
hexokinase in 40 with DS  
 
Dixon et al, 
2010 
1-19.7 years 114 Cross-sectional HB, MCH, MCHC, MCV, 
RDW, TS, ferritin, FEP, ZCP 
Bloemers et al, 
2010 
Children 41 
41 controls 
Prospective WBC and differential WBC 
count 
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The first reported abnormality of the full blood count in otherwise healthy children with DS 
was published in 1959 (Ridler and Shapiro, 1959).  In this study eight infants with DS were 
reported to have lower mean white blood cell counts (WBC) than non-DS infants, although 
the difference was not statistically significant, and review of the medical records did not reveal 
frequent or unusual infections in the DS group.  However, the numbers were small, follow-up 
was limited and there was no clear explanation of criteria used to identify or code infectious 
episodes.  Two subsequent studies also found low WBCs in children with DS, but again the 
numbers studied were small and, although clinical information was provided in one study, this 
was minimal (Roizen and Amarose, 1993; Kivivuori, Rajantie and Siimes, 1996).  More 
recently, a study of 41 DS children with age-matched controls has extended our 
understanding by demonstrating significantly lower absolute total leukocyte counts, 
lymphocytes, monocytes, and granulocytes, but 1.5-times higher numbers of pro-
inflammatory monocytes in DS children (Bloemers et al, 2010a).  The authors suggest that 
these monocytes might be involved in the development and maintenance of chronic 
inflammatory diseases often associated with DS (Scherberich, 2003). 
One of the earliest papers on DS and haematology is a case report of three siblings with DS, 
two of whom had marked haematological changes as neonates including haemolytic 
anaemia, thrombocytopenia and myeloid metaplasia (Behrman, Sigler and Patchefsky, 1966).  
Thrombocytopenia has since been consistently demonstrated in DS neonates (Miller and 
Cosgriff, 1983; Thüring and Tönz, 1979; Hohlfeld et al, 1994; Hord, Gay and Whitlock, 1995; 
Kivivuori, Rajantie and Siimes, 1996; Henry et al, 2007).  Thrombocytopenia has also been 
demonstrated in other trisomies.  In a study of 86 neonates with a trisomy, 70 of which had 
DS, 60% had thrombocytopenia (Thüring and Tönz, 1979).  The mean platelet count was 
104.6 (45, 175) x 109/l (mean; 10 and 90 percentiles) for those with DS.  In the two studies 
with follow-up the thrombocytopenia resolved (Miller and Cosgriff, 1983; Kivivuori, Rajantie 
and Siimes, 1996) – and in fact there was subsequently a tendency to thrombocytosis in later 
infancy (Kivivuori, Rajantie and Siimes, 1996).  This latter finding is not entirely surprising as 
thrombocytosis has also been demonstrated in infants without DS (Addiego, Mentzer and 
Dallman, 1974; Lundström, 1979; Heath and Pearson, 1989).  This probably reflects the fact 
that healthy children are unlikely to have a blood test performed on them, and so full blood 
count data comes from children who are more likely to be compromised in some way, 
particularly as a result of acute infection.  Thrombocytosis is a healthy physiological response 
to infection and so is not an unexpected finding in this context.  
The first indication of the presence of red cell abnormalities in children with DS came from a 
study ascertaining neonates with polycythaemia from a general population of neonates, which 
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reported a 20-fold excess of DS amongst those with polycythaemia (Weinberger and 
Oleinick, 1970).  Subsequently, a retrospective review of haemoglobin and haematocrit in 
babies referred for hospital treatment also found a raised haematocrit in the subgroup with 
DS (Lappalainen and Kouvalainen, 1972).  This did not appear to be associated with 
concurrent cardiac disease – most of the congenital cardiac disease in DS is not cyanotic, 
and even with congenital cyanotic cardiac disease polycythaemia would not be expected to 
appear for several days.  The authors suggested that placental dysfunction might be 
implicated.  In response to these findings, a retrospective review of DS neonates was 
conducted, and confirmed that the haematocrit and platelet counts were significantly elevated 
and reduced respectively in DS neonates (Miller and Cosgriff, 1983).  Another study 
measured erythropoietin levels, as a proxy marker of fetal hypoxaemia, in the umbilical cord 
blood of neonates with and without DS (Widness et al, 1994).  The erythropoietin levels were 
significantly higher in the DS group, but again within this group no significant effect of 
concurrent cardiac disease was observed.  Unfortunately, in this study the haematocrit was 
only available in a small number of cases.  Interestingly, babies with DS were noted to have 
lower birth weights which could reflect fetal hypoxaemia resulting from placental insufficiency.   
To date only one prospective study of full blood counts in neonates with DS has been 
reported, and this only followed 25 neonates for 12 months (Kivivuori, Rajantie and Siimes, 
1996).  Neonates known to have a haematological abnormality were excluded.  Full blood 
counts were taken at frequent intervals, and although 64% infants were polycythaemic in the 
first week of life, this resolved after 8 weeks.  The pattern of change of haemoglobin was 
noted to be similar to that already described in infants without DS, falling to a nadir at around 
2 months and then rising slowly to reach a plateau towards the end of the first year of life.  
The next red cell change to be described in children with DS was macrocytosis; this had been 
recognised in adults with DS since the late 1960’s (Naiman, Oski and Mellman, 1965; 
Eastham and Jancar, 1970; Howell et al, 1973; Akin, 1988; Wachtel and Pueschel, 1991).  A 
retrospective review compared full blood counts from children with DS to those from two 
control groups: one with and one without cardiac disease (Starc, 1992).  Both the mean red 
cell volume (MCV) and mean red cell haemoglobin (MCH) were significantly higher in children 
with DS.  Additionally, the haemoglobin and haematocrit were higher in DS, but this was only 
significant in comparison to the control group without cardiac disease.  Interestingly, for DS 
children having concurrent cardiac disease made little difference until 2-7 years of age when, 
compared to those without cardiac disease, a significantly higher haemoglobin, MCH and 
mean cell haemoglobin concentration (MCHC) was observed.  The authors of this review 
make the point that comparing the full blood count from a child with DS against standard 
21 
 
parameters might be misleading, and state the case for establishing reference values for 
haematology parameters in DS.  For example, a child with DS and iron deficiency might have 
an MCV that was low for DS, but which appeared normal when compared to standard charts.  
In this scenario, iron deficiency might not be diagnosed until late in its course.  This possibility 
has been investigated in a study of 114 children with DS, which found iron deficiency/iron 
deficiency anaemia was present in 15 children.  However, it would have been missed in 13 of 
these 15 children if red blood cell indices alone, and not iron studies, had been used for 
screening (Dixon et al, 2010).  
The association between red blood cell macrocytosis and DS was confirmed in a 
retrospective analysis of 60 000 full blood counts of which 146 were found to be macrocytic 
(Pappo, Fields and Buchanan, 1992).  The most common association was with drugs, but 
there was an excess of children with DS amongst those with macrocytosis.  Following on 
from this came the first report of full blood counts from prospectively recruited healthy 
children with DS who were not institutionalized (Roizen and Amarose, 1993).  Importantly, 
this study included a control group matched for age and sex.  Both the MCV and the 
haematocrit were significantly higher in DS.  There was no significant difference in red cell or 
serum folate levels, and although compensated hypothyroidism was not uncommon in the DS 
group it did not appear to be associated with a high MCV.  Three cases were also examined 
by haemoglobin electrophoresis, but there was no sign of persisting fetal haemoglobin.  
Reticulocytes were looked for in two samples, but were absent.  It had previously been 
speculated that the high MCV might be an early sign of bone marrow failure, but there was no 
report of associated bone marrow failure in over two years of follow up.   
Another study of full blood counts in DS also looked at a range of relevant red blood cell 
parameters in 50 children with DS and 68 age matched controls in an attempt to determine 
the underlying cause of the macrocytosis (David et al, 1996).  In addition to a significantly 
higher MCV, it found a significantly higher haemoglobin, MCH, haematocrit, and red cell 
distribution width.  However, red blood cell count, MCHC, red cell and serum folate, vitamin 
B12, haptoglobin, red cell creatine, serum iron, ferritin and hexokinase were not significantly 
different from non-DS controls.  The authors postulate that the high MCV might reflect 
enhanced erythropoiesis in response to impaired oxidative metabolism, and further propose 
that this might occur as a gene dosage effect given that the gene for a superoxide dismutase 
(SOD1) is located on chromosome 21 - superoxide dismutases are essential enzymes that 
eliminate superoxide radicals and thus protect cells from damage induced by free radicals. 
Alternatively the authors consider whether there might be an alteration in the folate 
remethylation pathway resulting from reduced thymidylate synthase activity and consequent 
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prolonged RNA synthesis in the red cell precursor - the gene for cystathione β synthase, 
regulating a critical step of the re-methylation pathway, is found on chromosome 21.  This 
latter theory is compatible with normal folate parameters.   
The only longitudinal data available on neonates with DS (Kivivuori, Rajantie and Siimes, 
1996) not only confirmed red cell macrocytosis, but also showed an increase in MCV over the 
first year of life.  This was not observed to be associated with a reticulocytosis and serial 
erythropoietin levels were low to normal.  In view of the multiple potential haematological 
abnormalities the authors iterated the need for reference values for full blood counts in DS 
infants to help management. 
The largest report of full blood counts in neonates with DS was published recently – one of a 
series of reports on haematological parameters in neonates to have come from the 
Intermountain Healthcare Hospital organization which represents 23 hospitals in Salt Lake 
City, Utah and in the surrounding area (Henry et al, 2007).  In this retrospective review of 
computerised medical records 266 neonates with DS were identified.  Of these, 158 had had 
full blood counts taken in the first week of life.  The most common finding was of neutrophilia, 
present in 80%.  Thrombocytopenia and polycythaemia were noted, consistent with previous 
reports, and further analysis showed a correlation between the two, with polycythaemia being 
almost three times as likely if thrombocytopenia was present.  Blasts consistent with a 
diagnosis of transient myeloproliferative disorder were noted in 6%.  In contrast, the incidence 
of anaemia, thrombocytosis and neutropenia appeared similar to the general population.  
There were, however, several problems with this study: not all DS neonates had a full blood 
count raising the possibility that those who did had adverse clinical features; clinical 
information was limited; there no information about the source of sample – an important 
variable; and finally, there was no information about the morphology.      
Taken together it is clear that various abnormalities of the full blood count are associated with 
DS at the neonatal stage.  These may include polycythaemia, macrocytosis, 
thrombocytopenia, leucopenia and neutrophilia.  However, the quality of much of the data is 
limited, most being based on anecdotal reports or on small series.  One possible reason for 
the paucity of data is that the haematological changes have not usually been associated with 
serious clinical disease.  Moreover, although follow-up are limited, it has been suggested that 
most haematological abnormalities tend to resolve spontaneously over the first year of life – 
indeed this is the standard teaching in medical textbooks.  However, there is now increasing 
evidence that some haematological changes present in DS neonates might actually be very 
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significant in predicting a group at particularly high risk of early serious haematological 
disease, specifically myeloid leukaemia of Down syndrome (ML-DS).   
2.2.2 Malignant haematological disorders 
The first case report of acute leukaemia in DS was published in 1930 (Brewster and Cannon, 
1930).  Subsequently, a postal survey by Krivit and Good confirmed a growing suspicion that 
acute leukaemia occurred with increased frequency in children with DS (Krivit and Good, 
1957).  Large epidemiological studies from the 1990s onwards have consistently reported a 
20-30 fold increased risk of acute leukaemia in DS (Hasle, Clemmensen and Mikkelsen, 
2000; Yang, Rasmussen and Friedman, 2002; Hill et al, 2003; Agarwal et al, 2005). 
Interestingly, this increase is not mirrored by other cancers.  Indeed, the available 
epidemiological evidence suggests that while the incidence of testicular cancer may be 
increased, the incidence of many other cancers appears to be reduced (Bennett et al, 1976; 
Hasle, Clemmensen and Mikkelsen, 2000; Hill et al, 2003; Goldacre et al, 2004).    
Much of the data on leukaemia in DS is derived from trial series, which may be incomplete 
and potentially subject to bias.  Trial entry for children with DS has lagged behind that of the 
general population.  Indeed, data from the UK Childhood Cancer Study, a national 
population-based study which recorded all diagnoses of childhood cancer and leukaemia 
over a four year period from 1990-1994, indicated that while trial entry approached 90% in 
non-DS children with leukaemia, it was greatly reduced in those with DS being around two-
thirds for those with acute lymphoblastic leukaemia (ALL) and half for those with acute 
myeloid leukaemia (AML) (James et al, 2008).  Until trial entry improves, population based 
studies remain a more robust way of examining this high risk population.    
Transient myeloproliferative disorder 
Transient myeloproliferative disorder (TMD; also referred to as transient abnormal 
myelopoiesis; or transient leukaemia) is a clonal myeloproliferative disorder of myeloid origin 
which has been recognised in neonates with DS for over 50 years (Schunk and Lehman, 
1954).  Typically the child is asymptomatic and the disorder resolves spontaneously within 3 
months (Zipursky and Doyle, 1993; Zipursky et al, 1997; Zipursky, 2003).  In a small minority 
of patients there are clinical changes, notably liver fibrosis, pleural and pericardial effusions 
and disseminated intravascular coagulation.  When these occur the child may be very sick, 
and without treatment they are life threatening.  The exact incidence of TMD is unknown – 
historically the diagnosis was not routinely sought and there are no agreed diagnostic criteria.  
Typically, there is a high WBC count, with blasts on the blood film often with 
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thrombocytopenia, a leukoerythroblastic picture and megakaryocyte fragments (Zipursky et 
al, 1999).  The oft-quoted incidence of 10% is derived from a study by Zipursky which 
reported an incidence of 10% in a small series that examined blood films from newborn DS 
infants (Doyle and Zipursky, 1994).  Another study examined 79 DS fetuses by ultrasound for 
hydrops fetalis and hepatosplenomegaly, using these as proxies for TMD, and reported an in 
utero prevalence of 14% (Smrcek et al, 2001).  Zipursky has suggested that the population 
picked up by ultrasound in utero are at high risk of intrauterine death, and that those picked 
up postnatally are an additional group, giving a total prevalence of TMD in utero of 
approximately 20% and in newborns of approximately 10% (Zipursky, 2003).  However, it is 
not clear whether hydrops fetalis and hepatosplenomegaly can always be assumed to equate 
to a diagnosis of TMD in a fetus with DS.  There are certainly many other causes of hydrops 
fetalis (White, 1999), and it has been described in DS in association with other diagnoses 
(Fujimoto et al, 1983; Ilagan et al, 1992; Rutigliani et al, 2007).  Moreover, in contrast to the 
higher estimates from older studies, two recent studies both reported much lower frequencies 
(Ahmed et al, 2004; Pine et al, 2007).  TMD was only diagnosed in 9/158 (6%) full blood 
counts taken from DS neonates when these were analysed retrospectively (Henry et al, 
2007).  Another retrospective analysis, this time of Guthrie cards of children recorded as 
having DS on a congenital malformation registry, found a GATA1 mutation and inferred a 
diagnosis of TMD in 22/590 (4%) cases (Pine et al, 2007).   
The significance of TMD has been unclear until recent years, and as most children are well 
and as the changes typically resolve spontaneously, it has previously attracted little clinical 
attention.  Similarities between acute megakaryoblastic leukaemia (AMKL) and TMD have 
long been recognised, for example, the blasts have a similar immunophenotypic profile 
(Yumura-Yagi et al, 1992; Ito et al, 1995; Litz et al, 1995; Karandikar et al, 2001; Langebrake, 
Creutzig and Reinhardt, 2005).  A significant breakthrough came in 2002 when a consistent 
mutation of GATA1, producing a short form of GATA1 (GATA1s), was demonstrated 
exclusively in children with AMKL and DS – but not in children with AMKL without DS, in DS 
children with other types of acute leukaemia, or in healthy DS children (Wechsler et al, 2002).  
GATA1 is a key DNA-binding transcription factor that regulates the growth and maturation of 
erythroid cells, megakaryocytes, eosinophils and basophils/mast cells. It is not expressed in 
lymphocyte or other myeloid lineages.  It is encoded on the X chromosome and has a 
phosphorylated double zinc finger structure. Both zinc fingers help GATA1 bind DNA and 
interact with other proteins.  Other groups have since confirmed that a GATA1 mutation is 
pathognomonic of AMKL in DS and have demonstrated similar mutations of GATA1 in DS 
neonates with TMD (Hitzler et al, 2003; Mundschau et al, 2003; Rainis et al, 2003; Xu et al, 
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2003; Greene et al, 2003).  Follow up of several individual cases has shown that the mutation 
becomes undetectable as the TMD resolves, but may recur with the development of AMKL 
(Shimada et al, 2004; Xu et al, 2006; Kanegane et al, 2007).  Examination of Guthrie cards 
for children with DS diagnosed with AMKL in early childhood revealed similar GATA1 
mutations (Ahmed et al, 2004).  There are few prospective studies of neonates with TMD.  A 
prospective follow up study of 48 newborns diagnosed with both DS and TMD reported the 
subsequent development of AMKL in 8 (17%) and ALL in 1 (2%) (Massey et al, 2006).  The 
same group have recently reported on a larger group of 135 DS neonates with TMD of whom 
21 (16%) developed MDS or AML with a median time of 441 days (Gamis et al, 2011).  
Interestingly, 4 of the 21 who developed MDS or AML had received intervention therapy for 
TMD, typically with intravenous cytarabine.  A further 2/135 neonates developed ALL.  A 
European report of 146 infants with TMD found a similar incidence of subsequent TMD with 
23% developing myeloid leukaemia after 5 years of follow up (Klusmann et al, 2008).   A 
retrospective Japanese study of 70 infants with TMD reported an increase in early death in 
those with a white cell count of >100 x109/l and for preterm infants, but did not look at 
subsequent malignancy (Muramatsu et al, 2008).  It is not possible at present to predict which 
neonates with TMD are likely to develop subsequent leukaemia, although significant 
correlations with the later development of AML and karyotypic abnormalities in addition to 
trisomy 21 (Massey et al, 2006) and also with an increased time taken for the TMD to resolve 
(Gamis et al, 2011) have been described. 
One of the problems in this area has been a lack of agreed diagnostic criteria for TMD.  This 
reflects the initial uncertainty as to whether it was or was not a malignancy – an uncertainty 
which arose from its unusual clinical features, particularly the typical wellness of the child and 
the spontaneous regression.  In the most recent study of children with TMD (Gamis et al, 
2011) it was defined as follows: ‘<3 months of age at presentation with any non-erythroid 
blasts in the peripheral blood coupled with any of the five following criteria: verification of 
blasts with a second sample, >5% non-erythroid bone marrow blasts, hepatomegaly or 
splenomegaly, lymphadenopathy, or cardiac or pleural effusions…organomegaly or 
adenopathy were determined by the clinician’s physical exam and did not have strict criteria’.  
Given the association of GATA1 and TMD it may well be that assessment of GATA1 status 
forms part of new diagnostic criteria for TMD, but it is important to note that this has not been 
the case in the majority of literature to date and it is not currently in routine clinical use.   
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Acute myeloid leukaemia 
Both myeloid leukaemia of Down syndrome (ML-DS), a specific disease within this 
population; and sporadic AML, representing a heterogeneous group of AML subtypes, appear 
to be increased in DS.   
Myeloid leukaemia of Down syndrome 
AMKL occurs ~500 fold more often in children with DS compared with the general paediatric 
population (Zipursky, Poon and Doyle, 1992; Lange et al, 1998; Creutzig et al, 1996; Khan, 
Malinge and Crispino, 2011).  It is now clear that GATA1 mutations, resulting in GATA1s, are 
acquired in utero, and are associated with TMD.  Typically, this will resolve, but the GATA1 
may reappear in association with the development of AMKL (Gurbuxani, Vyas and Crispino, 
2004).  There are several unusual features of AMKL in DS: it occurs in the first 5 years of life; 
tends to be preceded by a myelodysplastic prodrome of 4-24 months (Creutzig et al, 1996); 
and is exquisitely sensitive to chemotherapy (Zwaan et al, 2000).  Additionally, there is a 
suggestion that response to treatment is improved further if it is treated early (Creutzig et al, 
2004).  Cytogenetic analysis typically shows absence of favourable chromosomal 
translocations such as t(8;21), t(15;17), inv 16, t(1;22), although unbalanced translocations, 
particularly +8, del 6q, +11, +21 appear to be increased (James et al, 2008). 
Given that the natural history of myelodysplasia in DS is progression to AMKL, and as there 
is no biological, prognostic or therapeutic reason to differentiate them, the term myeloid 
leukaemia of DS (ML-DS) was proposed to encompass myelodysplasia and AMKL with an 
obligate GATA-1 mutation in children with DS (Hasle et al, 2003).   
Sporadic AML 
Myeloid leukaemia in children 4 years or older with Down syndrome often lacks a GATA1 
mutation, whilst the cytogenetic changes and risk of relapse are more akin to sporadic AML.  
Analysis of AML subtypes by several groups has suggested that acute erythrocytic leukaemia 
may be specifically increased in children with DS (Levitt, Stiller and Chessells, 1990; Creutzig 
et al, 1996; Lange et al, 1998; James et al, 2008), whilst other studies have shown a spread 
of subtypes (Agarwal et al, 2005; Abella et al, 2008). 
Acute lymphoblastic leukaemia 
The discovery of an exclusive mutation of GATA1 in children with DS and AMKL has 
generated considerable excitement in the paediatric haematology world.  However, the 
attention concentrated on this has somewhat obscured the fact that in absolute terms acute 
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lymphoblastic leukaemia (ALL) remains at least as common as AML in children with DS 
(Rosner and Lee, 1972; Hill et al, 2003; Agarwal et al, 2005; James et al, 2008).  The mean 
age at diagnosis for DS-ALL is 4.8 years, which is not significantly different to non-DS ALL 
(James et al, 2008).  ALL in DS is a more heterogeneous disease than AML in DS, which is a 
distinct entity, and there are distinct clinical and biological features which distinguish it from 
non-DS ALL (Maloney, 2011).   Precursor B-cell ALL is the predominant form, with T-cell ALL 
being extremely rare (Pui et al, 1993; Chessells et al, 2001; Bassal et al, 2005; James et al, 
2008; Maloney et al, 2010).  High hyperdiploidy is typically underrepresented, and 
chromosomal translocations associated with adverse outcomes such as 11q23/MLL, t(9;22), 
t(1;19) are often absent (Pui et al, 1993; James et al, 2008; Maloney et al, 2010).  An 
activating mutation of JAK2 has recently been demonstrated in ~20% DS, compared with 
~10% non-DS high risk ALL, and appears to be associated with a distinct ALL phenotype 
(Bercovich et al, 2008) 
2.2.3 Blood cell morphology 
Most of the papers that report any blood cell morphology in neonates with DS have done so 
in the context of TMD.  There is one report of blood cell morphology in 13 young children with 
DS which noted a common finding of large platelets with abnormalities of the membrane and 
granules (Boisseau et al. 1976).   
In the papers pertaining to TMD several morphological features, other than simply the 
presence of blasts, have been documented.  There are often platelet abnormalities with  
thrombocytopenia (Cantù-Rajnoldi et al, 1988; Cook et al, 1989; Zipursky et al, 1999; Henry 
et al, 2007), and the presence of megakaryocytes or megakaryocyte fragments in the 
peripheral blood (Suda et al, 1988; Zipursky et al, 1999; Webb, Roberts and Vyas, 2007) 
being most commonly reported.  Although the latter review also states that giant platelets are 
a feature, this is not substantiated by data (Webb, Roberts and Vyas, 2007).  There is one 
mention of thrombocythaemia – in a report of one patient who also had a neutrophilia, 
eosinophilia and basophilia (Suda et al, 1987).   
Zipursky, who pioneered the morphological and clinical advances in recognising and 
understanding TMD describes a leukoerythroblastic picture (Zipursky et al, 1999) and early 
reports described a leukaemoid reaction (Cantù-Rajnoldi et al, 1988; Fernandez de Castro et 
al, 1990) with some reports specifically commenting on the presence of nucleated red blood 
cells (Henry et al, 2007; Webb, Roberts and Vyas, 2007).   
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Where the morphology of the blasts is described in TMD they are reported to have the 
features of megakaryoblasts with  blebbed cytoplasmic outline (Zipursky, Poon and Doyle, 
1992) although a recent review discussing TMD states that there are ‘deeply basophilic blast 
cells usually indistinguishable from neonatal blasts but present in greater number’ (Webb, 
Roberts and Vyas, 2007).  A small series of 4 children with DS and acute leukaemia includes 
2 neonates (Brunning et al, 1974).  This notes the presence of prominent basophilic 
inclusions in some, but not all, blasts. A study of 5 patients with TMD looked at the 
ultrastructural features of the blasts and concluded that they were heterogeneous with 
evidence of megakaryocytic, granulocytic and erythroid lineages (Bessho et al, 1988).  This 
diversity calls into question the initial diagnosis of TMD in this paper, especially as Zipursky 
comments that blasts are frequent in neonates with DS whether or not they have TMD 
(Zipursky, Poon and Doyle, 1992), and highlights again the need for clear diagnostic criteria 
for TMD.  Similarly, in the large retrospective review of the haematology of DS neonates 
blasts were noted in 9/158 cases, of which 3/9 were referred to a haematologist for follow up 
because of an increasing blasts count which was inferred to indicate TMD (Henry et al. 2007). 
2.3 Existing and historical cohort studies 
DS cohort studies are rare.  There are only two comparable birth cohorts: the National Down 
Syndrome Project (NDSP), based in Atlanta (Freeman et al, 2007), and a prospective birth 
cohort (Bloemers et al, 2007) developed in Holland.  The NDSP, which recruited children 
between 2001 and 2004, grew out of the Atlanta Down Syndrome Project, which had 
recruited children between 1989 and 1999.  The NDSP was designed to examine the 
molecular epidemiology of DS and to assess risk factors for DS associated congenital 
defects.  Although 907 infants were recruited, follow up ceased after a single telephone 
interview.   The Dutch cohort study recruited 241 children with DS between 2003 and 2005, 
and has followed them until two years of age.  To date, the Dutch cohort has reported on the 
risk of respiratory syncitial virus (Bloemers et al, 2007), recurrent wheeze (Bloemers et al, 
2010b), immune dysregulation (Bloemers et al, 2010a; Bloemers et al, 2011) congenital heart 
defects (Weijerman et al, 2010) in children with DS.  Neither the NDSP nor the Dutch cohort 
has addressed haematological issues.   
2.3.1 Summary 
The need to describe the haematology of DS neonates in a systematic manner and to 
establish reference ranges for neonates with DS is clear.  In addition to determining these, it 
is important that clinical information is collected.  There are many potential associations 
between neonatal haematological changes and important clinical conditions, including serious 
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contemporaneous conditions such as neonatal sepsis.  Once the reference ranges are 
developed, it will be important to determine whether deviations from them have similar 
significance to deviations in non-DS neonates.  There are also DS specific neonatal 
conditions, notably TMD, that are not fully understood.  There is a clear discrepancy between 
older and more recent reports of the incidence of TMD, and a better understanding of the 
normal neonatal haematology of DS may help explain this.  Similarly, there are unanswered 
questions about the neonatal management of DS neonates that will be addressed by this 
work, including the basic question of whether a FBC should be checked in all children with 
DS.  Finally, looking towards the future, as the clinical outcome of children can be considered 
alongside the natural history of haematological indices it may be possible to highlight features 
that are of prognostic significance.  All this will mark a very significant contribution to the 
healthcare of neonates with DS. 
2.4 Haematological reference ranges for neonates 
2.4.1 Introduction 
This section considers the development of haematological reference values for non-DS 
neonates.  The CDSS is an observational study of DS neonates.  It would not have been 
appropriate to take samples from healthy non-DS neonates in order to construct 
contemporaneous reference ranges as these already exist.  Moreover, it makes more sense 
to compare the values obtained in the CDSS with these existing ranges as this is what they 
will be compared with in daily clinical practice.  However, it is very important that the 
development of the existing ranges is understood in order to understand their strengths and 
weaknesses.  The term reference, and not normal, is used as blood samples are not usually 
taken from healthy neonates.  This has not always been the case.  It is apparent that reports 
from the first half of the last century do include results from healthy neonates, particularly 
those who were in socially vulnerable situations at a time when there were less stringent 
ethical constraints upon research.  Adherence, rightly, to ethical considerations (Rice, 2008; 
Puri et al, 2009) means that although accurate automated techniques for determining 
haematological values are now well developed it is very difficult to study healthy children, as 
this would require an invasive procedure (Coleman, 2007).   
The first reports of haematology parameters in neonates were published at the end of the 19th 
century: in 1866 von Korber identified that the haemoglobin of neonates, now recognised as 
fetal haemoglobin, was more resistant to alkalinisation than adult haemoglobin (von Korber, 
1926); soon after this Schücking presented a formulae for calculating neonatal blood volume 
(Schücking, 1879).   Although more recent reports have considered red cell, white cell and 
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platelet parameters on the same sample, older reports typically concentrated on one cell type 
– reflecting the limitations of older analysers and of manual counting.  Accordingly, this 
discussion will focus on each cell type in turn.  Today full blood count (FBC) analysis is an 
integral part of the management of sick neonates.  However, before the 1970s the FBC was 
not thought to be especially useful in neonatology.  Since then, and particularly as a result of 
the pioneering studies done by Rosenfeld’s group in Dallas in determining reference ranges 
(Manroe et al, 1979; Mouzinho et al, 1994), the FBC has become of great importance in the 
management of sick or preterm neonates.   
In the last few years an invaluable contribution to the field of neonatal reference ranges has 
been made by the Intermountain Healthcare Hospitals organization which represents 23 
hospitals in Salt Lake City, Utah and in the surrounding area.  This group have published 
reference ranges based on retrospective computerised results from very large data sets of 
neonates (Christensen et al, 2008; Schmutz et al, 2008; Christensen et al, 2009; Wiedmeier 
et al, 2009; Jopling et al, 2009; Christensen et al, 2010; Christensen et al, 2011).  The 
electronic records store demographic and clinical information, including history and 
examination results, problem lists and discharge summaries as well as the computerised 
laboratory records required for analysis.  The same automated counter, a Beckman Coulter 
LH750, was used in all the hospitals.  There are, however, several weaknesses to these 
reports.  Although clinical records are used to exclude neonates with features known to affect 
the parameters being studied some in these categories may have been included as records 
are not always complete.  Furthermore, all reports are retrospective and lack important 
information about the source of the sample so that the ranges include samples from a variety 
of sources.  Also, there is no information about morphological assessment.  Taken together 
these weaknesses would tend to give wider reference ranges.  A further problem is that the 
hospitals in this geographical area are at high altitude, which has been shown to affect red 
and white blood cell indices in neonates.  However, despite these limitations this body of work 
provides the best reference sets to date, and as well as contributing to the clinical 
management of neonates, these provide an excellent and timely reference for the CDSS.  
2.4.2 Measurement of haematological parameters 
The first reports of haematological parameters relied on manual techniques involving simple 
reagents, centrifuges, glass slides, microscopes, counting chambers and colorimeters from 
which the haemoglobin concentration, packed cell volume (PCV) and red blood cell count 
(RCC) could be estimated.  Further red cell indices, notably the mean cell volume (MCV), 
mean cell haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC) could then 
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be derived using simple calculations.  These manual techniques were refined and used for 
many decades (Wintrobe, 1929a; Wintrobe, 1929b; Spivak, 2003) until they were superseded 
by automated blood cell analysers based on the principle of impedance counting able to 
measure indices directly (Coulter, 1956).   Automated counting has since developed 
considerably, with newer machines incorporating a variety of techniques such as 
fluorescence flow cytometry, laser light scatter, white light scatter and absorbance, direct 
current (for impedance measurements) and radiofrequency current (for determining the 
internal structure of a cell).  Modern analysers are precise, accurate and have the advantage 
of being able to turn over a large number of samples rapidly with little manual input.  Manual 
techniques remain important in determining reference values and in investigating anomalous 
automated results (Barnes et al, 2005), but are no longer employed routinely.  The 
established techniques used by modern analysers and the recommended units used to 
measure haematology parameters are described in Appendix 1.  
Several organisations are involved in the oversight of the techniques used in haematology 
laboratory analysis.  The International Society for Laboratory Hematology (ISLH; 
www.islh.org) is a non-profit organisation with an international membership of laboratory 
professionals and is closely allied to the recently revived International Council for 
Standardisation in Hematology (McFadden et al, 2008).  Both organisations are dedicated to 
the development of standards and guidelines for laboratory haematology to enable 
increasingly reliable and reproducible results.  At a more local level, hospital haematology 
laboratories take part in a national accreditation process, administered by the United 
Kingdom Accreditation Service (UKAS; www.ukas.com) and Clinical Pathology Accreditation 
UK Ltd (CPA; www.cpa-uk.co.uk ), and regular external quality assessment, co-ordinated by 
the UK National External Quality Assessment Scheme for Haematology (NEQAS; 
www.ukneqas.org.uk).  Further details are given in Appendices 2 and 3.    
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2.5 Red blood cell parameters in neonates 
2.5.1 Development of reference ranges for red blood cell parameters 
 ‘Many writers have noted the lack of standard values for the number of red corpuscles, 
amounts of haemoglobin and percentage of packed corpuscles in the blood of the newborn 
infant’ 
Quinn DeMarsh, Factors influencing the blood picture of the newborn, 1948 
Several reports at the turn of the 19th century identified differences in neonatal blood 
parameters compared with adult blood – notably, a significantly higher HB and larger RBC 
(Schücking, 1879; von Korber, 1926).  Accordingly, in the early 20th century there were many 
attempts to define standard ranges for red cell values in neonates (Chuinard, Osgood and 
Ellis, 1941; DeMarsh, Alt and Windle, 1948).  It soon became evident that the red cell indices 
changed rapidly over the first few days and weeks so that very specific ranges would be 
needed relating to the exact postnatal age (Gairdner, Marks and Roscoe, 1951).  The initial 
reference ranges were very wide, and it was apparent that, as well as postnatal age, many 
other factors influenced these values (Lanskowsky, 1960).  The focus shifted to defining 
these factors, and on determining their effects.   
Although the older reports were helpful in identifying some of the factors affecting the RBC, 
manual analysis was subject to considerable variation (Chuinard, Osgood and Ellis, 1941).  
Reference ranges derived from automated results were obtained on apparently healthy 
neonates with a capillary sample being taken on between 10 and 19 infants daily for a week 
and then less frequently for up to 12 weeks in a hospital where early cord clamping was 
standard (Matoth, Zaizov and Varsano, 1971).  Reported parameters included haemoglobin, 
haematocrit, RBC and reticulocyte count.  Other groups since then have also studied 
neonatal blood counts using automated analysers aiming to define standard reference values 
in different neonatal populations, with results usually being presented as the mean value and 
either one or two standard deviations.  The relevant studies are summarised in Table 2-3.  
Reference ranges pertaining to cord blood have not been considered here, as cord blood 
sampling is not part of the study protocol. 
The Intermountain Healthcare Hospitals have published three reports relating to RBC indices 
in neonates (Christensen et al, 2008; Jopling et al, 2009; Christensen et al, 2011).  Neonates 
identified from their clinical records as having clinical features that suggested their RBC 
indices may not be considered normal were excluded, for example those diagnosed with 
anaemia, those who required a RBC transfusion, or associated with a history of placenta 
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prӕvia or abruption.  The most definitive report on the initial RBC values was published in 
2008 and considered 17364 tests performed on 12016 neonates within 24 hours of birth 
(Christensen et al, 2008).   
2.5.2 Factors affecting the red blood cell indices 
By the 1940s it was evident that many factors influence neonatal red cell indices resulting in 
wide ranges (DeMarsh, Alt and Windle, 1948).   
Timing of cord clamping 
This was one of the first variables to be identified. Over a century ago Schücking calculated a 
lower blood volume in two infants whose cords were tied early, compared with 4 infants in 
whom the cord was not tied for several minutes (Schücking, 1879).   Subsequently, DeMarsh 
reported that early cord clamping was associated with lower RCC and haemoglobin in babies 
tested in the first week of life compared with infants in whom clamping was delayed until the 
placenta had separated from the uterus (DeMarsh et al, 1941).  This finding was confirmed in 
a study comparing values at 1 and 3 days in babies with immediate and delayed cord 
clamping (DeMarsh, Windle and Alt, 1942).  Although, the accuracy of the values presented 
is doubtful as the calculation of total blood volume assumed that whole body and venous 
haematocrit are the same, the principle has been confirmed in modern studies using 
automated analysers.   It is now well recognised that where clamping of the umbilical cord is 
delayed by >2 minutes from the time of birth a significant amount of extra blood is transferred 
from the placenta to the fetus resulting in an increase in total RCC.   
Further, two systematic reviews and a meta-analysis of controlled trials also conclude that 
delaying umbilical cord clamping for a minimum of two minutes following birth has a benefit 
both immediately and into infancy (Hutton and Hassan, 2007; McDonald and Middleton, 
2008).  Specifically, delayed cord clamping was associated with a higher haematocrit, better 
iron status and a clinically significant reduction in the risk of anaemia.  This association has 
also been demonstrated in preterm infants (Ultee et al, 2008).  However, at present early cord 
clamping is standard in UK hospitals.  
 
 
Table 2-3. Summary of key studies reporting neonatal reference ranges for red blood cell indices. 
 
References Number of 
neonates 
Gestational 
age  
Timing of sampling Site of 
sample 
Country Indices reported Manner reported 
        
1971 Matoth  32
 
term weekly counts from 
0-12 weeks 
capillary Israel HB, HCT, RCC, MCV, 
MCHC, reticulocyte 
count 
mean±1S, graphs against time (HB, RCC 
only) 
1976 Zaizov 135 24 weeks  
–term 
d1 capillary Israel HB, HCT, RCC, RDW, 
reticulocyte count 
mean±1SD 
1986 Ogala 99 term d1; 1,2 and 6 weeks; 
 3, 6 months 
venous Nigeria HB, HCT, RCC, MCV mean±1SD, range  
2000 Özbek 95 term d1 capillary 
venous 
Turkey HB, HCT, RCC, MCV, 
MCH, MCHC, RDW 
mean± 1SD, 
 
2003 Kayiran 141 term d7, d14, d21, d28 capillary 
venous 
Turkey HB, HCT, RCC, MCV, 
MCH, MCHC, RDW 
mean± 1SD, 
2006 Őzyűrek 77
a 
term d7 venous Turkey HB, HCT, RCC, MCV, 
MCH, MCHC, RDW 
mean±SE (range) 
2008 Christensen 12016
 
22-42 weeks d1 not 
recorded 
North 
America 
MCV, MCH, MCHC mean± 1SD, graph with 95% CI, expected 
values by gestation (MCV, MCH) 
2009 Jopling 39 559 ( HB) 
41957 (HCT) 
22-42 weeks at least once 
between d1-28 
not 
recorded 
North 
America 
HB,HCT mean± 1SD, graph with 95% CI by 
gestational age and postnatal age 
2009 
Christensen
b 
39 559 ( HB) 
41957 (HCT) 
12016 (MCV, 
MCH, MCHC) 
22-42 weeks at least once 
between d1-28 
not 
recorded 
North 
America 
MHB,HCT, MCV, MCH, 
MCHC 
graph with mean, 5
th
 and 95
th
 percentile by 
gestational age, smoothed curves for 
MCV, MCH 
 
a. This group included appropriate for gestational age and small for gestational age neonates; samples were also taken from 109 neonates on d1, but as these were cord blood 
samples they are not included here; b. This paper summarises the work presented in Christensen 2008 and Jopling 2009, as well as papers on WBC and platelets.   The only 
new information is smoothed curves giving reference ranges for MCV and MCH.  Note that this table does not include papers which include babies who have received red blood 
cell transfusions (Obladen, Diepold and Maier, 2000); or where manual processing was used (Sasanakul et al, 1993).
 
 
Source of sample 
Variations in neonatal RBC indices according to the source of the sample were first identified 
almost a century ago (Haden and Neff, 1924) when the haemoglobin and RCC of capillary 
and venous samples were compared.  A series of investigations was reported by DeMarsh 
into the effect of the timing of cord clamping an apparent difference between capillary and 
venous samples was noted (DeMarsh et al, 1941; DeMarsh, Windle and Alt, 1942), leading to 
a study with the primary purpose of investigating the effect of early and late cord clamping, 
but with a secondary purpose of obtaining saggital sinus samples and comparing these with 
the capillary sample results obtained in the initial study (DeMarsh, Alt and Windle, 1948).  
This showed that the haemoglobin and RCC values obtained from the saggital sinus were 
lower than those reported from capillary samples.  A third study, reported in the same paper, 
performed to compare capillary and saggital sinus samples taken simultaneously from the 
same child, confirmed a higher RCC and haemoglobin in the capillary samples (DeMarsh, Alt 
and Windle, 1948).   
Around the same time another group replicated these findings, also describing a higher 
haematocrit in capillary compared with venous samples from neonates (Vahlquist, 1941).  
This group also showed that the capillary haemoglobin fell after the first week, so that it was 
similar to the venous haemoglobin by the end of the second week.  Subsequently, a study of 
capillary-venous differences beyond the first postnatal week, in 44 neonates of mixed 
gestational age and weight showed that although the values begin to approach one another 
with increasing postnatal age, mean capillary values still remain higher at 8-10 postnatal 
weeks (Rivera and Rudolph, 1982).  This phenomenon was most marked in neonates with 
low birth weight (LBW) with the mean haemoglobin and mean haematocrit being 11-12% 
higher in capillary samples from those weighing <1500 grams at birth.  However, by 8-10 
weeks of age the mean haemoglobin and mean haematocrit were only 4-7% higher in the 
LBW group and only 3-5% higher in those with birth weight >2500 grams.  
Similar findings were reported recently in paired venous and capillary samples from 95 
healthy term newborns taken within 24 hours of delivery: haemoglobin, haematocrit and RCC 
were all significantly higher in capillary samples (Ozbek, Gürakan and Kayiran, 2000).  The 
same group developed their work by taking simultaneous venous and capillary samples from 
a further 141 infants at all or some of the following time-points: 7, 14, 21 or 28 days old 
(Kayiran et al, 2003).  Again, the venous-capillary differences were shown to narrow but still 
to persist over time, with higher haemoglobin, haematocrit and RCC in the capillary samples.  
Comparison of arterial and capillary or venous samples taken in a rapid sequential manner in 
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preterm babies indicates that arterial haemoglobin values are lower than either venous or 
capillary values, with the difference being the most pronounced between capillary and arterial 
values (Thurlbeck and McIntosh, 1987).   
The mechanism underlying these differences is unclear although it may be partly accounted 
for by the movement of plasma from the capillary bed into the interstitial compartment 
resulting in local haemo-concentration consistent with the higher haemoglobin, haematocrit 
and RCC of capillary samples.  Interestingly, the venous/capillary difference appears to 
become more marked in infants with neonatal sepsis which may well reflect compromise of 
the microcirculation with increased capillary leakage (Olvera-Hidalgo and Silva-Carrillo, 
1976).  Ideally therefore there would be separate reference ranges for venous, arterial and 
capillary samples.  However, in practice this has been difficult to achieve as the largest data 
sets have been analysed retrospectively, and source of sample is poorly recorded on forms in 
clinical practice (Christensen et al, 2008; Jopling et al, 2009).   
Postnatal age 
A fall in haemoglobin with increasing postnatal age had been observed in reports from the 
first half of the last century (Vahlquist, 1941).  The effect of postnatal age was specifically 
studied in 25 infants, with 105 venous samples, and also 102 bone marrow samples, being 
taken from birth to 3 months (Gairdner, Marks and Roscoe, 1951).  Venous sampling was 
chosen as this was believed to be less subject to variation.  The haemoglobin was seen to 
rise abruptly over the first day of life from ~18g/dl to ~20g/dl before falling to ~11-12g/dl in the 
eighth week and then remaining stable.  A fall in the RCC and MCH was also observed after 
birth, but this was accompanied by a fall in MCV and so appeared less dramatic.  The MCHC 
remained fairly constant throughout the 3 months.  Comparison of these values with the 
erythroid activity of the bone marrow caused the authors to conclude that `erythropoiesis 
ceases when the oxygen saturation just after birth increases from about 65% in the umbilical 
vein to 95% just after birth’.   
A similar pattern of postnatal changes in red cell values was confirmed and refined using 
automated counters in 1971 by Matoth and co-workers (Matoth, Zaizov and Varsano, 1971).  
Capillary samples were used throughout.  This work suggested that the RCC nadir occurs 
during the 7th week, earlier than that of the haemoglobin, which was explained by the 
continuing fall in MCV.  Importantly, Matoth also showed that erythropoiesis does not cease, 
but rather slows down in the immediate postnatal period.  The reticulocyte count then 
increases from around the 5th week, but given the rapidly increasing weight and, blood 
volume, is initially unable to compensate adequately.  The haemoglobin and RCC then rise 
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slowly from the 9th week, reflecting an increased red blood cell production, and the 
reticulocyte percentage falls to a steady-state.  The authors note that the macrocytes, present 
at birth, are less dense than adult RBC, and suggest that these may be younger cells 
released early into the circulation during a period of increased antenatal erythropoiesis.      
Following this, Stockman studied the natural history of red blood cell values in 40 preterm 
LBW infants (Stockman and Oski, 1980).  The study states that the birth weights, all <1500 
grams, were appropriate for gestation, so that prematurity rather than birth weight is the 
important variable.  Capillary samples were taken at 1, 3 and 7 days of age and then weekly 
thereafter for the first seven weeks of life.  A similar pattern to that seen in term infants was 
observed: the haemoglobin, RCC, MCV and MCH all fell with increasing postnatal age, 
suggesting that this, and not post-conceptual age, was the determining factor.          
Finally, the most definitive work to date on red cell indices in the neonatal period reviewed the 
haemoglobin from 39559 and haematocrit from 41957 samples taken during the neonatal 
period (Jopling et al, 2009).  Neonates born 29-34 weeks gestation and those born 35-42 
weeks gestation were considered separately.  In both groups the haemoglobin and 
haematocrit fell throughout the neonatal period.  Importantly, in this very large dataset the rise 
in haemoglobin and haematocrit previously described in the immediate postnatal period 
(Gairdner, Marks and Roscoe, 1951) was not observed.  Instead, a fall occurred during this 
period in the 29-34 week gestational age group, while values in the older group appeared to 
stay level before steadily falling from day 2.  Early cord clamping to allow the preterm infant to 
be passed to a paediatrician, early use of intravenous fluid and consequent haemodilution, 
and frequent blood sampling may all play a part in the early fall in the younger group.   
Birth weight, low birth weight or very low birth weight babies 
Birth weight and gestation are closely related variables, but one cannot simply use either as a 
surrogate for the other. Low birth weight (LBW) is defined by WHO as weight < 2500 grams; 
while very low birth weight (VLBW) is defined as weight < 1500 grams.  Only a few studies 
have compared results for babies of similar gestation but who were either appropriate for 
gestational age (AGA), or SGA.  
A British study compared samples taken from birth to 14 days from 101 VLBW, AGA 
neonates with samples from 42 VLBW, SGA neonates (McIntosh, Kempson and Tyler, 1988).  
Initially, the SGA neonates had a higher haemoglobin and lower MCHC, whilst other red cell 
indices were similar.   Results beyond the first day were difficult to interpret because of red 
blood cell transfusion.  A more recent study compared cord blood samples from day 1 and 
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venous samples from day 7 from 73 term SGA neonates with 59 AGA term neonates 
(Ozyürek et al, 2006).  Not all cases had samples at both time points.  The SGA group initially 
had a higher haematocrit, RCC and MCV; but there were no significant differences in these 
by day 7.  The MCHC remained lower in the SGA group at both time points.   
Gestational age 
The improved survival of babies born prematurely and/or at LBW, or even at very low birth 
weight (VLBW), has made the development of reference ranges for this population a pressing 
clinical need.  The first study to investigate the effect of gestational age on red cell values in a 
systematic manner considered capillary samples from 125 neonates born from 24 weeks 
gestation to term (Zaizov and Matoth, 1976).  Although the numbers for each gestational 
period are small there was no appreciable change in the haemoglobin or haematocrit over 
this period.  However, the MCV gradually decreased from a mean 135 ± 0.2fl (mean ± SD) at 
24-25 weeks gestation to 119 ± 9.4fl at term with a corresponding increase in the RCC from 
4.65 ± 0.43 x1012/l at 24-25 weeks to 5.14 ± 0.7 x1012/l at term.  There was a parallel 
decrease in the reticulocyte count with increasing gestational age from 6.0 ± 0.5% at 24-25 
weeks to 3.2 ± 1.4% at term.   
A retrospective review designed to define haematological values in healthy, VLBW infants 
and to study the effect of gestation and race was published in 2000 (Alur et al, 2000).  
Results of arterial full blood counts obtained within 3 hours of birth from 188 healthy neonates 
born ≤31 weeks gestation were reported.  Babies deemed small for gestational age (SGA) 
were excluded.  The analysis considered three gestational groups: 23-25 weeks; 26-28 
weeks; and 29-31 weeks.  Haemoglobin and haematocrit increased, while MCV and MCH 
decreased, with increasing gestational age.  The RDW was similar for all three gestational 
groups.   
One of the first in the series of large scale retrospective reports from the Intermountain 
Healthcare Hospitals reported results from 12 016 neonates ranging from 22 to 42 weeks 
gestation, and provides an analysis of MCV, MCH and MCHC by gestational age 
(Christensen et al, 2008).  The MCV and the MCH decreased with advancing gestational age: 
the MCV falling from 119 ± 7fl (mean ± SD) at ≤ 25 weeks to 106 ± 4fl at 40 weeks.  Thus, 
even at term, the MCV is much higher than in adults with the average neonatal MCV being 
higher than the upper limit of normal for adults (Bain, 2002) – as had been noted first by 
Wintrobe almost 90 years earlier (Wintrobe, 1929b).  The MCH fell from 40 ± 2pg at 25 weeks 
gestation to 36 ± 2pg at 40 weeks.  The MCHC did not vary significantly with gestation.  In a 
review of their work the same group present these data afresh, with new graphs giving 
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mathematically smoothed curves for the MCV and MCH values by gestational age 
(Christensen et al, 2009).  Finally, in the study of neonatal haemoglobin and haematocrit, 
reported by Jopling, the large dataset was broken down into those born 29-34 weeks 
gestation and those born at 35-42 weeks gestation (Jopling et al, 2009).   Comparing values 
between the two groups the preterm infants initially had a lower haemoglobin and 
haematocrit.  The fall in both was also more rapid in this group so that values throughout the 
28 days remained lower than in the group of neonates born at 35-42 weeks gestation.               
Additionally, there are several reports of haematological values in fetuses, sampled in utero in 
order to establish antenatal diagnosis, for example of toxoplasmosis or haemophilia.  In the 
first, 409 pregnancies were studied (Forestier et al, 1986).  Results from 163 term babies with 
preceding fetal samples were used to construct fetal reference values (mean ± SD) for four 
gestational groups: 18-20 weeks; 21-22 weeks; 23-25 weeks; and 26-30 weeks.  Consistent 
with the more recent studies above, the HB and HCT rose with increased gestational age, 
while the MCV and MCH fell – the MCHC remained constant as the RCC increased.  The 
same group have since reported haematological values from a much larger dataset of 2860 
apparently normal fetuses (Forestier et al, 1991).  Again the haemoglobin, haematocrit and 
RCC rose with increasing gestation, while the MCV fell.        
Ethnicity 
The impact of ethnicity is not clear.  Red cell indices were reported for a Jamaican birth 
cohort of 243 children, none of whom had a haemoglobinopathy.  Sequential samples taken 
from birth onwards showed similar values for haemoglobin, RCC, MCV and MCH as well as a 
similar postnatal pattern of change (Serjeant et al, 1980).  However, differences were 
subsequently reported in two studies from Nigeria.  In the first, cord blood samples were 
collected from 100 term neonates and processed manually (Abdurrahman and Adekoje, 
1983).  The haemoglobin and haematocrit were both lower than published comparable values 
in Caucasian neonates.  The subsequent study, also from Nigeria, reported on venous 
samples from 99 healthy term babies taken at 1 day; 1, 2 and 6 weeks; 3 and 6 months 
(Ogala, 1986).  At birth the mean values ± SD were haemoglobin 16.2 ± 1.7 g/dl; haematocrit 
0.49 ± 0.05; RBC 4.88 ± 0.5 x1012/l; and MCV 101 ± 5.8 fl.  A similar pattern of postnatal 
change to that already described for RBC values was reported.  The lower absolute values of 
haemoglobin, haematocrit and RCC cannot be accounted for by sickle cell disease, as this 
was excluded.  However, the frequency of carrier status for α or β thalassaemia is thought to 
be as high as 25% in this population (Kotila et al, 2009).  The authors suggest that the lower 
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red cell values may be accounted for by lower socioeconomic status, endemic malaria, or 
racial differences.   
Several studies have been able to compare neonates from different ethnic groups within the 
same general population.  A retrospective review comparing arterial full blood counts 
obtained within 3 hours of birth in neonates born ≤31 weeks gestation in North America, 
reported statistically higher haemoglobin, haematocrit and MCV values in white compared 
with black infants (Alur et al, 2000).  However, there is little information about potential socio-
economic differences between the two groups.  Subsequently, a study designed to establish 
normative data for black VLBW neonates reported similar ranges to those already established 
in white neonates – although some of the red cell indices, notably the haemoglobin, were at 
the lower limits of the established ranges (Stancheva et al, 2002).   
Some of the best data on neonatal haematology reported from a non-Western country comes 
from a report by the HIV Prevention Trials Network who report haematological data from HIV 
uninfected women and their infants as a control group from five centres in Malawi, Tanzania 
and Zambia (Mwinga et al, 2009).  They report haemoglobin and haematocrit taken at birth 
from 1900 healthy term neonates and processed on an automated analyser.  The results are 
given as mean ± SD, and as a range with 95% CI: haemoglobin 18.5 ± 4.3g/dl (10.1-28.2) 
and haematocrit 0.548 ± 0.121 (0.297-0.802).  In contrast to the previous reports these are 
higher than results typically reported for Western populations.      
Nucleated red blood cells 
It is not unusual to find nucleated red blood cells (NRBC) in the peripheral blood of neonates 
(Lippman, 1924), and they are variously reported per unit blood volume (/mm3 or /l) or per 
100 WBC – the former being preferred due to variability in WBC.  A recent review of NRBC in 
neonates concluded that a high values were associated with prematurity, increased 
erythropoiesis from chronic hypoxia, anaemia, maternal diabetes, bone marrow stress 
causing premature release for example in infection, and from postnatal hypoxia for example 
from acute blood loss (Hermansen, 2001).  This also showed that the NRBC falls rapidly with 
increasing postnatal age, halving in the first twelve hours so that they have all but 
disappeared by the 3rd or 4th postnatal day.  Subsequently, a prospective study set up to 
establish neonatal reference ranges for NRBC reported cord blood values from 455 
premature and 240 term neonates.  In addition, this confirmed that the NRBC falls with 
increasing gestation and birth weight (Perrone et al, 2005).  The most recent reference 
ranges, and the largest data set, was published in 2010 after a retrospective analysis of 35 
396 neonatal computer records (Christensen et al, 2011).   
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2.6 White blood cell parameters in neonates 
  ‘Blood leucocyte counts in newborn babies have generally been considered to be so 
variable and unpredictable as to be of little value for clinical purposes’  
Marietta Xanthou, Neonatal Research Unit, Institute of Child Health, London. 1972   
  ‘special efforts [should] be made to develop leukocyte reference values for all ages, but 
especially in the pediatric age groups including neonatal and premature infants’ 
Hematology Resource Committee of the College of American Pathologists. 1978 
2.6.1 Development of reference ranges  
Of all the haematological parameters studied in neonates, the white blood cell (WBC) count 
and its differential have probably generated the most interest clinically – to the extent that the 
reference ranges are often referred to by name.  However, initial attempts to generate 
reference data were problematic.  One of the first of these was a study of the WBC and 
differential for 1081 children aged from birth to 15 years (Kato, 1935).  This showed a very 
high WBC and neutrophil count at birth which increased and peaked within 24 hours, before 
falling rapidly in the first few days.  The pattern for the rest of the neonatal period was quite 
variable, reflecting low numbers of neonates sampled at each stage.  Another study, 
published in the same year also showed a wide variation in the WBC during the neonatal 
period, with a reported range of 5-24 x109/l (Washburn, 1935).  The reported rapid changes 
with age, and the very wide ranges, caused some highly regarded authors in the field of 
neonatal haematology to conclude that attempts to define reference ranges in neonates were 
‘not only unnecessary here but might be more confusing than valuable’ (Smith, 1959; 
Wintrobe, 1967).     
An account of the total and differential WBC by Xanthou was published in 1970 (Xanthou, 
1970).  This reported serial counts, analysed on an automated counter, on 55 healthy term 
neonates, and a further 14 neonates with a birth weight <2500 grams – 13 of whom were 
born at <39 weeks gestation.  This was followed by a subsequent report of the WBC in ill 
neonates (Xanthou, 1972).   
The seminal paper defining reference ranges for normal blood neutrophil concentrations was 
reported in 1979 using data from 304 healthy neonates and 130 with perinatal complications 
unlikely to affect neutrophil count (Manroe et al, 1979).  These are still referred to by name as 
the ‘Manroe charts’.  In addition to providing reference data, this paper demonstrated the 
importance of the differential WBC – particularly neutropenia – in identifying neonates at risk 
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of bacterial disease and convincingly stated the case for the role of WBC analysis in the 
management of sick neonates.  Later the same group published neonatal reference ranges 
for lymphocyte, monocyte and eosinophil counts from the same cohort (Weinberg et al, 
1985), and then for neutrophil counts in a population of VLBW neonates (Mouzinho et al, 
1994).   These have both been widely regarded as the benchmark reference ranges for the 
respective populations.  However, this place has recently been challenged by a publication 
from the Intermountain Healthcare Hospitals which set out to compare the Manroe and 
Mouzinho ranges in a much larger sample size and using modern cell counting instruments 
(Schmutz et al, 2008).  In addition, they aimed to investigate the effect of high altitude.  The 
study reported results from 30 354 tests performed on neonates of 23-42 weeks gestation 
between 1 January 2004 and 31 May 2007.  They excluded neonates who were in a group 
known to be associated with an increased frequency of abnormal neutrophil counts, namely: 
those born to mothers with pregnancy induced hypertension; those with identified early onset 
bacterial sepsis; those with a subsequent diagnosis of congenital neutropenia; and those with 
trisomy 13, 18 or 21.  The ranges published by Schmutz are given as the 5th percentile value, 
the mean value and the 95th percentile value in order to offer the clinician a readily 
understandable expected range.  In contrast the Manroe and Mouzinho papers show the 
entire range of values as scatter plots.  Although neutrophilia would be diagnosed at a higher 
count, for example >13 x109/l at 72h compared with >7 x109/l using Manroe, neutropenia 
would be diagnosed similarly whether using Manroe or Schmutz for term and near term 
infants which agree on a diagnosis of neutropenia at a neutrophil count <2.5 x109/l after 72h 
or using Mouzinho or Schmutz for preterm neonates, at a neutrophil count <1 x109/l.   
 
 
 
Table 2-4. Summary of relevant reports of white blood cell count and differential counts in the general neonatal population. 
 
References 
Number of 
neonates 
Gestational 
age  
Timing of sampling 
Site of 
sample 
Country Indices reported
c 
Manner reported 
        
1970 Xanthou 69 55 term 
14 preterm 
every 6h for 24h (72h 
if term), daily until at 
least d20 (d10 if term) 
capillary UK neutrophil, metamyelocytes, 
eosinophils,basophils, lymphocytes, 
monocytes 
mean±1SD , 
graphs of mean±1SD, range 
v postnatal age 
1979 Gibson 38 27-35 at least once between 
d1-45 
capillary North 
America 
eosinophil graphs of mean±1SD, range 
v time from nadir weight 
1979 Manroe 304
a 
26-44 at least once between 
d1-28 
most 
capillary, 
few venous 
North 
America 
WBC
c
, neutrophils, I:T mean±2SD 
graphs of range v postnatal 
age 
1981 Bhat 45 <37 d1, then twice weekly 
until discharge 
not 
specified 
North 
America 
eosinophil count graphs of mean, SD and 
range by postnatal age   
1981 Lloyd 24 <33 1,12,24,48,72,96,120 
hours 
capillary UK mature and band neutrophils mean, median, range 
1984 Weinberg 210
a 
36 term 
174 preterm 
at least once between 
d1-28 
capillary North 
America 
monocytes, lymphocytes, eosinophils 5,50and95 percentile values  
graphs of range v postnatal 
age  
1985 Scott-
Emuakpor 
182
 
107 term  
40 preterm  
35 post-term 
d1, d7, 4
th
 week venous Nigeria WBC
c
, neutrophils, band forms, I:T, 
monocyte, lymphocyte, eosinophil, 
basophil 
WBC given as mean± 1SD 
differential values are given 
as mean and range 
1994 Mouzinho  135 29.9±2.3 
(1SD) 
at least once between 
d1-28 
capillary North 
America 
mature and immature neutrophils, I:T mean±1SD 
 
  
44 
 
References 
Number 
of 
neonates 
Gestational 
age  
Timing of 
sampling 
Site of 
sample 
Country Indices reported
c
 Manner reported 
1995 Schelonka 193 term d1 
 
capillary North 
America 
Mature and immature neutrophils, I:T mean, range with 10-90% CI  
2000 Özbek 95 term d1 capillary 
venous 
Turkey WBC
b
, neutrophils, monocyte, 
lymphocyte, eosinophil, basophil, 
metamyelocyte, myelocyte 
mean± 1SD, 
 
2003 Kayiran 141 term d7, d14, d21, d28 capillary 
venous 
Turkey WBC
b
, neutrophils, I:T, monocyte, 
lymphocyte, eosinophil, basophil, 
metamyelocyte, myelocyte 
Whether different in capillary 
cf venous sample only, no 
numerical value given  
2006 Őzyűrek 77
b 
term d7 venous Turkey WBC, neutrophils, I:M, I:T, monocytes, 
eosinophils, basophils, metamyelocytes, 
lymphocytes,  
mean±SE (range) 
2008 Schmutz 30354
 
22-42 wks at least once 
between d1-10 
not 
recorded 
North 
America 
Neutrophil, immature neutrophil mean± 1SD, graph with 95% 
CI, expected values by 
postnatal age  
2009 Mwinga 1897 term birth, 4-6 weeks not 
recorded 
Malawi, 
Tanzania, 
Zambia 
WBC mean± 1SD, 
and range with 95% CI, 
2009 
Christensen
b 
>30 354 22-42 wks at least once 
between d1-10 
not 
recorded 
North 
America 
Neutrophil graph with mean, 5
th
 and 95
th
 
percentile by gestational 
age, smoothed curves for 
MCV, MCH 
 
a. This study also reported on a further group of babies with perinatal complications. 
b. This group included appropriate for gestational age and small for gestational age neonates; samples were also taken from 109 neonates on d1, but as these were cord blood 
samples they are not included here. 
c. Italics indicate that this parameter was obtained by manual methods.  Regular type indicates that this parameter was obtained using an automated analyser. 
I:M immature : mature neutrophil ratio; I:T immature : total neutrophil ratio 
 
 
2.6.2 Factors affecting white blood cell indices  
Postnatal age 
Postnatal age was identified early on as a key factor affecting the WBC – and it was partly the 
rapid changes reported in the first few days of life that caused some to be suspicious of the 
clinical utility of the WBC.  In a cross-sectional study of WBC in children Kato found a high 
neutrophil count at birth, estimated mean at ~ 12.5 x109/l (Kato, 1935).  Moreover, the 
neutrophil count, and hence the WBC, then increased further peaking between 12 and 24 
hours with estimated mean neutrophil count ~15 x 109/l.  This then fell rapidly to a nadir at 
around the 4th postnatal day and the pattern for the rest of the neonatal period was quite 
variable, which probably reflects the small numbers of neonates sampled at each stage.   
In the paper by Xanthou the neutrophil count rose in all cases reaching a peak at 12 hours, 
followed by a gradual fall and then remaining stable from around the 10th day (Xanthou, 
1970).  The mean neutrophil count at birth and 12 hours in term compared with LBW babies 
respectively were 8 x109/l and 13 x109/l, compared with 5 x109/l and 8 x109/l.  The dramatic 
early increase in neutrophils is not accompanied by an increase in neutrophil precursors and 
is presumed to represent demargination of existing neutrophils. 
Manroe similarly reported a peak neutrophil count at 12-14 hours, then a fall to the 5th 
postnatal day and a plateau thereafter (Manroe et al, 1979).  The values are given graphically 
as a range with 95% CI.   The range of the neutrophil count during this plateau phase was 
very similar to that given by Xanthou: 1.8-5.4 x109/l compared with 1.8-5.5 x109/l.   Schmutz 
found that the timing of the peak neutrophil count varied with gestational age: occurring at 6-
8h in those born ≥ 28 weeks gestation compared with 24h if born  <28 weeks gestation.  In 
both groups the neutrophil count gradually fell over the first 72 hours of life, remaining stable 
thereafter (Schmutz et al, 2008). 
Sample site 
A comparison of the WBC from arterial, venous and capillary samples taken from the same 
healthy term neonates in a rapid sequential manner found that the mean arterial WBC and 
venous WBC were respectively 77% and 82% of the mean capillary value (Christensen and 
Rothstein, 1979).  This relationship was confirmed in two subsequent studies.  In the first, 60 
paired venous and capillary samples were taken from 30 healthy term neonates on the first 
and second day of life (Peevy, Grant and Hoff, 1982).  On both days the neutrophil count was 
significantly higher in capillary samples.  Similarly, in a study of 13 paired venous-capillary 
and 21 paired venous-arterial samples, the neutrophil count was respectively higher in 
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capillary than venous, and higher in venous than arterial samples (Thurlbeck and McIntosh, 
1987).   A more recent study of capillary-venous differences in the full blood counts of 95 
healthy term newborns taken within 24 hours of delivery reported a higher WBC in capillary 
compared with venous samples (Ozbek, Gürakan and Kayiran, 2000).  When the WBC 
differential was analysed it became apparent that the increase in capillary WBC was 
accounted for by an increase in neutrophils, which may tend to demarginate in the 
microcirculation.   
The main flaw in the three main papers on WBC reference ranges is that the source of the 
sample was not recorded (Manroe et al, 1979; Mouzinho et al, 1994; Schmutz et al, 2008).  
However, Schmutz considered that very few counts were likely to have been derived from 
arterial samples so that given the very large number of samples the effect was likely to be 
small. 
High altitude 
Studies examining the effect of high altitude have consistently reported that neutrophil counts 
increase with altitude (Carballo et al, 1991; Maynard, Reed and Kircher, 1993; Schmutz et al, 
2008).  The Intermountain Hospitals group suggest that this explains the higher upper limit 
they report as this is similar to the two earlier studies of neonates at high altitude (Carballo et 
al, 1991; Maynard, Reed and Kircher, 1993), despite differences in counting methods, but 
higher than the upper limit of the Manroe study which was at low altitude (Manroe et al, 
1979).  The mechanism underlying this is not understood, although it presumably relates to 
reduced oxygen delivery to the fetus at high altitude. 
Sex 
In contrast to previous studies, which had typically reported that there was no variation with 
sex, Schmutz found that neutrophil counts were significantly higher in females, although the 
reasons for this are unclear (Schmutz et al, 2008).   
Ethnicity 
It was recognised in the 1970s that neutrophil counts were lower in black compared with 
white Americans (Karayalcin, Rosner and Sawitsky, 1972) – but, it is not clear whether this is 
also true for neonates.  A Nigerian study reported serial WBC taken during the neonatal 
period from 107 term, 40 preterm and 35 post-term neonates (Scott-Emuakpor et al, 1985).  
Manual differential counts were done on 85, selected at random.  The mean WBC was high 
at 12.6 x109/l, with no difference between the groups of different gestational ages.  However, 
differential analysis indicated that the mean neutrophil count was lower at 5.7 x109/l and the 
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mean lymphocyte count higher at 5.1 x109/l than comparable values reported in Western 
populations.  In contrast, a study which compared the differential WBC of cord blood from 242 
neonates from five different ethnic groups reported no difference between any of the ethnic 
groups, and concluded that the differences observed in adults are acquired later (Chan, 
Hayes and Bain, 1985).  This is consistent with the very large Intermountain Healthcare 
Hospitals analysis which found no variation in the differential WBC count either between 
black and non-black, or Hispanic and non-Hispanic (Schmutz et al, 2008).   
Stress 
In a study designed to identify factors that might affect the WBC of neonates, Christensen, 
who almost 30 years later would be one of the pioneers of the Intermountain Healthcare 
Hospitals work on neonatal reference ranges, considered source of sample and the effect of 
crying (Christensen and Rothstein, 1979).  Arterial, venous and capillary samples were taken 
in a rapid sequential manner from neonates who had been ‘resting quietly for an hour’.  
Sampling was then repeated after one of three procedures likely to induce crying: 
circumcision, chest physiotherapy or heel prick testing.   The WBC increased after crying.  
The increase was most pronounced in neonates who had demonstrated violent crying, for 
example following circumcision, with a specific increase in immature neutrophils. 
Labour is considered to be stressful for the neonate, as well as for the mother.  Schmutz 
reported significantly higher neutrophil counts at 18 hours in neonates born after labour 
compared with those delivered by a labour-free caesarean section (Schmutz et al, 2008).  
The ratio of immature to total neutrophil count did not increase suggesting neutrophil 
demargination occurring as a rapid response to the release of stress induced 
catecholamines.    
Maternal pregnancy-induced hypertension 
Manroe found that 57% of neonates whose mothers had had hypertension during pregnancy 
had neutrophil counts below the reference range of the control neonates, while no values 
exceeded the reference range (Manroe et al, 1979).  This effect appeared to be limited to the 
first 72 hours, and was independent of gestation or birth weight.  The association between 
maternal hypertension and neonatal neutropenia has been confirmed in subsequent reports 
(Koenig and Christensen, 1989; Juul, Haynes and McPherson, 2004).     
Early-onset bacterial sepsis 
Two years after her work on WBC reference ranges in term and preterm neonates, Xanthou 
published the serial WBC counts of 35 ill preterm and term neonates taken throughout the 
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neonatal period (Xanthou, 1972).  The total WBC was not informative, but importantly, they 
found that in those with proven or suspected bacterial infection the absolute neutrophil count 
increased.  However, on closer inspection this was due to an increase of immature 
neutrophils or band forms and masked a significant fall in mature neutrophils to < 1.0 x109/l.  
The eosinophil count also fell in those with proven or suspected bacterial infection to 0 x109/l.  
Published immediately back-to-back with this report was a paper from Newcastle similarly 
describing neutropenia in three neonates with fatal bacterial sepsis (Gregory and Hey, 1972).    
The study by Manroe identified neutropenia (a neutrophil count below the reference range 
determined for healthy neonates in the same paper) as being the most important predictor of 
infection, with 77% neutropenic neonates having suspected or confirmed bacterial infection 
(Manroe et al, 1979).  In contrast, neutrophilia (a neutrophil count above the reference range 
determined for healthy neonates in the same paper) was less specific with only 58% 
neonates having suspected of confirmed bacterial infection.  Further, it was shown that an 
increase in the immature: total neutrophil ratio (I:T), and not the absolute number of immature 
forms, was predictive of infection.  The utility of the Manroe ranges in identifying neonates 
with sepsis was validated in subsequent reports (Benuck and David, 1983; Rodwell, Leslie 
and Tudehope, 1988).  However, it must be noted that Rosenfeld, the Professor of Pediatrics 
in the unit at the University of Texas which generated the Manroe ranges, was quick to 
emphasise that they had ‘never reported or suggested a “sepsis-scoring system”’ (Rosenfeld, 
1995).  He believed that the ranges were useful to assess serial FBCs in conjunction with the 
clinical course to inform decisions about discontinuing antibiotics, rather than in helping to 
diagnose neonatal sepsis. 
The recognition that neutropenia was frequent in healthy preterm babies when their counts 
were considered against the Manroe ranges, led to the publication of specific ranges for 
preterm neonates.  A study of the comparative usefulness of the Manroe and Mouzinho 
ranges in the diagnosis of sepsis in VLBW neonates was published – again by the same 
group – in 1997 (Engle et al, 1997).  This found that although deviations from the original 
Manroe ranges were more sensitive predictors of neonatal sepsis, deviations from the 
Mouzinho ranges were more specific.  Additionally, this paper suggested that the association 
with neutropenia and infection was most important in the first week of life, after which 
neutrophilia was more common with an increase in immature neutrophils and I:T.  Where 
neutropenia was associated with infection later on in the neonatal period it tended to be 
associated with Gram-negative infection. 
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Gestational age 
The study of WBC by Xanthou, had considered healthy term and premature babies, but 
differences between the groups were not described in detail and only 14 premature babies 
were included (158).  With the increasing survival of neonates at early gestation, it became 
apparent that, even in the absence of infection, preterm neonates often appeared to be 
neutropenic when considered against the Manroe charts (Lloyd and Oto, 1982; Mouzinho et 
al, 1992).  This led to the determination of reference ranges for neutrophil counts in 63 
preterm VLBW neonates with a mean gestational age of 29.9 weeks (Mouzinho et al, 1994).  
These confirmed that the neutrophil count was lower, and the ranges wider.  Interestingly, the 
reference ranges for immature neutrophils and I:T were very similar to the earlier reports from 
older preterm and term neonates.     
2.6.3 Specific considerations:  eosinophils, monocytes, basophils and lymphocytes 
Eosinophils 
An increase in the eosinophil count at one week and also an increase in the eosinophil count 
of premature compared with term neonates were described in the 1950s (Medoff and 
Barbero, 1950; Burrell, 1952).  In the paper by Xanthou the eosinophil count varied between 
healthy term and LBW neonates (Xanthou, 1970).  In term neonates the mean fell from >0.8 
x109/l in the first few days to 0.5 x109/l from the 4th day until the end of the neonatal period.  
The range also narrowed during this time.  In the LBW group the mean eosinophil count was 
<0.6 x109/l during the first week, rising to just over 1.0 x109/l at the end of the neonatal period.  
In a subsequent study of ill neonates, Xanthou reported eosinopenia in neonates with proven 
or probable infection (Xanthou, 1972).   
A study of the natural history of the eosinophil count in 38 healthy neonates all born <36 
weeks gestation found an eosinophilia (defined as eosinophil count >0.7 x109/l) in over three 
quarters of those studied (Gibson, Vaucher and Corrigan, 1979).  The eosinophil count 
tended to rise from ~day 19, reaching a peak after a week.  However, in those who had an 
infection this increase was halted and the eosinophil count was low.  A prospective study of 
45 premature neonates reported an association with eosinophilia and smaller, preterm 
neonates, parenteral nutrition, endotracheal intubation and blood transfusions (Bhat and 
Scanlon, 1981).  
Definitive reference ranges were published by Weinberg, reporting data from 848 counts 
taken from 479 neonates (Weinberg et al, 1985).  The reference ranges were given as the 5th-
95th percentile values for 0-60 hours, 61-120 hours and 121-720 hours.  These were 
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compared with counts from three groups of neonates who had a clinical condition known to 
affect the neutrophil count: 82 neonates with ABO incompatibility; 68 neonates with maternal 
hypertension; and, 140 with suspected or proven sepsis.  There were no significant 
differences reported with sex, birth weight or gestational age.  Eosinophil values were 
constant throughout the neonatal period, and consistent with earlier reports there was an 
early fall in eosinophils in those with suspected or proven sepsis.    
Finally, in their largest analysis to date the Intermountain Healthcare Hospitals group have 
published reference ranges based on 63 371 counts from neonates from 22 to 42 weeks 
gestation, taken throughout the neonatal period (Christensen et al, 2010).  The results were 
given as mean and 5-95% range.  These values for the counts on day 1 increased linearly 
with increasing age, with mean (range) for a 40 week gestation neonate of 0.55 x109/l (0.14 – 
1.3).  The values were stable throughout the neonatal period, with only a slight increase in the 
upper limit for the 4th week.              
Monocytes 
The monocyte count appears to be comparatively stable throughout the neonatal period, 
although several reports have suggested that it is slightly higher in the first 24 hours and then 
falls slightly over the first week, remaining stable thereafter (Xanthou, 1970; Weinberg et al, 
1985).  Monocyte counts were higher in neonates with suspected or proven sepsis, typically 
occurring during the recovery phase at the end of the neonatal period (Weinberg et al, 1985).  
The same study reported an increased monocyte count in the first few days in neonates with 
ABO incompatibility.   
Xanthou reported a slight rise in monocytes during the first 12 hours of life followed by a fall 
until the 3rd day and then a rise to the 7th day before levelling out from day 10 in both groups 
at ~ 1.0 x109/l, considerably higher than in adults (Xanthou, 1970).  The reference range 
produced by Christensen describes a linear increase in monocyte count with increasing 
gestational age (Christensen et al, 2010).  On the first day of life in a 40 week gestation 
neonate the mean (range) monocyte count was 1.4 x109/l (0.3-3.3).  The monocyte count 
increased slightly during the first two weeks of life. 
Lymphocytes 
The reference data published by Weinberg (Weinberg et al, 1985) was consistent with earlier 
reports (Kato, 1935; Xanthou, 1970) with regard to both value and pattern with a fall from the 
3rd day to the 5th day then rising to plateau at a slightly higher value than initially.  The 5th 
percentile value was lower and the 95th percentile higher for neonates with suspected or 
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proven sepsis.  There was also a lower lymphocyte count in children born to hypertensive 
mothers, but this effect only lasted for the first few days.   
Basophils 
There is little reported on the basophil count of neonates.  Xanthou reported that the pattern 
of change of basophils over time resembled that of eosinophils and stated that the number of 
basophils was low, but did not provide any figures (Xanthou, 1970).  There is an early, but 
very detailed report of the basophil count in 20 neonates on samples taken at birth, half an 
hour, 4 hours, 24 hours, then at 2, 3, 4, 5 and 7 days (Mitchell, 1955).  This reported a rapid 
rise in the basophil count over the first 24 hours followed by a rapid fall.  The peak count at 24 
hours was 0.52 x 109/l ± 0.28 (mean ± SD).     
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2.7 Platelet parameters in neonates 
For many years attempts to define neonatal reference ranges for platelets were hampered by 
inadequate manual techniques with very wide reported references ranges which were 
consequently of little clinical value (von Farnos, 1926).  In 1950 Brecher and Cronkite 
published a landmark paper, describing a demonstrably reproducible technique that is still 
used today as the standard means of obtaining a manual platelet count (Brecher and 
Cronkite, 1950).  The use of this technique to define reference ranges for neonates was 
reported in 1961 using modified phase microscopy on 204 paired capillary samples taken 
within 96 hours of birth from 105 healthy term neonates (Ablin et al, 1961).  The count was 
determined for each sample and the average for each pair was taken.  Although the trend 
was towards an increase with postnatal age, this was not significant, and the reported mean 
±2SD for the period was 200 ± 100 x103/mm3.  In 1973 Sell published reference data for a 
variety of haemostatic factors based on samples taken in the first 36 hours from 106 healthy 
neonates of varying gestational age, with a reported mean platelet count for term neonates of 
300x103/mm3.     
Automated counters improved accuracy further, although early analysers which relied on 
differentiating RBC from platelets according to size only, typically using a cut-off of 40 fl, 
would erroneously count giant platelets as RBC.  This would falsely increase the RCC – and 
thus the MCHC, whilst reducing the MCH – whilst giving a falsely low platelet count.  This 
problem has been addressed by more modern analysers which additionally use laser light 
scattering, flow cytometry and optical impedance to distinguish between RBC and platelets.  
The Intermountain Healthcare Hospitals have published neonatal reference data for platelets, 
based on the records of over 47 000 patients (Wiedmeier et al, 2009).  This report is taken as 
the definitive reference data set.     
The most relevant reports of platelet values in apparently healthy neonates are summarised 
in Table 2-5. 
 
 
Table 2-5.  Summary of relevant reports of reference platelet values in the general neonatal population. 
 
References Number of 
neonates 
Gestational 
age  
Timing of sampling Site of sample Country Indices reported Manner reported 
        
1987 Patrick 143 24 weeks -
term 
d1 
 
venous North America PLT count, MPV, PDW mean±1SD 
2000 Özbek 95 term d1 capillary 
venous 
Turkey PLT count, MPV mean± 1SD 
 
2003 Kayiran 141 term d7, d14, d21, d28 capillary 
venous 
Turkey PLT count, MPV mean± 1SD 
2006 Őzyűrek 77
a 
term d7 venous Turkey PLT count, MPV mean±SE (range) 
2009 Mwinga 1893 term birth, 4-6 weeks not recorded Malawi, 
Tanzania, 
Zambia 
PLT mean± 1SD, 
and range with 95% CI, 
2009 Wiedmeier 47291 22-42 weeks at least once between 
d1-90 
not recorded North America PLT count, MPV mean± 1SD, graph with 95% 
CI by gestational age and 
postnatal age 
2009 Christensen
b 
Not stated 22-42 weeks at least once between 
d1-28 
not recorded North America PLT count, MPV graph with mean, 5
th
 and 95
th
 
percentile by gestational age, 
smoothed curves for MCV, 
MCH 
        
 
 
2.7.1 Factors affecting neonatal platelet indices  
Postnatal age 
Both studies using the Brecher and Cronkite method on healthy term (Ablin et al, 1961) and 
healthy premature neonates showed a trend for the platelet count to increase during the 
neonatal period (Aballi, Puapondh and Desposito, 1968).  A similar rise in platelet count over 
the first 10 days of life was reported for venous samples from 60 healthy neonates with birth 
weight < 2500 grams (Appleyard and Brinton, 1971), and in a further group of 155 healthy 
neonates (Arad et al, 1986).  Another study comparing venous and arterial platelet counts in 
AGA and SGA neonates with birth weights <1000 grams reported a nadir at around the 4-5th 
postnatal day, before rising with age (McIntosh, Kempson and Tyler, 1988).  The nadir in the 
SGA neonates was just below 100 x109/l.   
One of the few non-Western papers is a prospective study of venous platelet counts in 
healthy term neonates in Thailand (Sasanakul et al, 1993).  This relied on the Brecher and 
Cronkite method, rather than automated counting.  There is a high incidence of 
haemoglobinopathy in this population, but as a visual methodology was used, it is assumed 
that cases with haemoglobinopathies were excluded (Wanapirak et al, 2004; Nathalang et al, 
2005).  Samples were analysed by postnatal age, and showed an initial plateau at ~280 
x109/l before a rise and then a slight fall.  However, the time intervals range from 12 hours to 
7 days so that the exact relationship with postnatal age is hard to determine.  A much larger 
non-Western study set up to look at the impact of HIV, reported platelet counts of 240.8 ± 
102.7 x109/l (mean ±SD) with range 76 – 458 x109/l (95% CI) in 1893 healthy control 
neonates based on samples taken at birth and using an automated counter (Mwinga et al, 
2009).        
A rise in platelet count during the neonatal period was demonstrated in a study comparing 
venous-capillary differences in 141 term neonates sampled at weekly intervals (Kayiran et al, 
2003), and in another study by the same group comparing SGA with AGA term neonates 
(Ozyürek et al, 2006).  However, the definitive contribution comes from the report by the 
Intermountain Healthcare Hospitals (Wiedmeier et al, 2009).  This shows an increased 
platelet count with increasing postnatal age to a peak at around day 15, followed by a slight 
fall to day 28.  The data is provided graphically: the mean count at birth is ~250 x109/l, rising 
to ~420 x109/l and then falling to ~320 x109/l at day 28.      
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Gestational age 
In response to a mixture of reports comparing term with premature neonates indicating similar 
(Fogel, Arias and Kung, 1968), slightly lower (Wolff and Goodfelllow, 1955) and very much 
lower platelet counts (Medoff, 1964) for the latter, a larger study reported results of 298 
healthy premature LBW and VLBW neonates, and 88 healthy term controls, using the 
Brecher and Cronkite method (Aballi, Puapondh and Desposito, 1968).  Samples were taken 
within the first 48 hours of life, and repeated during the second and fourth weeks for some of 
the premature neonates only.  The platelet count in the premature neonates was significantly 
lower (P<0.05) than in term neonates over the first 48 hours; but with a mean of 220 
x103/mm3 was not as dramatically low as some earlier reports had suggested.  Further, the 
authors concluded that a platelet counts of <100 x103/mm3 was an abnormal finding in a 
premature neonate.  The exact gestational ages are not given in the above studies.  
However, in a study looking at a variety of haemostatic factors in 106 healthy neonates, the 
platelet count within the first 36 hours was analysed by gestational age: 27-30 weeks; 31-33 
weeks; 34-36 weeks; 37-39 weeks and 40-42 weeks (Sell and Corrigan, 1973).  Interestingly, 
the platelets counts were similar for all gestational groups, with no significant variation.  The 
results are given graphically only, and appear to have a mean of between 250 and 300 
x103/mm3.  For many years these were regarded as standard reference data.  However, the 
numbers are small with only 8 neonates in most premature group. 
The reports of haematological values in fetuses mentioned above also included platelet 
counts.  In the first study of 163 fetuses, reference values are given for four gestational 
groups: 18-20 weeks; 21-22 weeks; 23-25 weeks; and 26-30 weeks.  There were no 
significant differences in platelet counts between these groups, with mean values of 242-259 
x109/l at all gestations (Forestier et al, 1986).  The subsequent larger dataset of 2860 
apparently normal fetuses reported similar mean values of 232-247 x109/l in fetuses from 18 
weeks gestation onwards (Forestier et al, 1991).  The largest dataset of over 47 000 
neonates ranging from 22-42 weeks gestation, reported that the platelet count rose with 
increasing gestational age from mean ~ 200 x109/l at 22 weeks to ~250 x109/l at term 
(Wiedmeier et al, 2009). 
There are a few studies which have considered platelet size and gestational age.   A study of 
27 term and 10 premature neonates did not show a significant difference in mean platelet 
volume between these groups, being 8.47 fl and 8.08 fl respectively (Kipper and Sieger, 
1982).  This study did show an association with thrombocytopenia and increasing mean 
platelet volume.   However, a larger study of 78 term and 65 premature neonates did show a 
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significant difference with a mean platelet volume of 9.06 ±0.82 fl (mean ± SD) for term and 
8.51 ±0.97 fl (mean ± SD)  for premature infants.  This conflicts with a study of 101 fetal blood 
samples taken in utero at intervals between 8-40 weeks gestation and using flow cytometry to 
calculate platelet size which demonstrated a fall in mean platelet volume with increasing 
gestational age (Meher-Homji et al, 1994).   
Birth weight 
A report of venous samples taken from 60 healthy neonates <2500 grams at days 1, 3, 5, 7, 
10, 14, 21 and 28 days found similar results to term neonates (Appleyard and Brinton, 1971).  
Another study compared results, taken during the first 14 days, from 143 neonates with birth 
weight <1000 grams: 101 were AGA, 42 were SGA (McIntosh, Kempson and Tyler, 1988).  
The mean platelet count was significantly lower in the SGA neonates.  The results are only 
given graphically, but indicate an initial count of >200 x109/l in the AGA compared with ~130 
x109/l in the SGA group.  In both groups the platelet count fell to a nadir at around the 4-5th 
postnatal day, before rising with age.  The nadir in the SGA was just below 100 x109/l.   
Another study designed to determine neonatal reference ranges for MPV, also reported on 
platelet count, and found a significantly higher count in 119 neonates with birth weight >2000 
grams at 323 ± 107 x103 /mm3 (mean ± SD) compared with 284 ± 114 x103 /mm3 (mean ± 
SD) in 36 neonates with birth weight <2000 grams (Arad et al, 1986).  A recent study 
compared venous counts in 64 SGA neonates with 45 AGA neonates (Ozyürek et al, 2006), 
reporting significantly higher platelet counts in the AGA group of 215 ± 6.0 x109/l (mean ± SE) 
compared with 182 ± 8.0 x109/l for the SGA group.  A similar trend was apparent in the 40 
SGA and 37 AGA neonates who were also sampled on day 7.  
The data on mean platelet volume and birth weight is scarce, but this was studied in a subset 
of 52 neonates with birth weight >2000 grams and 15 neonates with birth weight <2000 
grams (mean ± SD)(Arad et al, 1986).  The mean platelet volumes were 8.45 ±1.1 fl (mean ± 
SD) and 8.67 ±0.82 fl respectively.  Interestingly, the mean platelet volume increased over 
the first 20 days of life. 
Source of sample 
Capillary and venous platelet counts were compared in 95 healthy term neonates (Ozbek, 
Gürakan and Kayiran, 2000).  The results for the venous samples were significantly higher at 
213 ± 77 x109/l compared with 179 ± 68 x109/l for capillary samples taken simultaneously.  
The difference was most marked if there was also a high WBC.  The process of obtaining a 
capillary sample may induce platelet activation with consequent aggregation and a reduction 
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in count.  The same group subsequently published longitudinal data from a further 141 infants 
who were sampled at 7, 14, 21 or 28 days of age (Kayiran et al, 2003).  At all these times 
platelet counts from capillary samples were significantly lower than the corresponding venous 
count.       
Ethnicity 
A Nigerian study reported 633 platelet counts, determined by phase microscopy, for 338 
healthy term neonates on samples taken between 1 hour and 28 days (Effiong, Usanga and 
Mellits, 1976).  There was a rise during the neonatal period from 207 ± 72 x109/l (mean ± SD) 
during the first postnatal week to 282 ± 94 x109/l for the remaining three weeks.  A similar rise 
in platelet count was reported for neonates in Thailand (Sasanakul et al, 1993) and in the 
control group of the African study considering the impact of HIV (Mwinga et al, 2009).  The 
mean values in all three studies were comparable to those reported for Caucasian 
populations.  
Mean platelet volume 
As well as bringing a welcome accuracy and reproducibility to the measurement of 
haematological parameters the use of automated counters also extended the range of 
parameters that could be measured routinely.  One such parameter was the mean platelet 
volume (MPV), which became recognised as a predictor of the haemostatic potential of adult 
patients with severe thrombocytopenia (Bessman, Gilmer and Gardner, 1985).  An increased 
MPV is usually associated with increased thrombopoiesis.  The first paper on neonatal MPV 
determined by automated counting was published in 1982, reporting similar mean values for 
term and preterm neonates of 8.47 µ3 and 8.08 µ3 respectively (Kipper and Sieger, 1982).  
This was rapidly followed by a report aiming to provide neonatal reference ranges for MPV 
based on data from 155 neonates (Arad et al, 1986).  In these analyses, the group was 
broken down by weight with 119 having birth weight >2000 grams and 36 with birth weight 
<2000 grams.  Again, there was no significant difference in the mean MPV between the 
groups (8.67 +/- 1.03 µ3 and 8.89 +/- 1.10 , µ3 respectively), but the MPV rose in both with 
increasing postnatal age suggesting increased production of platelets in the early postnatal 
weeks.   
MPV was analysed by the Intermountain Healthcare Hospitals group who found that the MPV 
remained fairly constant from 22 to 42 weeks, with a numerically small but statistically 
significant fall with increasing gestational age (Wiedmeier et al, 2009).  The MPV rose over 
the first two postnatal weeks, with a subsequent slight fall to 28 days.  As before, the 
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published data is presented graphically, giving an estimated MPV a birth of 7.5 µ3 and a 
maximum 95th percentile value of 12 µ3 during the neonatal period. 
2.8 Blood cell morphology in neonates 
There is very little published peer-reviewed literature on the morphological appearances of 
blood cells in apparently healthy neonates using conventional microscopy.   
The red blood cell morphology of term and preterm infants has been compared with that of 
adults and children using interference-contrast microscopy (Holroyde, Oski and Gardner, 
1969).  Pits or craters were more common in the red blood cells of preterm and term infants 
compared with adults or older children, occurring in 47% preterm and 24% term infants 
compared with 3% of adults.  The frequency fell rapidly so that term infant values were similar 
to adults by 2 months of age.  Preterm infants took longer to reach adult values.  Interestingly, 
an inverse correlation was reported between birth weight and the number of pitted cells.  It 
was suggested that the pitted red blood cells indicated hyposplenism – or more broadly 
reduced reticuloendothelial function.    
A second study of neonatal red blood cell morphology described a technique using light 
microscopy and preparations fixed with 2% glutaraldehyde which was used to compare the 
red blood cells of term and preterm neonates with those of adults  (Zipursky et al, 1983).  This 
reported an increased incidence of abnormal shapes in the neonates with more bowl shaped 
and irregular red blood cells and fewer disc shaped cells compared with adults.  Zipursky 
identified a need for normative neonatal values to be determined. 
Coulombel used phase contrast microscopy to describe two distinct reticulocyte shapes: a 
multilobular and a cup-shaped form (Coulombel, Tchernia and Mohandas, 1979).  Sequential 
studies indicated that the multilobular form was immature compared with the mature cup-
shaped form, and it was only seen in the peripheral circulation where there had been 
erythropoietic stress.  Only the cup shaped form was seen in apparently healthy neonates.  In 
clinical practice supravital staining with cresyl blue is used to stain reticulocytes.  The results 
of manual reticulocyte counting were compared with results from an automated analyser 
(Advia 120) on samples from children >1 year old, term and preterm infants (Wiegand et al, 
2004).  The automated and manual results were similar for children >1 year old, but the 
automated analyser produced lower results than the manual for neonatal samples.  This 
appeared to be because there was an increase in very mature reticulocytes in the neonatal 
samples which did not retain sufficient stain for automated detection. 
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Red blood cell changes associated with hyposplenism are also recognised as a feature of 
neonatal blood morphology with Howell-Jolly bodies, acanthocytes and spherocytes being 
present (Bain, 2002).  Nucleated red blood cells are present in the first few days of life, but 
have disappeared by the fourth post-natal day in healthy term infants (Bain, 2002). 
There is very little written about white blood cell morphology, but in a paper looking at 
lymphocyte vacuolation used as a screening tool for children with possible metabolic disease 
it is noted that monocytes may show non-pathological cytoplasmic vacuolation – especially if 
there has been a delay in making the film (Anderson et al, 2005). 
Megakaryocytes are not commonly seen in the peripheral blood as they tend to be trapped in 
the fine capillary system due to their large size, and may just be visible as bare nuclei 
(Pedersen, 1978).  Megakaryocytes are relatively more common in neonates compared with 
older children and adults, although they are also seen post-partum, post-operatively, in 
infection, inflammation, malignancy, disseminated intravascular coagulation and in 
myeloproliferative disorders (Pedersen and Petersen, 1980; Tinggaard Pedersen and 
Laursen, 1983; Murray and Roberts, 1995).  There is an inverse relationship between post-
conceptual age and the percentage of megakaryocyte progenitors in peripheral blood 
(Saxonhouse et al, 2004).  The percentage of megakaryocyte progenitors also falls with 
increasing hypoxia (Saxonhouse et al, 2006). 
A study of nine healthy term neonates described the presence of micromegakaryocytes 
(Levine et al, 1996).  Over a third of all megakaryocytes had a diameter of <13 microns, and, 
in addition had reduced nuclear lobation despite being mature.  A preliminary study of 100 
healthy neonates measured the percentage of circulating megakaryoblasts in the peripheral 
blood, and reported that 0.02% cord blood nucleated cells were megakaryocytes (Bayliff et al, 
2003). 
Although there are a number of rare congenital syndromes associated with changes in 
platelet size and colour, there are no specific changes described in the healthy neonatal 
population.   
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2.9 Summary 
Reference ranges for haematological parameters in neonates are established (Ablin et al, 
1961; Matoth, Zaizov and Varsano, 1971; Manroe et al, 1979; Mouzinho et al, 1994) and 
historical standards are typically quoted in text books (Orkin and Nathan, 2009).  More 
recently, reference ranges based on very large data sets using computerised records for the 
Intermountain Healthcare Hospitals in North America have been published and these 
represent the most comprehensive data to date (Christensen et al, 2008; Schmutz et al, 
2008; Christensen et al, 2009; Wiedmeier et al, 2009; Jopling et al, 2009). 
The literature on factors associated with changes in haematological parameters in neonates 
is small, but associations with birth weight, gestational age and postnatal age in particular are 
well recognised.  Finally, the literature on blood cell morphology in neonates is very limited, 
although some specific features of blood cell morphology in neonates have been described.   
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 Chapter 3 Children with Down Syndrome Study: methods   
3.1 Introduction 
The first part of this chapter describes the feasibility assessment and development work that 
was required to determine how a birth cohort of children with DS might be set up within the 
context of the National Health Service (NHS) in the UK.  As there was no existing or historical 
cohort of this nature within the UK, a series of scoping exercises were required to understand 
the care pathways for a child with DS.   
The latter part of this chapter describes the study design, setting, participants, sample 
collection, data collection, sample management, data input and statistical analysis of the 
CDSS with regard to this thesis.  The complete study protocol is provided in Appendix 4. 
A timeline of this work for the study is shown in Figure 3-1.     
 
Figure 3-1. Timeline of the planning work involved in designing and establishing the CDSS.  
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3.2 Consultation phase 
3.2.1 Consultations with professional stakeholders 
Initial discussions about the proposal to study the haematology of children with DS from the 
neonatal stage onwards took place within a core group comprising of researchers from the 
Epidemiology and Cancer Statistics Group (ECSG; previously called the Epidemiology and 
Genetics Unit), and clinicians from the Leeds Teaching Hospitals (paediatric haematologists, 
a neonatologist and a community paediatrician).  Once a decision had been made to develop 
a study, contact was made with two key stakeholder groups within the UK: the Down 
Syndrome Association (DSA) and the Down Syndrome Medical Interest Group (DSMIG).  A 
series of meeting with the core group and with a medical representative from the DSMIG and 
a non-medical representative from the DSA then took place, with further email discussion 
between face to face meetings.   
In addition to discussion with individuals from the DSA and the DSMIG the study plans were 
presented in an interactive session of the Annual Scientific Meeting of the DSMIG on 
25/11/2005 attended predominantly by hospital and community paediatricians. 
3.2.2 Consultation with clinicians 
The next part of the consultation phase involved hospital paediatricians and neonatologists.  
The decision to work within the secondary care setting was predicated on the need to obtain 
blood samples from the neonatal period.  The aim of these consultations was to understand 
key points in the practice of clinician involved in the management of babies and children with 
DS, and to canvas their willingness to participate.  The emphasis was on understanding 
clinical practice and on listening to the experiences and observations of clinicians.   
At the time of setting up the study, there were 12 hospitals offering neonatal care within the 
Yorkshire area.  These are shown in Figure 3-2.   
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Figure 3-2. Map of the hospitals within the Yorkshire Neonatal Network. 
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The neonatal lead clinician at each of these hospitals was contacted, and a meeting 
requested with each of them.  In addition the study proposals were presented at a Forum 
Meeting of the Yorkshire Neonatal Network on 11/10/2005 attended by the neonatal lead 
clinician from each hospital in Yorkshire.  At each of these meetings the basic study aims 
were outlined and the following questions were asked: 
1. How and when do you make and give the diagnosis of DS to a family? 
2. Do you take a full blood count in the neonatal stage? 
3. What is the subsequent care pathway of a child diagnosed with DS in your hospital? 
4. When do they have blood tests taken in their early years?    
5. Would you be interested in participating in a study of babies and children with DS? 
3.2.3 Consultation with families 
Once there was agreement over the design and wording of the study literature, the final 
phase of the consultation process began.  This comprised of a series of informal meetings 
with families of children with DS to review and discuss the proposed study design and the 
literature.   
Twenty families with a child with DS who lived within a 20 mile radius of the study centre, 
were contacted by letter explaining what was proposed and asking if they were willing to 
review the study literature.  Of the twenty families invited to participate, ten families 
responded immediately to say that they would like to take part in the consultation.  All of the 
ten families chose to meet in their homes, and each spent several hours reviewing the study 
documents and discussing the study.   
Each meeting was a semi-structured interview which involved the following: 
1. Explanation of the study rationale and study design 
2. Family review of the study paperwork including the parent information sheets; parent 
consent forms and initial questionnaire; 
3. Family reflection on their experience of the newborn stage, particularly relating to 
communication and diagnosis; 
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4. Family opinion on whether they would have participated in such a study had it existed 
when their child was born.  
5. Family opportunity to suggest anything that they felt might be important or relevant 
that had been missed out; 
3.3 Key points emerging from consultations  
In addition to addressing the areas identified for discussion above, other strong themes 
emerged from the consultations.  These themes, along with the response to the specific 
areas for discussion, are considered below and their impact on the study design is described. 
3.3.1 Consultation with stakeholders 
The main outcome of discussions with the DSA and the DSMIG was their active support, 
especially in attending meetings during the study design process and their subsequent 
promotion of the study.  The stakeholders were particularly concerned with three areas of 
study design:  
Broadening the scope of the study 
Given the many important and unanswered questions relating to other aspects of health 
within this population, a decision was taken early on to broaden the scope of the study.  
Preference for a phased study 
It was very clear from discussions with the DSA and clinicians that they were concerned 
about how the newborn stage would be managed.  For most families the diagnosis of DS is 
unexpected: of the estimated 765 live births in England and Wales in 2009, 717/765 (94%) 
were postnatal diagnoses (Morris, 2010).  Individual families vary considerably in the 
responses they have to being told that their newborn baby has DS, but most experience 
varying degrees of associated negative feelings including grief, loss, anger, and sadness 
around the time of diagnosis (Hames, 1993; Skotko, 2005; Gath, 1985).  Hence, it would 
have been much easier to set up a study in which families of a child with DS were 
approached when they were beyond this initial period.  However, since a key aim was to 
collect biological samples in the neonatal period a way in which this could be done in an 
acceptable and sensitive manner needed to be negotiated.   
After lengthy discussions it was decided that a phased process would be more appropriate.  It 
was agreed that in the newborn period, when families were most vulnerable, the minimum 
amount of information and samples needed would be requested.  However, the ‘door would 
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be left open’ so that we could subsequently go back to families to invite them to take part in 
the next part of the study when their child was a little older.  The newborn stage is therefore 
essentially a cross-sectional study of neonates with DS, whilst the follow up group is a 
prospective cohort study of DS neonates. 
Preference for local recruitment  
Various possibilities for recruiting the children were considered.  One option was to have one 
person, who would represent the study and was from outside the hospital setting, who would 
move from hospital to hospital to invite families to take part at the request of the local 
clinician.  However, this idea was rejected as it was thought to be more appropriate for the 
study to be discussed with the family by the local clinical team with whom they already had a 
relationship.  This avoided the family having to meet another new face, at a potentially difficult 
time, and would also mean that there was no time pressure surrounding the discussions 
about the study.  The fact that there were likely to be a series of meetings between the 
clinician and family lent itself well to introducing the study, as there would be subsequent 
natural opportunities for the family to ask questions and discuss the study further.   
3.3.2 Consultation with clinicians 
The areas addressed with clinicians are all discussed in detail below. 
Making and giving the diagnosis 
Most babies are diagnosed with DS in the first few days after birth, and whilst they are still in 
hospital.  The phenotypic features of DS may be recognised by a midwife, doctor or parent 
leading to further examination and cytogenetic testing to confirm the presence of a somatic 
trisomy 21.  The stage at which a diagnosis of DS was likely to be made differed between the 
individual clinicians, with most preferring to have cytogenetic confirmation before making the 
diagnosis.  All clinicians said that the child would stay in hospital pending the cytogenetic 
results - which usually took 48 hours - unless there were extenuating circumstances.  Once 
the diagnosis of DS was clear this was usually discussed with the family by a senior clinician, 
often a Consultant Paediatrician.  There then tended to be a series of meetings with the 
family on several occasions to discuss the diagnosis and its implications.   
Although most clinicians usually waited for cytogenetic confirmation to give a definite 
diagnosis of DS, it was clear that in some cases a clinical diagnosis was made.  It was 
therefore left to the clinician to decide at which stage they thought a diagnosis of DS was 
certain, and to decide when discussions about the study were appropriate.  
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Taking a full blood count in the neonatal period 
It was normal practice in all twelve hospitals for neonates with a suspected diagnosis of DS to 
have blood taken for cytogenetic testing to confirm the diagnosis, even in cases where an 
antenatal diagnosis had already been made.  Most clinicians agreed on the clinical features 
of a sick neonate that would prompt taking an additional blood sample for a full blood count.  
However, in the majority of babies these features are not present and consultation revealed a 
wide variation in practice as to whether a routine full blood count sample was be taken in an 
apparently  well neonate.  Practice varied between hospitals and also between clinicians in 
the same hospital.  There was no hospital in which clinicians all routinely checked a full blood 
count in all neonates with DS.  Only a minority of paediatricians were aware of transient 
myeloproliferative disorder (TMD) and its ramifications, and those that were tended to be the 
ones who had previously managed a child with the disease.   
Care pathways following diagnosis 
Arrangements for following up a child with DS tended to be informal.  The initial care would 
be led by the consultant on call, who was variably a neonatologist or general paediatrician 
depending on the composition of consultants on the on call rota.  This consultant might 
continue to manage the child throughout their childhood, or might refer the child on to a 
colleague during the diagnostic process, on discharge from hospital, during the first or second 
year of life, or once they had successfully come through management of a particular clinical 
problem.  The consultant colleague then responsible for care was variably a hospital or 
community paediatrician who might or might not have a special interest in neurodisability or 
Downs syndrome.  The different pathways are described in Figure 3-3. 
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Figure 3-3. Carepathways for children following a diagnosis of DS. 
 
Taking blood tests during the early years 
The DSMIG provide guidelines for the management of children with DS, available on their 
website and also in specific inserts which fit in the Personal Child Healthcare Record (PCHR) 
– the PCHR is a book given to a child’s parents/carers on their birth which is used to record 
growth, development, and use of health services.  The DSMIG recommends that the inserts 
are given to every family once a diagnosis of DS is made (Appendix 5).  The guidelines 
recommend that a yearly blood sample is taken for thyroid function testing in areas where 
finger-prick testing is available.  This applies to most hospitals in the region.  Where finger-
prick testing is not possible a minimum schedule of blood tests at 12 months, 3-3½ years and 
5 years is recommended.   
Although all clinicians in the twelve hospitals were aware of the DSMIG inserts provided for 
the PCHR, awareness of the content of the guidelines provided in these was variable and 
adherence to them appeared to be low.  Prior to the consultation with the clinicians it had 
been supposed that most children would be having routine annual blood tests, when an extra 
sample could be taken for the study.  It was decided that the aim would still be to take an 
opportunistic sample when the ‘routine’ bloods were taken, but it was recognised that these 
may be less frequent than at first expected.  
Consultant on call when 
diagnosis of DS suggested – 
variably a neonatologist or 
hospital paediatrician 
Child referred to another 
consultant during initial 
admission   
Child followed up by new 
consultant – variably a 
hospital or community 
paediatrician with or 
without a special interest in 
DS or neurodisability 
Child referred to another 
consultant on discharge 
Child referred to another 
consultant after period of 
follow-up 
Child stays under the care of 
the same consultant  
Child followed up 
throughout childhood by 
original consultant 
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Willingness to participate in the proposed study 
All the clinicians across the 12 hospitals were keen to participate, and agreed to assign a lead 
clinician for each hospital. In one Trust where the study was presented at a joint meeting of 
two hospitals in the Trust some of the clinicians from one of the hospitals had already been 
taking part.  At this meeting one of the senior paediatricians commented that he did not like 
studies as a rule, but had found this one easy to discuss and that the families had found it a 
positive support.  The outcome of the contact with each hospital is outlined in Table 3-1. 
Table 3-1. Willingness of clinicians in the Yorkshire Neonatal Network to participate. 
Hospital Initial response Outcome 
Airedale General 
Hospital 
Invitation to present the 
study at  the paediatric 
consultants’ meeting on 
05/12/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
Bradford Royal 
Infirmary 
Invitation to present the 
study to the neonatal lead 
clinician and to the lead for 
DS on 21/9/05 
Agreement to participate after further email 
discussion and study lead appointed  
Calderdale Royal 
Hospital 
Immediate agreement to 
participate from the 
Neonatal Lead Clinician  
Study lead agreed in advance of presentation. The 
earliest date that could be set to present the study 
to the department was 18/06/06. 
Dewsbury and 
District Hospital 
Invitation to present the 
study to the paediatric 
consultants on 18/11/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
Harrogate District 
General Hospital 
Invitation to present the 
study to the paediatric 
departmental meeting on 
3/11/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
Huddersfield Royal 
Infirmary 
Invitation to meet the 
neurodisability lead on 
26/09/05  
Agreement to take part after discussion with 
paediatric consultant colleagues and study lead 
appointed.  Subsequent study presentation to joint 
meeting with Calderdale Royal Hospital on 
18/06/06  
Hull Royal Infirmary 
Invitation to present the 
study to all the paediatric 
consultants on 7/12/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
Leeds General 
Infirmary 
Invitation to present the 
study to the neonatal 
departmental meeting on 
21/11/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed. 
Subsequent meeting also with the antenatal 
screening coordinator on 21/11/05 
Pontefract General 
Infirmary 
Invitation to present the 
study to the paediatric 
departmental meeting on 
07/02/06 
Departmental agreement to take part at the end of 
the presentation and study lead appointed  
St James’s 
University Hospital 
Invitation to present the 
study to the neonatal 
departmental meeting on 
7/11/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
Scarborough District 
General Hospital 
Invitation to meet the 
Neonatal Lead Clinician on 
28/11/05 
Agreement to take part at the end  the meeting 
and study lead appointed 
York District 
General Hospital 
Invitation to present the 
study to the departmental 
meeting on 11/11/05 
Departmental agreement to take part at the end of 
the presentation and study lead appointed 
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Study co-ordination 
Many clinicians were concerned about the workload that the study might entail for them.  
Although the initial introduction to the study occurred in the clinical setting, the study was set 
up so that subsequent communication occurred directly between the families and the study 
centre.  A minimum amount of information was requested from the clinician at entry, primarily 
to ensure the information needed to identify the child, parents, referring clinician and general 
practitioner was correctly recorded.  Thereafter, the families interact directly with the study 
centre.  Families choose the pace at which they take part in the study allowing for the 
differences in adjustments to the diagnosis, and for the practicalities of managing a newborn 
– especially one who may have pressing medical needs.  Similarly, blood sampling kits for 
taking the samples during follow up are sent directly to the families who are then responsible 
for taking the kit to the relevant appointment. 
Communication of results 
Many of the clinicians expressed a wish for the results of the neonatal full blood count 
analysis to be fed back to them.  If a child was unwell and a full blood count was indicated 
clinically then this would be done immediately anyway and processed independently of the 
study in the hospital laboratory as usual.  However, clinicians said they would find it useful to 
identify apparently well neonates who might have a haematological abnormality, especially 
TMD.  In this case the full blood count result was not urgent, although it was important and 
the consensus was that it would be helpful for the neonatal full blood count result to be fed 
back to the clinician.  It was agreed that results of the subsequent blood tests would only be 
fed back if there was a concern from the study centre. 
3.3.3 Consultation with families 
This phase of the consultation was very significant as, although representatives from the DSA 
and the DSMIG had been involved from the start, it marked the first time that families had 
been directly approached.  In the course of developing the study a number of different people 
had expressed their opinion that, however important such a study might be, it would be 
practically too difficult to achieve given the sensitivities in approaching families with a 
newborn child diagnosed with DS.  It was therefore very encouraging that the family 
consultation found overwhelming support for the study from families who had been in such a 
position very recently themselves.  Several families expressed a view that we could ask for 
participation in the follow up right from the start, although the majority view was that the 
staged process was sensible.  Minor amendments to the wording of the study literature were 
made. 
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3.3.4 Summary of changes to study design following consultation  
1. The scope of the study was broadened to include other aspects of health;  
2. Participation was phased with newborn and follow up stages; 
3. Recruitment would be by a clinician already known to the family; 
4. Cytogenetic confirmation of DS was not required if a firm clinical diagnosis had been 
made; 
5. The amount of paperwork required from the local clinician would be kept to a minimum; 
6. The result of neonatal full blood count would be fed back to the clinician. 
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3.4 Study design 
3.4.1 Study type 
The CDSS is an observational birth cohort with two parts: a cross-sectional study during the 
neonatal period and a longitudinal study during the early years.  
3.4.2 Pilot phase 
The pilot phase ran from May 2006 to December 2006 inclusive and took place primarily 
within the Yorkshire Neonatal Network. The aim of this phase was to test the study design in 
a limited setting where there were existing links with the clinicians and hospitals.  The 
progress of the pilot phase up to 31/12/2006 was reviewed at a core group meeting on 
03/01/2007. 
3.4.3 Ethical permission 
Ethical approval for the study was granted by the Research Ethics Committee for Wales in 
March 2006: 06/MRE09/16.  This approval included site specific exemption.   
3.4.4 UKCRN Portfolio status 
The UK Clinical Research Network (UKCRN) is part of the National Institute for Health 
Research, which was created in 2006 as part of a major restructuring exercise aimed at 
developing and streamlining clinical research.  A central strategy is the recognition of well-
designed studies and the provision of an infrastructure to support these within the context of 
the local National Health Service.  The CDSS was registered as an UKCRN Portfolio study in 
April 2008 (Study ID 3088). 
3.5 Study setting 
Within the NHS managed clinical networks for neonatal care were established in 2004 
following the model of managed networks for cancer.  Each Neonatal Network 
(www.bapm.org/networks_info/) contains around 8-12 hospitals.  The initial study area was 
restricted to the 5 Neonatal Network areas most accessible from Leeds and York.  During the 
pilot phase the Trent Neonatal Network asked to participate in the study.  The CDSS was 
piloted in the Yorkshire Neonatal Network before being rolled out to five more Neonatal 
Networks: Northern, Greater Manchester, Cheshire and Merseyside, North Trent and Trent.  
The geographical target area is show in Figure 3-4.  
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Figure 3-4. Map of the target area for the CDSS. 
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Although most babies are born in a hospital maternity unit with an on-site neonatal service, 
this is not always the case.  There are some stand-alone maternity units which rely on 
neonatal support from another site – Wansbeck is an example of this, being supported by the 
Royal Victoria Infirmary in Newcastle.  In this case the stand-alone maternity unit was aware 
of the study taking place in the linked neonatal department.  Additionally, some babies are 
born at home.  Once the possibility of a diagnosis of DS was raised for a baby delivered at 
home they would be referred to the local neonatal service.  During the course of the study 
maternity units at Bishop Auckland, Huddersfield Royal Infirmary and at Trafford General 
Hospital closed down due to NHS reorganisation.   
In order to set the study up in an individual hospital contact was made with a clinician in each 
hospital, introducing the study and requesting an opportunity to present the study, usually to a 
paediatric departmental meeting.  Once a centre had confirmed that they wished to 
participate and a study lead had been appointed the relevant approval was sought from the 
local research and development department.  
3.6 Participants 
All children born with DS from 1st May 2006 onwards were eligible to take part in the newborn 
stage.  A minority of babies with DS are diagnosed prenatally - around 6% in 2009.  Families 
with a prenatal diagnosis of DS were not approached before birth.  
3.6.1 Identification of participants: newborn stage 
Identification of cases, approach and recruitment into the newborn stage typically took place 
after birth and prior to hospital discharge.  A supply of CDSS newborn entry packs was 
provided to each participating hospital to be kept readily accessible in the appropriate clinical 
area.  The contents of the CDSS newborn entry packs are shown in appendix 5.  When a 
newborn was identified as probably having a diagnosis of DS, and therefore being eligible for 
the study, a newborn entry pack was opened and an alert card completed.  The alert cards 
were prepaid cards addressed to the ECSG.  They did not have any personal information on, 
but functioned as a means to improve communication and thus recruitment rates, and also as 
a possible means of estimating participation rates.  
When appropriate the study was discussed with the family by a member of the clinical team 
looking after the child.  This was not necessarily the local study lead, but was a health 
professional closely involved in the care of the child.  At this stage families were given written 
information about the study provided in the CDSS newborn entry pack.  This written 
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information included the ‘parent information sheet – newborn’, and the ‘parental consent form 
– newborn’.  These are provided in Appendix 6. 
As well as explaining why, how and where the study was being done, the information sheet 
contained contact details should families have any queries.  These included a “freephone” 
number, an email address, the study website, and also a postal address. 
On the ‘parental consent form – newborn’ families were asked for permission to allow: 
1. A full blood count sample from their child to be sent for full blood count analysis and 
storage; 
2. Access to the medical records of the mother that pertained to the pregnancy and birth 
of the index child;   
3. Their GP and Health Visitor to be informed that they are taking part in the study 
4. The study centre to approach the family at a later date in order to discuss the next 
stage of the study. 
Families could opt out of any of the above and still participate.  The consent form was 
provided in triplicate - one copy for parents, one copy for the medical notes, and one copy to 
be returned to ECSG in a prepaid addressed envelope provided in the pack.   
The pathway for the newborn stage is described in Figure 3-5. 
 
Figure 3-5. Initial pathway into the CDSS. 
Newborn with DS 
identified  by  
clinician 
•alert card sent to 
the ECSG 
•CDSS discussed 
with the family 
Consent to take 
part in the CDSS 
given by the family  
•consent form sent 
to ECSG with 
hospital referral 
form 
•copies of consent 
form to notes and 
family 
Blood sample sent to 
CDSS haematology 
laboratory 
•fresh sample 
taken if family 
willing 
•or stored sample 
sent if <24 hours 
old 
•or no sample 
taken 
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3.6.2 Action taken after initial recruitment 
Once the ‘parental consent form – newborn’ had been received at the study centre a letter 
was sent to the hospital consultant to confirm that the child had been entered into the study.  
An information sheet about the CDSS and a copy of the full blood count result, where 
relevant, were also enclosed.  A letter was also sent to the child’s general practitioner to 
inform them that the child had been entered into the study, along with an information sheet 
regarding the CDSS and a copy of the newborn consent form.  A letter was also sent to each 
family on receipt of the ‘parental consent form – newborn’ to thank them for their involvement.  
The pathway following initial recruitment is shown in Figure 3-6.   
During the pilot phase of the study contact was made with the general practitioner or hospital 
clinician, when the child was around three months of age, to confirm that it was still 
appropriate to approach the family again.  Once confirmation was received the family were 
sent: a letter inviting them to join the follow up, an information sheet with further information 
about the study, and a basic questionnaire.  Following review of the pilot phase this process 
was amended so that families were sent a prepaid addressed card for them to return if they 
would like further information about the follow up stage as part of the initial letter they 
received thanking them for their participation in the newborn phase so that those who wished 
could join straight away.  If a card had not been received from the family then they would be 
contacted at the four month stage.  
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Figure 3-6. Study pathway following recruitment into the neonatal stage. 
 
3.6.3 Identification of participants: follow up   
Once a request for further information about the follow up study was received, the family were 
sent a ‘study information leaflet – follow up’ and a ‘parental consent form – follow up’ along 
with an explanatory letter.   All the literature for the CDSS is publically available on the 
website: www.cdss.org.uk. 
On the ‘parental consent form – follow up’ families were asked for permission to allow: 
1. Questionnaires about the child’s health and background to be sent out;  
2. Access to the child’s hospital records; 
3. Access to the child’s records held by the general practitioner and by the health visitor; 
4. Additional blood samples to be taken when the child was having a routine blood test; 
5. A buccal swab to be taken.  
Families were asked to complete the consent form, indicating which parts of the study they 
would like to take part in, and then to return the form in the prepaid addressed envelope 
provided.   
Family participate in 
newborn stage  
Letter to GP:  
informed about entry to CDSS 
study information sheet 
copy of consent form 
 
Letter to clinician: 
entry into CDSS confirmed 
study information sheet 
copy of full blood count results 
 
Letter to family: 
thanked for participation  
card to return to request information about 
follow up stage 
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3.7 Sample collection 
A blood sample kit was provided in the CDSS newborn entry pack.  This comprised of an 
EDTA tube, a form for the laboratory, and a prepaid addressed envelope so that it could be 
sent directly to the designated haematology laboratory for analysis.  The form accompanying 
the sample requested information about the child’s full name, date of birth, gender, hospital 
number, name of the sending hospital, name of clinician taking the sample, source of sample 
(venous or capillary), the date the sample was taken and the time at which the sample was 
taken.  Where possible it was requested that a fresh full blood count sample was taken in the 
EDTA tube provided.  If permission to take a fresh sample was not granted, but if there was a 
recent sample in the local hospital laboratory then this was retrieved and sent in the envelope 
provided.   
Subsequent blood samples were taken during the follow up stage when the child was having 
routine blood tests.  The DSMIG guidelines recommend that blood tests are taken annually to 
monitor thyroid function.  The packs for blood sample collection were sent directly to families.  
The packs contain an EDTA tube, a form and a pre-paid addressed envelope for return to the 
designated haematology laboratory.  Families were asked to take the pack to the clinic when 
a blood test was due and to then post it directly to the haematology laboratory in the pre-paid 
addressed envelope provided. 
3.8 Data collection 
3.8.1 Hospital referral form 
Socio-demographic information about children in the newborn stage was initially obtained 
from the ‘hospital referral form’ contained within the newborn entry pack.   Details requested 
included:  
1. Child’s full name, date of birth, sex, NHS number and hospital number; 
2. Mother’s full name and hospital number; 
3. Contact details for the child’s GP and paediatrician; 
4. Child’s birth weight and gestational age. 
This is the only paperwork that the clinicians were required to complete, and from this point 
on the study centre liaised directly with families.  A copy of the hospital referral form is 
provided in Appendix 6.  
79 
 
3.8.2 Initial questionnaire 
A questionnaire was sent to the family soon after recruitment.  This requested the following 
information: 
1. Address, postcode, telephone numbers and email address; 
2. Child’s full name, date of birth, sex, NHS number; 
3. Mother and father’s full names, dates of birth and NHS numbers; 
4. Contact details for the child’s GP and paediatrician; 
5. Details of the hospital attended for maternity care, and maternity number; 
6. Details of the hospital where the child was born, if different; 
7. Child’s birth weight, gestational age, mode of feeding and details of any admission to a 
Special Care Baby Unit or Neonatal Intensive Care Unit. 
In addition, there was a section for free text.  A key function of this was to ensure that all the 
family and medical contact details are up to date.  This latter is particularly important where 
the child was under the care of clinicians in a variety of health care settings so that when the 
abstraction of medical records starts all the relevant records will be accessed.   
3.8.3 Abstraction from medical records 
More detailed information will be abstracted from medical records, which include the 
obstetric, neonatal, general practitioner and health visitor records.  This will include socio-
demographic data as well as information on clinical status.  Studies of mortality in children 
with DS have shown that approximately 5-10% will die in the first year of life (Leonard et al, 
2000; Frid et al, 2004).  With this in mind the process of accessing hospital medical records in 
order to abstract medical information has already been started by ECSG staff.  This is also 
important as it can be difficult to retrieve hospital obstetric and neonatal records once an 
admission has been completed – and indeed in some hospitals records are being 
electronically archived soon after discharge if they are no longer considered as being ‘active’.  
The ECSG has experience of abstraction from other studies and has developed abstraction 
forms specifically designed for this setting. 
General practitioner and health visitor records are not archived in the same way as hospital 
records.  In order to make this process most efficient, this part of the abstraction will start 
once the children are 5 years old.    
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3.9 Sample management 
3.9.1 Processing of neonatal blood samples 
Neonatal blood samples were initially analysed at the haematology laboratory in St James’ 
University Hospital (SJUH), using an Advia 2120.  In October 2006 the location changed to 
the haematology laboratory at York Hospital (YH) where the samples were processed on a 
Sysmex XE2100.  A standard operating procedure for processing the samples was followed 
by the haematology laboratory (Appendix 7).  Both the haematology laboratories have full 
CPA accreditation (Appendix 2) and complete regular external quality assessment, co-
coordinated by the UK NEQAS Scheme for Haematology (Appendix 3).   
As part of the standard operating procedure three blood films were made on all neonatal 
blood samples upon arrival in the haematology laboratory, initially at SJUH, and then from 
October 2006 at York Hospital.  One of these slides was stained and two slides were left 
unstained.  The haematology laboratory at SJUH uses a Leishman stain, and a May-
Grünwald-Giemsa stain is used at York Hospital (Lewis et al, 2006).  Each stained slide was 
reviewed using the morphology review tool designed for the CDSS.    
After collection from the haematology laboratory, the remaining EDTA sample is stored at -
80°c and the three blood film slides made in the haematology laboratory were stored at room 
temperature in the University of York.  
3.9.2 Processing of follow up blood samples 
Follow up blood samples are all sent to the haematology laboratory at YH where they were 
processed on a Sysmex XE2100.  Again, three slides are made for morphological review.  
The remaining EDTA sample and the three blood film slides made in the haematology 
laboratory were then collected from the haematology laboratory and stored at -80°c in the 
University of York. 
3.10 Data management 
3.10.1 Data management 
All children enrolled in the study have been given a unique identifier.  Data and information 
collected throughout the study along with results of sample analysis is held in a secure 
database.  All questionnaires and additional paperwork is stored appropriately in locked 
cabinets for future use. 
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3.10.2 Data entry 
A database was designed specifically for the CDSS using a Microsoft Access interface and 
SQL server data storage.  More recently, a web-based interface was developed by ECSG 
staff.  The database records and links all the socio-demographic and clinical data for a study 
participant with information from their biological samples.  Data entry was performed by 
different members of the ESCG staff.  
3.11 Dissemination of information 
3.11.1 Feedback to clinicians 
The only result to be fed back to the clinician was the result of the neonatal full blood count 
analysis.  Clinicians were not routinely informed about subsequent results unless these were 
suggestive of a problem that might require clinical management in which case the result was 
discussed with a paediatric haematologist at the Regional Centre for Paediatric Haematology 
at Leeds General Infirmary and appropriate action taken. In order to standardise the 
procedure for referral to the Regional Centre for Paediatric Haematology a list of triggers for 
referral for a clinical opinion was drawn up (Appendix 8).  In cases where results met these 
criteria the hospital clinician was contacted and informed so that they could take things 
forward as clinically appropriate.  Regular progress reports about the study were produced for 
the lead clinicians in each hospital, and these were disseminated by email. 
3.11.2 Website and family forum 
Individual results were not fed back to families.  Instead, information about the study 
progress and about presentations or publications was made publically available on the study 
website (www.cdss.org.uk).  In addition, families taking part in the CDSS were also able to 
access a password protected message forum. 
3.12 Statistical analysis 
3.12.1 Neonatal full blood count analysis  
Analysis was restricted to full blood count results from children born between 1st May 2006 
and 1st October 2011 with a sample taken at ≤ 28 days of age.  Where multiple results were 
available for the same child only the first set of results meeting these criteria was included.  
The full blood count parameters studied were haemoglobin, haematocrit, red cell count, mean 
cell haemoglobin, mean red cell volume, nucleated red blood cell count , white blood cell 
count, neutrophil, lymphocyte, monocyte, eosinophil and basophil count, platelet count and 
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mean platelet volume.  Mean (95% CI) and ranges (5, 95% percentiles) were determined for 
each parameter.   
Regression analyses examining potential associations with birth weight, gestational age, 
postnatal age and sampling to processing interval on each of the full blood count parameters 
were assessed using a linear regression model (the Genmod procedure, The SAS System 
v9.2, SAS Institute, Cary, NC, USA) with non-linear effects assessed by the addition of a 
centred quadratic term for the factor under investigation to the model.  Associations with birth 
weight and gestational age were assessed only in children sampled in the first seven days of 
life, adjusting for age at sampling.  The effect of the sampling to processing interval, and also 
the effect of age at sampling were assessed by including all children sampled within the first 
28 days of life.  Trends in each parameter as the days between venepuncture and analysis of 
the sample increased were assessed graphically and using a univariable linear regression 
model (the Genmod procedure, The SAS System v9.2, SAS Institute, Cary, NC, USA).   
3.12.2 Neonatal morphological analysis  
Morphological analysis was restricted to blood films from children born between 1st May 2006 
and 1st October 2011 with a sample taken at ≤ 28 days of age.  Again, where there were 
multiple slides from samples taken from the same child only the first set of results was 
included.  The morphology review tool developed for the CDSS was used.  Regressions 
examining the presence or absence of particular anomalies used logistic regression – this 
approach was also used when assessing the proportions of cells with a particular abnormality  
Regressions using the numbers of a particular type of cell as the outcome (for example, the 
number of hypergranular neutrophils) were done with Poisson regression using the number of 
cells at risk (in this example, the total number of neutrophils) as an offset. 
3.12.3 Full blood count analysis beyond the neonatal stage 
Analysis was restricted to cases where there was a full blood count result from a child born 
between 1st May 2006 and 1st October 2011 and with a sample taken within 3 months of each 
birthday including their birth and up to their 4th birthday.  Where multiple results for the same 
child were available only the set of results closest to their birthday was included.  The full 
blood count parameters studied were haemoglobin, haematocrit, red cell count, mean cell 
haemoglobin, mean red cell volume, nucleated red blood cell count , white blood cell count, 
neutrophil, lymphocyte, monocyte, eosinophil and basophil count, platelet count and mean 
platelet volume.  Mean (95% CI) and ranges (5, 95% percentiles) were determined for each 
parameter.   
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 Chapter 4 Development of the morphology reporting tool 
4.1 Introduction 
This chapter describes the development of the morphology reporting tool used in the CDSS.  
This was a complex and lengthy process.  The chapter begins by reviewing the historical 
development of blood cell morphology and current attempts to standardise it.  The initial 
approach taken for morphology review was not successful, necessitating the development, 
validation and implementation of a new morphology reporting tool which would allow credible 
analysis.     
4.2 Historical development 
The appearance of blood cells was first described by Leeuwenhoek in 1674 (Leeuwenhoek, 
1674), although it was another 200 years before the successful development of dyes enabling 
the finer details of cell structure to be seen (Ehrlich, 1877).  An immediate outcome of this 
staining was the recognition that white blood cells could be further differentiated into 
neutrophils, basophils, eosinophils, monocytes and lymphocytes – a classification that still 
remains in use.   
The next advance was the development of manual methods for counting red blood cells, 
white blood cells, and platelets.  These techniques would be performed in tandem with 
microscopic examination of the blood film to determine the size and shape of red blood cells 
and platelets along with a differential white blood cell count.  Although the processes were 
refined and improved throughout the first half of the 20th century, variability between operators 
remained a concern until the laboratory process was revolutionised by the development of the 
first automated blood cell analyser in 1956.   This was based on the principle of single 
channel impedance counting and was able to measure indices directly (Coulter, 1956).  This 
breakthrough was followed by increasingly sophisticated multi-parameter analysers able to 
give information about all three cell types (red and white blood cells, as well as platelets) and 
to provide a white blood cell differential.  Thus, manual techniques gave way to modern 
analysers which are demonstrably precise, accurate and have the advantage of being able to 
turn over a large number of samples rapidly and with little manual input (Pierre, 2002). 
Initially the results from the automated analyser were complemented by results from 
microscopy examination.  However, microscopy examination can be a time consuming 
process.  The automated analyser is recognisably superior in cell counting and in obtaining a 
white blood cell differential, at least in cases with typical white cell structure.  Morphological 
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examination is therefore now reserved for specific cases where the automated analyser alone 
is inadequate.  There are three main situations in which this is the case: 
1. A problem with the sample – for example, platelet clumping, making the platelet 
count unreliable; 
2. Abnormal white cell morphology – making it impossible for the analyser to generate a 
differential; 
3. Numerical parameters outside accepted limits set by the local laboratory – each 
hospital sets ‘rules’ which indicate a need for a blood film to be made and examined.  
These ‘rules’ tend to be local, although there is a recommendation and protocol for 
local validation from the International Consensus Group for Haematology Review 
(Barnes et al, 2005; Cui et al, 2010; Woo et al, 2010).  
In the United Kingdom the National External Quality Assessment Service (NEQAS; Appendix 
2) has included blood film morphology in its assessment since 1968.  A Selection Committee 
chooses blood slides to be sent out for assessment.  Considerable effort is taken to ensure 
that the slides are spread, stained and fixed according to strict protocols in order to maintain 
batch integrity.  The slides are chosen for slide quality, as well as for interest and range of 
conditions.  Currently around six hundred laboratories participate in the scheme each 
receiving two slides on eight occasions over the course of a year.  Minimal clinical information 
is provided – typically only the age and gender of the patient, along with the haemoglobin and 
white cell count (not the platelet count).  Participants complete a report selecting a maximum 
of five coded comments from the sheet provided by NEQAS.  This simply records the 
presence of abnormal features; no attempt is made to grade the frequency of these.  In 
contrast to other NEQAS schemes, the performance of individual laboratories is not scored 
and it is recognised that this scheme ‘probably has not been standardised’ (personal 
communication; B de la Salle).  Rather, the scheme is provided as an educational tool to 
support laboratories in their in house training.  More recently, NEQAS has piloted a scheme 
using digital technology (Brereton et al, 2008).  
There are a few earlier isolated reports of attempts to apply quality control to morphology 
(Rajamäki, 1979; Rajamäki, 1980), but it has mostly remained uncontrolled.  In the earlier of 
these two reports 24 blood films were sent out to 206 different laboratories over a 4 year 
period.  None of the films had either a high white cell count or abnormal white blood cells.  
There was good inter-laboratory consistency for segmented neutrophils, lymphocytes, 
basophils and eosinophils, while band neutrophils and monocyte counts showed more 
variation.  It was suggested that the distinction between a band neutrophil and a segmented 
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neutrophil varied between laboratories and monocytes might be confused with lymphocytes in 
some cases – this problem did not affect the lymphocyte count as much as the number of 
lymphocytes was much greater.   Problems in differentiating between band and segmented 
neutrophils and between normal and reactive lymphocytes are well recognised (Koepke, 
1977). Overall, the author concluded that inter-laboratory assessment was a useful tool to 
improve the quality control of morphology.  Following this a Finnish inter-laboratory 
proficiency testing programme in haematological morphology was set up (Rajamäki, 1980).  
The two main components of this were the use of a standardized form to collect results and 
the creation of a reference board who decided what was referred to as the “morphological 
'truth'”.  One of the important points to emerge from this national process was the decision 
that a consensus of ≥80% with the reference board was the appropriate cut-off for inter-
laboratory reliability. 
The Finnish work highlights the potential for inter-laboratory and inter-observer variability in 
the calculation of the manual white blood cell differential.  Nonetheless when automated 
differential counting was first introduced the manual differential count was considered as the 
gold standard against which the automated count must be viewed (Simmons and Elbert, 
1975; Bain et al, 1980), and, despite the recognition of its weaknesses, performance against 
the manual count is still a key element in the assessment of new automated differential 
counting techniques (van de Geijn et al, 2011).   Lewis turns this idea around, making the 
point that the automated count can be used to assess the reliability of the manual differential 
(Lewis, 1990).  Automated differentials are based on the assessment of much greater 
numbers of white blood cells than manual differential counts which are typically based on 100 
or 200 cells.  Even the very earliest automated counters generated a differential from 
counting ~10000 white blood cells.  This means that there is a greater likelihood of sampling 
bias in a manual count.  The way that the film is stained and spread can then become critical 
in the reliability of the manual count.    
The importance of the morphological assessment of blood cells, and the inherent problems of 
standardisation have since led to an internationally focussed drive to apply external quality 
assessment processes to morphological assessment of blood films (Vives Corrons et al, 
2006; Gutiérrez et al, 2008).  In a similar manner to the Finnish effort to apply external quality 
control to the assessment of the white blood cell differential count, the Spanish Haematology 
and Haemotherapy Association describe an external quality assessment scheme which 
focussed on the ability of laboratories to recognise significant morphological features for all 
cell lines (Gutiérrez et al, 2008).  Over a 6 year period 25 blood films were sent to 604 
participants who were required to choose the four most important morphological features on 
86 
 
each film from a given list.  In addition to the blood film, they were provided with basic clinical 
details.  Again, the results were compared with an independent assessment of what the “true” 
answer was.  Interestingly, one of the most significant findings was that the most reliable 
results came from laboratories attached to hospitals, which consistently outperformed those 
from stand-alone laboratories. 
An important contribution has also been made recently by the European Leukaemia Net 
Morphology Faculty which has produced a consensus statement, based on the reports of 28 
expert morphologists, and a freely available web-based glossary for the identification of 
haematopoietic cells in the context of malignancy (Zini et al, 2010).  However, at the current 
time there is no standard means of reporting blood cell morphology, particularly benign 
haematology, and so one had to be developed for the purposes of the study.  
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4.3 Initial approach to morphology review 
4.3.1 Development of the morphology proforma 
In the absence of a recognised tool for reporting blood cell morphology one needed to be 
developed specifically for the study.  As a starting point the cytomorphology lead for the 
current MRC UKALL study was contacted and blood film review proformas used for the 
Medical Research Council UK ALL, AML, MDS and Interfant trials were obtained (Jenny 
Britton; personal communication).  These proformas were themselves based on the landmark 
paper from the French-American-British collaborative group proposing consensus criteria for 
the classification of acute leukaemias following review of over 200 blood slides (Bennett et al, 
1976).  They all consisted of a small section with some basic clinical details on, followed by a 
space for the reviewer to add their manual white blood cell differential count and ending with 
a section for the reviewer to note specifically whether certain morphological features were 
present of absent – and if present to grade them. 
A proforma for the study was drawn up, based on this same model, and in discussion with a 
small group of experienced consultant paediatric haematologists.  It was agreed that the 
basic clinical details that would be provided would be the child’s gender, ethnic origin, 
gestational age, date of birth, age when sample taken and source of sample.  The automated 
full blood count was to be provided.  The reviewer was required to complete two main tasks: 
firstly, to determine the white blood cell differential count; and, secondly, to assess specific 
morphological features for all cell lines.  During the initial morphology review there were 
various versions of the proforma, each with minor amendments.  The proforma used for the 
majority of the reviews was version 3, which is shown in Figure 4-1.  The amendments made 
to the different versions included the following: 
1. The addition of specific morphological abnormalities for comment.  The initial list of 
abnormal morphological features was drawn up from the form used for the 
myelodysplasia review and also from articles reporting on morphological features 
found in blood films for babies with DS reviewed in the previous chapter.  After some 
of the early films had been reviewed, other morphological abnormalities were noted 
and were added to the form.  These included: eosinophil vacuolation, basophil 
vacuolation, lymphocyte vacuolation, monocytes with stellate nuclei,   
2. Changes to the grading system used to indicate the severity of a particular feature.  
Initially, the reviewer was asked to decide the degree of a particular feature and to 
assign it as absent; mild (1-10%); moderate (11-20%); or severe (>21%).  However, 
some reviewers expressed concern over the use of percentages to describe the 
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degree and incidence of dysplasia.  This generated lively debate.  It was suggested 
that the categories could be simplified to occasional=<10%, moderate=10-50% and 
plentiful=>50% to try to make it less subjective.  However, the final consensus was 
that percentages should be abandoned in favour of purely descriptive terms.   
3. Some reviewers tended to identify the haematopoietic lineage of blasts, where seen 
and where possible, and so this option was included.   
4. It was noted that the platelets were frequently commented on as being ‘pale’ or 
‘ghostly’ and so a questions were added specifically asking whether the platelet colour 
was felt to be abnormal, and if so whether the platelets appeared paler than normal.   
5. Finally, in the light of concerns about discrepancies between the manual and 
automated counts a question was introduced specifically asking if the two were felt to 
be congruous. 
 
89 
 
Figure 4-1. Proforma used for initial morphology reviews. 
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4.3.2 Inter-operator variability in the differential white blood cell count 
The interim analysis considered the reviews made on 13 slides.  Eleven of these had been 
reviewed by all three reviewers (slides 005D, 022D, 030D, 033D, 038D, 039D, 046D, 049D, 
053D, 079D, 095D)  and a further 2 slides had been reviewed by two reviewers (slides 007D, 
010D).  Preliminary analysis of the differential white blood cell count indicated that most 
results were in agreement using the standard from the Finnish inter-laboratory proficiency 
testing programme in haematological morphology (Rajamäki, 1979), which requires results to 
be ≥80% of the ‘truth’, here taken as the mean value for the three reviewers.  All agreed on 
three films where a differential count was not possible – this was important as it is likely that 
more mistakes might be made trying to do a white blood cell differential on a poor film where 
many cells are disrupted. 
Where there were obvious discrepancies between the three reviewers these were as follows.  
Comparison is with the other two reviewers: 
1. Reviewer 1: 
a. Lower neutrophil counts (slides 038D, 046D, 049D) 
b. Higher lymphocyte counts (slides 022D, 030D, 039D, 046D, 049D, 053D)   
c. Lower monocyte counts (slides 010D, 022D, 049D, 053D) 
2. Reviewer 2: 
a. Lower monocytes  (slides 039D, 046D) 
b. Reported blasts, but did not designate a sub-type in contrast to at least one 
other reviewer (slides 022D, 030D, 039D, 046D, 049D, 053D, 079D) 
3. Reviewer 3: 
a. Lower lymphocyte counts (slides 005D, 030D, 038D, 046D) 
b. Higher monocyte counts (slides 005D, 039D)  
c. Higher myelocyte counts (slides 038D, 079D) 
d. Metamyelocyte count >50% of the others at 7x 109/l (slide 005D) 
e. Eosinophil count >50% of the others at 13x 109/l (slide 030D) 
f. Nucleated red blood cells >35% of the others at 212x 109/l (slide 038D) 
g. Higher blast count (slide 038D, 053D) 
h. Ascribed a blast type in 3 films where neither of the others did (slides 038D, 
046D, 049D, 053D), and in 4 films where only one other did (slides 022D, 
030D, 039D, 079D) 
i. Isolated abnormality where a much higher blast count was recorded whilst 
reviewer 1 recorded a much higher monocyte count (slide 038D)  
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Figure 4-2. Deviation of the manual from the automated differential white blood cell count. 
In order to try to understand these discrepancies and to determine whether they were due to 
systematic or to random errors the mean percentage for each differential white blood cell type 
was calculated for each reviewer and was compared with the mean percentage derived from 
the automated differential count.  The results are presented in Figure 4-2 as the deviation 
from the automated count. 
The automated count usually reported neutrophils, without distinguishing between neutrophil 
precursors such as myelocytes, metamyelocytes or promyelocytes.  Three of the counts were 
processed on the Sysmex XE-2100 which does report the immature granulocyte count, 
although there was only one case in which cells were recorded in this category 
(corresponding to slide 038D).  The mean counts were adjusted to give the total for the 
combined counts for mature and precursor neutrophils.  The deviation of the manual 
neutrophil values from the automated value consequently reduces, as seen in the amended 
comparisons shown in Figure 4-3. 
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Figure 4-3. Deviation of the manual from the automated white blood cell differential count with 
mature and precursor neutrophils combined. 
 
This confirms the initial impression that there were important discrepancies between 
reviewers.  Reviewer 1 reports a lower neutrophil count when compared with the automated 
count.  Reviewer 3 reports a lower lymphocyte count and a higher blast count when 
compared with the automated count.  Reviewer 2 appeared to be most consistently nearest 
the automated count.   
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4.3.3 Inter-operator variability in the nucleated red blood cell count 
The mean nucleated red blood cell counts for all three reviewers were very different from the 
automated mean.  On examination of the individual counts the automated analyser only 
recorded the presence of nucleated red blood cells in four cases.  In contrast, nucleated red 
blood cells were recorded by all reviewers for 7 slides (slides 005D, 007D, 010D, 038D, 
039D, 046D, 053D), and by at least one reviewer for 3 further slides (slides 022D, 049D, 
079D).  In two cases where nucleated red blood cells were recorded on the automated count 
these were low at 1 cell/100 white blood cells.  These cases corresponded with slides 022D, 
079D.  For slide 022D manual counts of 0, 2 and 3 cells/100 white blood cells were recorded, 
whilst for slide 079D manual counts of 0, 0 and 2 cells/100 white blood cells were recorded.  
The corresponding mean nucleated red blood cell counts of 1.7 and 0.7 cells/100 white blood 
cells are therefore close to the machine count.  In the other two cases where an automated 
nucleated red blood cell count was recorded (corresponding to slides 038D, 039D) the 
automated count appears much lower than the manual count.  For slide 038D the mean 
manual count was 172 cells/100 white blood cells compared with an automated result of 38 
cells/100 white blood cells.  For slide 039D the mean manual count was 31 cells/100 white 
blood cells compared with an automated count of 10 cells/100 white blood cells.   This is 
shown graphically in Figure 4-4. 
 
 
Figure 4-4. Comparison of nucleated and automated nucleated red blood cell counts. 
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4.3.4 Inter-operator variability in reporting blasts 
Blasts were not recorded in any of the automated reports.  In contrast, blasts were reported 
on the manual count for 11 slides (slides 005D, 007D, 010D, 022D, 030D, 038D, 039D, 
046D, 049D, 053D, 079D).  Moreover, all reviewers agreed on the presence of blasts for nine 
of these, with only one reviewer not recording blasts for two of the slides (slides 007D, 038D).   
4.3.5 Inter-operator variability in reporting morphological features 
These were analysed by considering specific cell types.  Unlike the white blood cell 
differential count where there is an automated count with which to compare the manual 
counts there was no external reference for these features. 
1. Neutrophils  – assessment of the degree of the following features was specifically 
requested: hypo or agranular neutrophils, hypersegmentation, Pelgeroid nuclei and 
vacuolation.  Reviewer 1 appeared less likely to report these features compared with 
the reviewers 2 and 3 (slides 007D, 010D, 030D, 046D, 049D).  There were no slides 
where everyone agreed on the grading of a feature.  If grading was condensed so that 
occasional, some, moderate and plentiful were grouped together to indicate the 
presence of a feature, and if presence or absence only was compared then there was 
full agreement for just one slide (039D).  Even with this, there was disagreement 
about the presence or absence of at least one of the neutrophil features in all the 
remaining slides. 
2. Monocytes  – assessment of the degree of the following features was specifically 
requested:  vacuolation, stellate nucleus, an elongated nucleus, azurophilic granules.  
There were three slides with complete agreement between the three reviewers (005D, 
039D, 053D).  If just presence or absence was considered then there was full 
agreement in a further two slides (022D, 079D).  The remaining discrepancies were 
between occasional/none, some/none and moderate/none.  In three cases the 
discrepancy related to just one feature (030D, 038D, 046D). 
3. Blasts – two questions were asked relating to blasts: can a type be ascribed; and, is 
there cytoplasmic blebbing.  There was agreement between the three reviewers on 
the presence of cytoplasmic blebbing for four slides (030D, 039D, 046D, 079D).  
Reviewer 1 was alone in reporting cytoplasmic blebbing for a further five films (007D, 
010D, 022D, 038D, 049D), although curiously did not for one film where both other 
reviewers reported blebbing (053D).  There was disagreement in blast type in one film 
between myeloblasts and monoblasts (005D). 
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4. Red blood cells – grading of the following features was requested: macrocytosis, 
polychromasia, poikilocytosis, basophilic stippling and target cells.  There was only 
one slide on which all three reviewers agreed (007D).  If the grading was condensed 
to consider just presence or absence then there was agreement in a further four 
cases (005D, 010D, 022D, 079D).  The most common discrepancy was in whether 
basophilic stippling was or was not seen (038D, 039D, 049D).  The discrepancies 
tended to be between similar grades, for example some/occasional and were never 
between moderate/none. 
5. Platelets – the reviewers were asked whether giant platelets and megakaryocyte 
fragments were present, whether the platelet number appeared consistent with the 
automated count, and whether there was a change in platelet colour.  There was 
agreement about the presence of giant platelets between all three reviewers in almost 
all slides, with a discrepancy in just three slides (049D, 053D, 095D) - although in one 
of these the recording of no giant platelets was qualified by the comment ‘slightly 
bigger’ (049D).  The reporting of megakaryocyte fragments was very variable between 
reporters.  Reviewer 2 was more likely to report megakaryocyte fragments, being the 
only person to report them in three slides (005D, 007D, 039D).  Reviewer 3 was the 
least likely to report megakaryocyte fragments only reporting them in one slide (046D), 
and saying ‘difficult to distinguish’ when both other reviewers saw them (079D). 
4.3.6 Intra-operator variability  
A further six slides were reviewed twice by the same reviewer, reviewer 2, to assess intra-
operator variability (slides 058D, 061D, 073D, 076D, 086D, 088D).  The reviews were on 
separate dates and with no knowledge of what had been written down before.   
In contrast to the inter-operator analysis there were very few discrepancies.  The following 
were noted in assessment of the morphological features: 
1. The only discrepancies for reporting neutrophil features were between some/none . 
2. There was agreement for most other white blood cell features.  There was a 
discrepancy between some/occasional for monocytic features and just one 
some/none discrepancy for the presence of cytoplasmic blebbing. 
3. There was only one disagreement as to whether a red blood cell feature was present 
or absent, again relating to basophilic stippling.  Otherwise there was full agreement 
for red blood cell features if some/occasional were grouped and if some/moderate 
were grouped.   
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4. There was full agreement for platelets if were grouped. If grading was condensed so 
that some/occasional, some/moderate, and moderate/plentiful were grouped together 
then there was full agreement for platelet features. 
Overall, there was a higher degree of intra-observer consistency compared with inter-
observer consistency.  However, it was clear that grading still posed a problem.  Where this 
varied between occasional, some or moderate it was at least simply an assessment of degree 
that varied.  However, for some of the neutrophil features, and for one occurrence of 
basophilic stippling the variation was still between some and none. 
4.3.7 Errors inherent to the process 
There were both random and systematic errors present relating to the way that the review 
had been set up.  Random errors occur when a measured value differs from the true value 
because of chance.  These occurred here particularly because a limited number of white 
blood cells are reviewed manually – the automated differential white blood cell count is based 
on at least 100 fold more white blood cells than the manual count.  The particular 100 or 200 
white blood cells included in the count may vary depending on the part of the film reviewed, 
the way the film is spread or chance. 
Systematic errors, or bias, occur when measured values differ from the truth in a systematic 
manner.  In fact, here ‘truth’ was not well defined.  This is seen in three key areas: 
1. There was no stated plan for review; instead it was assumed that each would count a 
similar number of white blood cells, however, reviewing the completed assessments it 
became apparent that the number reviewed varied from 50-200, compounding the 
random error above. 
2. There were no stated cell definitions; again it was supposed that all would identify a white 
blood cell or a morphological abnormality in a similar manner.  Although there might be 
thought to be , and appeared to be, some ground for this assumption when considering 
the identification of a white blood cell some of the other changes were more subtle and 
systematic differences became evident on the analysis. 
3. Descriptive terms were imprecise - it was not clear whether, for example, ‘some’ 
monocyte vacuolation meant that some of the monocytes were vacuolated, or whether it 
meant that some of each monocyte was vacuolated. 
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4.3.8 Errors specific to individual reviewers 
It had been assumed that each reviewer would complete the morphology assessment in a 
comparable fashion.  The systematic errors evident in the inter-operator assessment, which 
were compounded by the lack of clarity of instruction and definition as described above, 
illustrate how unfounded this assumption was.   
A further area in which this was apparent was in the grading system. When grading the 
degree of a feature judgement tended to be retrospective and based on an impression - 
different versions of the proforma had used a percentage or a word to try to grade a feature, 
for example reporting neutrophil hypogranulation as moderate.  However, this classification 
tended to be a retrospective judgement based on the overall impression, and so was very 
subjective.  
There was also an explicit tendency for at least one reviewer to compare what was seen with 
an internal idea of what was normal based on experience – the reviews had been completed 
by senior paediatric haematologists with considerable experience in looking at neonatal blood 
films.  From some of the comments it became clear that at times the appearances were being 
internally calibrated against experience so that the degree of a feature was being recorded in 
relation to what was expected and not as an absolute feature.   
4.3.9 Errors relating to the automated count 
The analysis of the white blood differential results also highlighted systematic errors inherent 
in the automated count.  These particularly related to identification of neutrophil precursors, of 
blasts and of nucleated red blood cells. 
The automated count did not differentiate well between mature neutrophils and neutrophil 
precursors compared with the manual count.  Most samples were processed on the Advia 
2120, which aims to flag the presence of immature granulocytes, but not to quantify them 
(Harris et al, 2005).  It uses two methods to produce the white blood cell differential.  The 
primary method is based on cytochemistry and measures light generated from a reaction 
involving intracellular myeloperoxidase to differentiate between cell types.  The second 
method uses a reagent to lyse the cells before measuring high angle light scatter (relating to 
the nuclear contents) and low angle light scatter (relating to cell size) which is depicted 
graphically.   
Although the lack of quantification of neutrophil precursors is therefore not surprising for the 
Advia 2120, one of the advantages of the Sysmex XE-2100 is supposed to be its ability to 
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quantify immature myeloid and lymphoid cells, as well as identifying the five main white blood 
cell sub-populations (neutrophil, basophil, eosinophil, monocyte and lymphocyte) (Herklotz 
and Huber, 2001).  The Sysmex XE-2100 also uses two methods to generate a differential 
white blood cell count.  Light from a semi-conducting laser is used to examine each cell, and 
then a cell type is assigned based on the combination of two out of three of forward scatter 
(which relates to cell volume), side scatter (which relates to the cell contents), and side 
fluorescence (which relates to the amount of RNA and DNA within the cell)(Herklotz and 
Huber, 2001)(Herklotz and Huber 2001)(Herklotz and Huber 2001)(Herklotz and Huber 
2001)(Herklotz & Huber 2001).  If there are abnormalities flagged in one channel then this 
should be corrected by the other channel as the immature granulocyte is specifically 
calculated and is then subtracted from the neutrophil total.     
The presence of blasts was not reliably picked up by the automated analyser. There are few 
reports of the performance of either the Advia 2120 or the Sysmex XE-2100 in detecting 
blasts.  A recent study of the Advia 2120 found a sensitivity of 100%, but with relatively low 
specificity of 49% (Shelat, Canfield and Shibutani, 2010).  This would suggest that false 
positives are more likely and does not explain the findings here.  The performance of the 
Sysmex XE-2100 specifically in identifying blasts was evaluated using samples with a manual 
blast count of >10% (Jung et al, 2010).  The Sysmex recognised that there was a white cell 
abnormality in 72% cases, resulting in it reporting an invalid white blood cell differential count.  
Interestingly, in the samples for which it did produce a differential count it tended to assign 
lymphoblasts as lymphocytes and myeloblasts as monocytes.  This report compares with an 
earlier study which compared the Sysmex XE-2100 with three other analysers (Kang et al, 
2008).  The Sysmex performed best with a sensitivity for identifying blasts of 90.9%.   
The automated count did not always report nucleated red blood cells compared with the 
manual count.  As this interim analysis occurred in the early stage of the study most samples 
were processed on an Advia 2120 with only three samples processed using a Sysmex XE-
2100.  A previous study of the performance of the Advia 2120 in reporting nucleated red 
blood cells compared with a manual count as a gold standard reported a sensitivity and 
specificity of 77.3% and 74.6% respectively (Kratz et al, 2006).  Importantly, most of the false 
negative samples were at nucleated red blood cell counts ≤ 10/100 white blood cells.  This 
would account for most of the false negatives seen here (slides 007D, 010D, 049D, 053D).  
Nucleated red blood cells were reported on all three of the samples processed on the 
Sysmex XE-2100.  This uses a separate channel to count the nucleated red blood cells with a 
specific reagent to lyse red blood cells and then to denucleate, shrink and stain the nuclei of 
nucleated red blood cells allowing enumeration.  Importantly, this also stains the nuclei and 
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intracytoplasmic organelles of white blood cells, but does not alter their size or shape allowing 
them to be distinguished from the red blood cells.  The nucleated red blood cells calculated in 
this channel are subtracted from the lymphocyte total generated initially from flow cytometry 
as it will have included them.   
The high performance of the Sysmex XE-2100 in detecting low levels of nucleated red blood 
cells has been demonstrated elsewhere (Ruzicka et al, 2001; Briggs et al, 2000; de Keijzer 
and van der Meer, 2002)and is consistent with these results.  Interestingly, it has also been 
reported that the Sysmex XE-2100 tends to record a lower nucleated red blood cell count in 
samples with a high manual count - >15 cells/100 white blood cells and especially where the 
manual count is >200 cells/100 white blood cell count (Ruzicka et al, 2001) which accords 
with the experience here.  The remaining incongruity, for slide 046D, where all three 
reviewers reported nucleated red blood cells but there does not appear to be an automated 
result can be explained by the absence of a machine count as the sample was clotted. 
Overall, the Sysmex XE-2100 appears better at picking up low level presence of nucleated 
red blood cells compared with the Advia 2120.  However, it is not accurate at higher counts 
and a manual count is required for enumeration if the nucleated red blood cell count is >15 
cells/100 white blood cells.  
4.3.10 Summary 
The initial approach taken with the morphology review was to design a proforma based on 
those used for blood cell morphology review in the UK Medical Research Council trials.  
However, it was rapidly apparent that there were frequent discrepancies between the results 
recorded by the three reviewers with unacceptable levels of intra- and inter-operator 
variability.  The factors contributing to this were examined in order to inform the development 
of a new strategy for morphology review.   
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4.4 Development of a new morphology reporting tool  
4.4.1 Rationale for revision  
The previous approach to morphology review had been based on the proformas used in 
major trials, adapted to be relevant to this setting.  This had so clearly failed to be useful that 
a wholly new approach was needed.  First, the requirements of the morphological review 
were defined.  This was primarily to enable objective analysis of the blood cell morphology of 
DS neonates within the study context.  However, it was also hoped that this new tool would 
be able to be used outside of the study context by a qualified haematologist or laboratory 
scientists with morphological expertise, to give similar results. 
4.4.2 Key elements of the new reporting tool 
The new tool for morphology review assumed as little as possible and had a standard 
operating procedure for analysis.  The key elements of this were as follows: 
1. The conditions that needed to be met for analysis to proceed were explicitly stated. 
2. Given the problems described in the automated count with regard to the differential white 
blood cell count, identifying blasts and in enumerating nucleated red blood cells these 
were all to form part of the review. 
3. The number of white blood cells counted in the differential was stipulated as 100 white 
blood cells. 
4. The nucleated red blood cell count was to be recorded per 100 white blood cells, and not 
as part of a total nucleated cell count.   
5. There were clear definitions of each abnormal feature considered.   
6. Importantly, in the new approach it was decided that each individual white blood cell 
would be reviewed as it was counted for the presence or absence of the particular 
features under consideration for that cell type.  The end number, for a specific feature, 
would then accurately refer to the percentage of cells with that feature for a given cell 
type.   
7. The number of fields to be reviewed for red blood cell and platelet features was 
stipulated as 20 fields at high power (x50).   
The format of the revised morphology reporting tool is seen in Figure 4-5.  The instructions for 
the new morphology review procedure are provided in Appendix 9. 
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Figure 4-5. Revised morphology review tool. 
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4.5 Evaluation of the revised morphology reporting tool  
The revised morphology reporting tool was used to report twenty four blood films from an 
unselected group of neonates having full blood counts and films made at Leeds General 
Infirmary.  The films had been made and stained according to a standard operatory 
procedure using a Leishman stain (Lewis et al, 2006).  Each slide was reported manually 
three times: reviews 1 and 2 were by the same reviewer at separate times; review 3 was by a 
different reviewer (this was reviewer 2, whose consistency had been demonstrated in the 
analysis above).  Comparison of reviews 1 and 2 enabled assessment of intra-operator 
variability, while comparison of these with review 3 enabled assessment of inter-operator 
variability.   
4.5.1 Comparison of the manual and automated differential white blood count  
Initially, the mean value for each white blood cell type, and for blasts, was calculated for each 
of the reviewers and these were compared with the automated result.  This is shown in Figure 
4-6. 
 
Figure 4-6. Comparison of the manual and automated counts using the new morphology 
reporting tool. 
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In contrast to the results obtained with the initial proforma these were very similar and so a 
more detailed slide by slide comparison was made.  First, the differential count for each white 
blood cell type recorded at each individual slide review was compared with the automated 
differential count for that cell type associated with each slide.  The automated count was 
taken as the baseline.  The deviation of each of the white blood cell differential from the 
automated baseline is shown, for each cell type and for each slide, for reviews 1, 2 and 3 in 
Figure 4-7. 
All of the results were within 20% of the baseline – the pre-set level of agreement considered 
to be satisfactory.  In fact, only one result approached this.  Almost all the results for the 
neutrophils, lymphocytes and monocytes were within 10% of the baseline, while all the results 
for eosinophils, basophils and blasts were within 5% of the baseline. 
Importantly, the results were variably greater than and less than the baseline – a pattern 
consistent with random rather than systematic error.  All three reviews appeared comparable 
in their similarity to the automated count.  There was not one series, or one reviewer, which 
looked obviously different. 
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Figure 4-7. Slide by slide comparison of the % difference in each of the manual white blood cell 
differential counts compared with the automated count which was taken as the baseline.   
 
Each bar represents the deviation for one slide.  Where there is no bar this indicates that there 
was no difference between the manual and the automated count.  
Review 1 = █ Review 2 = █ Review 3 = █ 
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Although there is close agreement between the three manual reviews and the automated 
count for the total neutrophil and neutrophil precursor count, when this is broken down into 
neutrophils, myelocytes, metamyelocytes, promyelocytes and blasts differences emerge.  
The data suggests that the automated count tends to consistently overestimate the mature 
neutrophils and to underestimate the neutrophil precursors.  This effect becomes more 
pronounced as the cell type being counted becomes more immature – especially given that 
the numbers become much smaller as the type considered is more immature.   
Metamyelocytes, promyelocytes and blast counts were all lower for the automated compared 
with the manual counts.  For example, blasts were present in three of the slides.  These were 
consistently identified by all three reviewers, but were identified in the automated differential 
count in only one case, slide 018M.  This was the slide which had the highest manual blast 
count, with a mean blast count of 4%.  When the blast percentage was lower than this the 
machine did not identify the presence of blasts. 
This is illustrated in Figure 4-8. All the results (the automated result and the three manual 
results) appear very similar when the total mature and immature neutrophil count is 
considered.  However, when this is broken down it can be seen that the mature neutrophil 
count is higher for the automated result and the precursors are lower when counted by the 
automated analyser. 
 
Figure 4-8. Comparison of the mean mature and immature neutrophil manual counts for each 
review with the automated counts which is taken as the baseline.  
Review 1 = █ Review 2 = █ Review 3 = █ 
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4.5.2 Comparison of the manual differential white blood cell counts 
A slide by slide comparison of the individual manual reviews was then made.  Review 1 was 
taken as a baseline, and review 2 was compared with it to assess intra-operator variability.  
Review 3 was compared with review 1 in order to assess inter-operator variability.  This is 
shown graphically in Figure 4-9. 
All of the results were within 20% of the baseline – the pre-set level of agreement considered 
to be satisfactory.  Almost all the results for the neutrophils, lymphocytes and monocytes 
were within 10% of the baseline, while all the results for eosinophils, basophils and blasts 
were within 5% of the baseline. 
Again, the results were variably greater than and less than the baseline – a pattern consistent 
with random rather than systematic error.  This indicated that there was good intra-operator 
and inter-operator reliability.   
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Figure 4-9. Slide by slide comparison of the % difference in each of the manual white blood cell 
differential counts for reviews 2 and 3 compared with review 1 which was taken as the baseline.   
 
Each bar represents the deviation for one slide.  Where there is no bar this indicates that there 
was no difference between the manual counts.  
Intra-operator comparison = █ Inter-operator comparison = █ 
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4.5.3 Assessment of morphological features in the neutrophils 
In order to assess the intra-operator variability the results for the percentage of cells noted to 
have the feature under consideration was calculated and then these results were compared 
slide by slide.  Review 1 was taken as a baseline, and review 2 was compared with it to 
indicate intra-operator variability.  Review 3 was compared with review 1 in order to assess 
inter-operator variability.  The comparisons are shown graphically in Figure 4-10.     
Each neutrophil was assessed to look for any of six possible features: hypersegmentation, 
hypogranularity, agranularity, hypergranularity, Pseudo-Pelger Hűet anomaly and 
vacuolation.  There were very few slides which had any agranular or hypersegmented 
neutrophils, and so there were only a handful of slides for which these numbers could be 
compared. 
Most of the results were within 10% of the baseline, although three results were just outside 
20% of the baseline.   
This indicated that there was reasonable intra-operator and inter-operator reliability.   
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Figure 4-10. Intra and inter-operator variability in the assessment of specific neutrophil 
features.   
 
Where there is no bar this indicates that there was no difference between the manual counts. 
Intra-operator comparison = █ Inter-operator comparison = █ 
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4.5.4 Assessment of morphological features in lymphocytes, monocytes, eosinophils 
and basophils 
The total numbers of lymphocytes, monocytes, eosinophils and basophils seen are small and 
the frequency of most of the features seen was low.  This means that small numerical 
differences in the number of cells reported to have a certain feature can make large 
percentage changes – for example, if 4 eosinophils are seen in a 200 white blood cell 
differential and none are noted to be vacuolated then the percentage vacuolation is 0%, but if 
just 2 are noted to be vacuolated this rises dramatically to 50%.  This is illustrated in which 
shows the variation in the percentage of monocytes with vacuolation against the average 
number of monocytes for that slide.  As the number of monocytes examined increases the 
variation decreases.  The graph also shows that the results are less consistent than those for 
the differential white blood cell count, with many of the results from reviews 2 and 3 being 
>20% from the baseline. 
 
 
 
 
Figure 4-11. Variation in the monocyte count from baseline against the total monocyte count. 
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4.5.5 Assessment of morphological features in the red blood cells 
Red blood cells were assessed so that a grade was assigned for macrocytosis, 
polychromasia, basophilic stippling and target cells –the grade indicated the fraction of the 
total red blood cell population estimated to display this feature.  The presence or absence of 
spherocytes and Howell-Jolly bodies was noted, but not graded.  The analysis of nucleated 
red blood cells is considered separately below. Review 1 was taken again as a baseline, and 
review 2 was compared with it to indicate intra-operator variability and review 3 compared 
with it to indicate inter-operator variability.  The results are shown in Table 4-1. 
When intra-operator variability was considered, there was complete agreement in the grading 
of macrocytosis in 21/24 (87.5%) cases; in the grading of polychromasia in 22/24 (91.7%) 
cases; in the grading of basophilic stippling in 22/24 (91.7%) cases; in the grading of target 
cells in 21/24 (87.5%) cases; in the recognition of spherocytes in 23/24 (95.8%) cases; and in 
the recognition of Howell-Jolly bodies in 22/24 (91.7%) cases.  When the degree of 
discrepancy was considered it was apparent that this was only ever of one grade – for 
example one review grading macrocytosis as grade 2 whilst the other review gave a grade of 
3.  
When inter-operator variability was considered, there was complete agreement in the grading 
of macrocytosis in only 10/24 (41.7%) cases; in the grading of polychromasia in 12/24 (50%) 
cases; in the grading of basophilic stippling in 20/24 (83.3%) cases; in the grading of target 
cells in 14/24 (66.7%) cases; in the recognition of spherocytes in 15/24 (62.5%) cases; and in 
the recognition of Howell-Jolly bodies in 18/24 (75%) cases.  More detailed analysis showed 
that there appeared to be systematic errors in the inter-operator comparison with review 3 
being less likely to report the presence of any of the red blood cell features compared with 
reviews 1 or 2.  When the degree of discrepancy was considered it was apparent that 
although this was almost always only a difference of 1 grade, there were three instances 
where the grade differed by 2 points, and one case where the grade differed by 3 points.   
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Table 4-1. Agreement in the identification and grading of red blood cell and platelet features. 
 
Feature being considered Intra-operator agreement  Inter-operator agreement 
 Number % Number % 
 
Macrocytosis 21/24  87.5 10/24 41.7 
Polychromasia 22/24 91.7 12/24 50 
Basophilic stippling 22/24 91.7 20/24 83.3 
Target cells 21/24 87.5 14/24 66.7 
Spherocytes 23/24 95.8 15/24 62.5 
Howell-Jolly bodies 22/24 91.7 18/24 75 
     
Giant platelets 22/24 91.7 17/24 70.8 
Megakaryocyte fragments 24/24 100 22/24 91.7 
Platelet colour 24/24 100 22/24 91.7 
 
Macrocytosis is also assessed by the automated machine which calculates the mean cell 
volume.  When the grade assigned at each of the three reviews was plotted against the mean 
cell volume ascribed by the automated machine it was apparent that there was a linear 
relationship between the grade and the mean cell volume.  This is shown in  
Figure 4-12. 
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Figure 4-12.  Relationship between the manual grade for red blood cell macrocytosis and the 
mean cell volume calculated by the automated analyser. 
4.5.6 Assessment of the nucleated red blood cells 
The nucleated red blood cell count for each of the reviewers was compared with the 
automated result, which was taken as the baseline.   This is shown in Figure 4-13. 
 
Figure 4-13. Slide by slide comparison of the % difference in the manual nucleated red blood 
cell count compared with the automated count, which was taken as the baseline.   
Review 1 = █ Review 2 = █ Review 3 = █ 
 
There was good correlation between the nucleated red blood cell count obtained for all three 
manual reviews, indicating good intra and inter-operator variability.  For most of the slides 
there was also a good correlation of all three manual counts compared with the automated 
count – with most of these falling within 10% of the automated count.  These were variably 
10% more or less than the automated count indicating that this was random error.  However, 
for manual reviews of 5 slides the manual count was >10% different from the automated 
count, and when this was so the manual count was always lower than the automated count.  
In some cases (review 1 and 2 of slide 3; review 2 of slide 18) the manual count differed by 
>40% from the automated count. 
This contrasts with the experience of the Sysmex XE-2100 automated count in the initial 
reviews where the results indicated that the manual nucleated red blood cell count was 
underestimated by the Sysmex XE-2100 if there was a high nucleated red blood cell count – 
a finding which has been reported elsewhere too (Ruzicka et al, 2001).  However, all of the 
blood samples associated with the slides examined in this validation exercise were processed 
on the Advia, and not on the Sysmex XE-2100. 
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4.5.7 Assessment of platelet features 
Platelets were assessed with regard to size and colour.  Review 1 was taken again as a 
baseline, and review 2 was compared with it to indicate intra-operator variability and review 3 
compared with it to indicate inter-operator variability.  The results are shown in Table 4-1. 
When intra-operator variability was considered, there was agreement in the presence of giant 
platelets in 20/22 (90.9%) cases; in the presence of megakaryocyte fragments in all cases; 
and in the colour in all cases.  When the only two discrepancies were considered these 
indicated a random error. 
When inter-operator variability was considered, there was agreement in the presence of giant 
platelets in 16/22 (72.8%) cases; in the presence of megakaryocyte fragments in 20/22 
(90.9%) cases; and in the assessment of colour in 20/22 (90.9%) cases.  Again there was no 
pattern to the discrepancies consistent with random error. 
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4.6 Final refinements and conclusions 
The evaluation exercise demonstrated that it is possible to standardise blood morphology 
review so that the results are reproducible.  This is essential if results are to be compared in 
any meaningful way. 
4.6.1 The value of the manual compared with the automated count 
Morphological analysis is labour intensive and time consuming – each review took ~15 
minutes to complete.  This is only worthwhile if the manual result is superior to the automated 
result and/or it yields extra, helpful, information. 
The overall differential white blood cell count was comparable whether assessed manually or 
using the automated analyser.  However, the automated count did not offer a satisfactory 
breakdown of neutrophil precursors, and the manual count was superior in identifying these.  
This effect became more marked with increasing immaturity and the manual review was 
superior in recognising the presence of blasts, when they were present at low levels.   
The manual review was also superior in identifying and counting nucleated red blood cells.  
When these were present at low levels they were not reliably recognised by the automated 
analyser.  When they were present at high levels there was a tendency for the Advia 2120 to 
over count these, whilst the Sysmex XE-2120 has been shown to undercount these.  The 
other parameter that could be compared between the manual and the automated result was 
the degree of macrocytosis.  There was no added value from commenting on the degree of 
red blood cell macrocytosis as it appears morphologically as this correlated directly with the 
automated mean red blood cell volume. 
The automated machine is not sufficiently sophisticated to be able to comment on the 
presence or absence of morphological features within the blood cells.  The main questions 
with regard to these are therefore:  
1. Can these be reliably assessed? 
2. If so, do they add important information? 
4.6.2 Intra-operator variability 
The intra-operator variability was acceptable for all aspects of the review, with the exception 
of the identification of morphological abnormalities within the lymphocytes, monocytes, 
eosinophils and basophils.  These became more reliable at higher counts – or when the 
monocyte population was a greater proportion of the total white blood cell differential.  
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However, in ~one fifth of cases the variation was >20% baseline.  This was deemed 
unacceptable. 
4.6.3 Inter-operator variability  
The inter-operator variability was acceptable for the differential white blood cell count, and for 
the identification of morphological abnormalities in the neutrophils.  As above, the 
identification of morphological abnormalities within the lymphocytes, monocytes, eosinophils 
and basophils was not reliable.  There was a much greater inter-operator variability in the 
assessment of red blood cell morphology.  Importantly, this also showed a consistent trend 
with review 3 being less likely to report an abnormality and being more likely to give a lower 
grade when considering an abnormality.  This was therefore a systematic error.  Reviewer 3 
was similarly less likely to report giant platelets although there was only a low level of inter-
operator variability when considering platelet colour.  
4.6.4 Final refinements 
In the light of the above the following refinements were made: 
1. Morphological features in the lymphocytes, monocytes, eosinophils and basophils 
were not considered; 
2. The degree of macrocytosis was not  graded as the machine mean cell volume was 
already being recorded; 
3. All reviews would be conducted by the same operator.  
4.7 Summary  
The interim analysis threw up an unexpected problem, namely the unreliability of the 
morphology results obtained using the initial proforma.  Although morphology is an explicitly 
subjective measure the extent of this came as a surprise as forms similar to the initial 
proforma are used in other studies and trials.   
The morphology review tool that was developed and tested here on a group of unselected 
neonatal slides demonstrated that it is possible to record the results of morphological analysis 
in a way that is sufficiently reliable that there can be meaningful analysis.  Moreover, the 
evaluation exercise proved that the manual differential count is important as it yields 
information which the automated count either cannot, or cannot reliably, contribute.  In 
particular, it provides important information about neutrophil precursors, blasts and the 
nucleated red blood cells.  
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 Chapter 5 Results: study participation and case demographics 
5.1 Introduction 
In the first part of this chapter the results of the pilot phase are presented, before 
concentrating on the CDSS as a whole.   
5.2 Pilot phase results 
5.2.1 Hospital participation within the Yorkshire Neonatal Network  
The study opened in two hospitals on 1st May 2006.  The final research and development 
approval for a further five hospitals within the YNN was received during May 2006, for a 
further four hospitals in June 2006 and for the final hospital in early July 2011.   
5.2.2 Hospital participation outside the Yorkshire Neonatal Network 
In addition, as contact with hospitals in the wider target area continued in parallel with the 
pilot study the study was also open in a further 29 hospitals by the end of the pilot study.  A 
presentation about the study had been made in 8 further hospitals, 7 of which had agreed to 
proceed, identified a local lead and for which I had submitted research and development 
approval.  The eighth hospital were keen to participate, but had not yet nominated a local 
lead.  Contact had been made successfully, and a date set to present the study had been 
agreed with 7 more hospitals.  A date to present the study had not been made in the final 5 
hospitals within the target area, although contact had been established with each of these.  
5.2.3 Recruitment within the Yorkshire Neonatal Network 
Sixteen children were recruited within the YNN during the 8 months of the pilot study.  Details 
of the recruitment by hospital and data on the live birth rates are presented in Table 5-1.  
These indicate an estimated number of 25 live births would have been expected within these 
hospitals during this period, giving an estimated ascertainment of 64% within the YNN. 
5.2.4 Recruitment outside the Yorkshire Neonatal Network  
During the pilot phase 17 children were recruited from hospitals outside the Yorkshire 
Neonatal Network. Details of the recruitment by hospital and data on the live birth rates for 
hospitals joining the study during the pilot period, but outside the Yorkshire Neonatal Network 
are presented in Table 5-2.  These indicate an estimated number of 23 live births would have 
been expected within these hospitals during this period, giving an estimated ascertainment of 
74% for this group of hospitals, and an overall estimated ascertainment of 69% (33/48).  
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Table 5-1. Recruitment for hospitals in the Yorkshire Neonatal Network during the pilot phase. 
 
Hospital Date study 
opened 
Duration 
opened by 
review point 
(months) 
Registered live 
births pa
a
 
Estimated 
number of DS 
live births in 
pilot phase 
Cases 
recruited to 
the CDSS 
      
Y1 26/05/2006 7 2394 1.5 3 
Y2 26/06/2006 6 5746 3.2 2 
Y3a 03/05/2006 7 5441
b
 3.5 1 
Y3b 03/05/2006 7 -  - 2 
Y4a 11/05/2006 7 6189
c
  4.0 0 
Y4b 11/05/2006 7 - - 3 
Y5 11/07/2006 5 1713 0.8 0 
Y6  14/06/2006 6 5384 3.0 2 
Y7a 01/05/2006 8 8786
d 
6.4 1 
Y7b 01/05/2006 8 - - 1 
Y8 26/06/2006 6 1615 0.9 0 
Y9 26/06/2006 6 3242 1.8 1 
      
Total - - - 25.1 16 
 
a. Data taken from www.hesonline.nhs.uk using 2006-2007 statistics with the exception of Hospital Y8 
as the statistics were inadvertently incorrectly recorded by the Trust that year.  Instead, data for 
Hospital Y8 is taken from the year 2008-2009. 
b. Hospitals Y3a and Y3b belong to the same Trust and these are the combined number of live births. 
c. Hospitals Y4a and Y4b belong to the same Trust and these are the combined number of live births.  
d. Hospitals Y7a and Y7b belong to the same Trust and these are the combined number of live births. 
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Table 5-2. Recruitment for hospitals outside the Yorkshire Neonatal Network during the pilot 
phase. 
 
Hospital Date study opened Duration 
opened by 
review point 
(months) 
Registered 
live births pa
a 
Estimated 
number of DS 
live births in 
pilot phase 
Cases 
recruited to 
the CDSS 
      
CM3 21/06/2006 6 2753 1.5 1 
CM4 26/10/2006 2 7994 1.5 0 
CM7 16/11/2006 1 3051 0.3 0 
CM8 19/12/2006 0 3002 0 0 
M2b 01/12/2006 1 5183
b
 0.7 0 
M2c 10/10/2006 2 - - 1 
M4 18/09/2006 3 4996 1.4 0 
M5 21/11/2006 1 3514 0.3 1 
M7 22/12/2006 0 4097 0 0 
M8 07/08/2006 4 1377 0.5 1 
NT1 22/06/2006 6 2571 1.4 0 
NT3 16/11/2006 1 2858 0.3 0 
NT4a 15/06/2006 6 4398
c
 2.4 0 
NT4b 15/06/2006 6 - - 0 
NT6 25/08/2006 4 6530 2.4 1 
NT7 24/08/2006 4 2685 1.0 1 
N1b 09/11/2006 1 5729
d
 0.5 0 
N1c 09/11/2006 1 -
 
- 0 
N2a 03/10/2006 2 2990
e
 0.5 0 
N2b 03/10/2006 2 - - 0 
N6 14/11/2006 1 1764 0.2 0 
N7 20/09/2006 3 5494 1.5 2 
N8 02/06/2006 6 1488 0.8 2 
N10a 14/11/2006 1 3727
f
 0.7 1 
N10b 14/09/2006 3 - - 2 
T2 27/10/2006 2 5304 1.0 0 
T3 11/09/2006 3 2668 0.7 0 
T4a 23/08/2006 4 10 105
g 
3.7 2 
T4b 23/08/2006 4 -
 
- 2 
Total    23.3 17 
 
a. Data taken from www.hesonline.nhs.uk using 2007-2008 statistics. 
b. Hospitals M2b and M2c belong to the same Trust and these are the combined number of live births. 
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c. Hospitals NT4a and NT4b belong to the same Trust and these are the combined number of live 
births. 
d. Hospitals N1b and N1c belong to the same Trust and these are the combined number of live births. 
e. Hospitals N2a and N2b belong to the same Trust and these are the combined number of live births. 
f. Hospitals N10a and N10b belong to the same Trust and these are the combined number of live 
births. 
g. Hospitals T4a and T4b belong to the same Trust and these are the combined number of live births. 
 
5.2.5 Protocol amendments 
Change of hospital laboratory 
The first test to be performed on each blood sample is full blood count processing, a test 
which is routinely performed in hospital haematology laboratories.  Initially the study was set 
up so that blood samples were sent to the hospital haematology laboratory at SJUH for full 
blood count testing.  This seemed appropriate as there would be consultant paediatric 
haematologists on site to review results immediately if there were concerns.  Following 
processing the samples were collected and taken to the ECSG at the University of York for 
storage.  Although, there is close collaboration between the ECSG and the Regional Centre 
for Paediatric Haematology at SJUH on a number of projects, they are 25 miles apart. 
Over the first few months transport problems with this arrangement, and so for logistical 
reasons a decision was made to change the location so that samples would be sent instead 
to the smaller hospital haematology laboratory at York Hospital, which is geographically close 
to the University.  The newborn entry packs which are kept at participating hospitals were 
recalled and reissued once the prepaid addressed envelopes had been amended.  This new 
set up worked extremely well.  Communication between the hospital laboratory and the study 
centre was excellent, so that it became possible for samples to reach the study centre having 
had a full blood count test and slides made, within 48 hours of venepuncture.  HPLC had 
already been completed on twenty samples by the time the system changed. 
Inclusion of access to maternity records in the newborn consent 
As the information from maternity notes pertains directly to the newborn sample, it was felt 
more appropriate that permission to review these maternity records was also sought when 
the family was initially invited to take part and so this was added to the newborn consent 
form.   
More flexibility over timing of the move to the follow up stage 
It was also decided to introduce more flexibility into the timing between the newborn and the 
follow up stage.  In the original design there was a set interval of three months between the 
initial participation –which typically occurred when the family were in hospital with their 
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newborn baby – and the next contact from the study centre when families were invited to take 
part further.  Before contact was made the study centre would check with the relevant health 
professional, usually the general practitioner, that there was nothing new in the families’ 
circumstances that would make this contact inappropriate.  The protocol was amended so 
that after the initial participation, in addition to a letter thanking them for taking part, families 
were sent a prepaid addressed card which they could return when they would like to find out 
more about the study.  If there had been no response by the time their child was 11 months 
old then they would receive a further invitation to participate. 
Ethical approval was requested and granted for these amendments.   The study literature 
was then updated to reflect the changes. 
5.2.6 Summary 
The main questions addressed by the pilot study were: 
1. Will hospitals participate? 
2. Will families participate? 
3. Does the design need any modification? 
It was clear that hospitals were willing to be involved, with all 12 hospitals in the Yorkshire 
Neonatal Network taking part, and an additional 29 hospitals taking part by the end of the 
pilot study period.  Further, the estimated ascertainment for both the groups of hospitals – 
those within the Yorkshire Neonatal Network and those in other Neonatal Networks – was 
between two thirds and three quarters which indicated that families were willing to participate. 
Although, the logistical side of the study worked well on the whole, but review of the pilot 
period indicated the need for two significant refinements: 
1. The location of the hospital laboratory processing the full blood counts moved to YH;  
2. The study literature was amended 
a. to request permission to access the relevant maternity records in the newborn 
consent stage; 
b. to allow more flexibility over the timing of the move to the follow-up stage. 
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5.3 Hospital participation 
Clinicians in each hospital with maternity services in the six Neonatal Networks which 
comprised the target area were identified and contacted in order to arrange a presentation 
about the study.  Each hospital was then visited at least once and a presentation about the 
CDSS was made to the relevant team.  Following the meetings a local study lead was 
appointed.  Applications for Research and Development (R&D) approval were coordinated by 
the CDSS.  These application procedures varied widely from hospital to hospital.  
Presentations about the study were also made to four separate Neonatal Network meetings 
at which the Neonatal Leads for each hospital within a given network met together. 
All hospitals with maternity services in the six Neonatal Networks within the target area took 
part in the CDSS.  Initially there were a total of 60 hospitals across the Neonatal Networks, 
but due to service reorganisation within the NHS several maternity units subsequently closed 
down.  More recently the CDSS was approached by the West Midlands (South) 
Comprehensive Local Research Network (CLRN) who had identified the CDSS from the 
UKCRN Portfolio database.  Following a presentation about the CDSS to clinicians from this 
CLRN the CDSS was established in three hospitals belonging to this network.   
The details of hospital activity, including the number of registered births per annum for each 
hospital and the number of cases recruited by each hospital are provided in Table 5-3.  
Children were recruited from all of the 6 Neonatal Networks and from the West Midlands 
(South) CLRN.  All of the hospitals within the Cheshire and Merseyside, Greater Manchester, 
Trent and Yorkshire Neonatal Networks recruited cases with the Yorkshire Neonatal Network 
being the most active and recruiting a total of 157 cases.  There was one hospital in the North 
Trent and 4 hospitals in the Northern Neonatal Networks which did not recruit any cases.  
These tended to be hospitals where there was a relatively low birth rate.  Only one of the 
three hospitals from the West Midlands (South) CLRN recruited cases into the CDSS. 
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Table 5-3. Participation in the CDSS by hospital and neonatal network. 
 
Location Date of 
presentation 
Date study 
opened 
 Registered births 
pa
a
 
Cases 
recruited to 
the CDSS 
  
CHESHIRE AND MERSEYSIDE  
      
CM1 16/11/06 05/02/07  3515 12 
CM2 16/11/06 24/04/07  3175 5 
CM3 07/06/06 21/06/06  2807 6 
CM4 23/08/06 26/10/06  8758 15 
CM5 06/12/06 22/02/07  987 6 
CM6 05/03/08 12/09/08  3132 1 
CM7 09/08/06 16/11/06  3250 10 
CM8 26/10/06 19/12/06  3078 3 
Network overall 09/06/06 -  28702 58 
      
GREATER MANCHESTER 
      
M1 23/01/07,20/11/07 12/03/07  3121 2 
M2a 11/07/06,21/11/06 22/03/08  10 343
b 1 
M2b 11/07/06,18/10/07 01/12/06  - 7 
M2c 11/07/06,13/10/06 10/10/06  - 2 
M2d 11/07/06,14/11/06 25/01/07  - 1 
M3 12/12/06 12/03/07  3149 4 
M4 10/07/06 18/09/06  5427 14 
M5 12/10/06 21/11/6  3898 8 
M6 06/12/07 26/02/08  3230 2 
M7 07/11/06 22/12/06  4707 6 
M8 05/06/06 07/08/06  1168 3 
M9 24/10/07 21/03/08  3484 12 
Network overall - -  38527 62 
      
 
a. taken from www.hesonline.nhs.uk using 2009-2010 data 
b. Hospitals M2a, M2b, M2c and M2d belong to the same Trust and these are the combined 
number of live births. 
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Location Date of 
presentation 
Date study 
opened 
 Registered 
births pa
a
 
Cases recruited 
to the CDSS 
      
NORTH TRENT      
      
NT1  23/05/06 22/06/06  2987 4 
NT2 16/01/07 14/06/07  1389 0 
NT3 05/09/06 16/11/06  2877 8 
NT4a 10/08/06 15/06/06  4697
c 7 
NT4b 28/11/07 15/06/06  - 5 
NT5 22/05/08 29/07/08  3859 1 
NT6 13/12/07 25/08/06  6775 1 
NT7 11/05/06 24/08/06  2778 11 
Network overall 17/03/06 -  25362 37 
      
NORTHERN      
N1a 13/09/06 08/01/07  6223
d 
- 
N1b 13/09/06 09/11/06  - 11 
N1c 25/10/6 09/11/06  - 6 
N2a 12/06/06 03/10/06  3021
e 
4 
N2b 30/11/06 03/10/06  - 0 
N3 27/09/06 08/01/07  959 3 
N4 27/09/06 08/01/07  4352 0 
N5 11/01/07 01/03/07  3055
f
 0 
N6 05/07/06 14/11/06  1929 3 
N7 02/05/06 20/09/06  6683 16 
N8 15/06/06 02/06/06  1564 4 
N9 13/12/06 12/03/07  3377 12 
N10a 07/08/06 14/11/06  3621
g 4 
N10b 14/06/06 14/09/06  - 10 
Network overall 14/06/06 -  34783 73 
      
c. Hospitals NT4a and NT4b belong to the same Trust and these are the combined number of live births. 
d. Hospitals N1a, N1b and N1c belong to the same Trust and these are the combined number of live births.  
No cases were recruited from N1a as the maternity unit closed. 
e. Hospitals N2a and N2b belong to the same Trust and these are the combined number of live births. 
f. There are several other maternity units associated with hospital N5, belonging to the same Trust, and all 
are included under this hospital. 
g. Hospitals N10a and N10b belong to the same Trust and these are the combined number of live births. 
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Location Date of 
presentation 
Date study 
opened 
 Registered 
births pa
a
 
Cases recruited 
to the CDSS 
      
TRENT      
T1 07/11/07 28/03/08  3641 1 
T2 04/08/06 27/10/06  6012 16 
T3 30/06/06 11/09/06  3033 6 
T4a 28/06/06 23/08/06  5640 27 
T4b 28/06/06 23/08/06  4560 13 
T5 11/09/07 28/03/08  2223 5 
Network overall - -  25109 68 
      
YORKSHIRE      
Y1 05/12/05 26/05/06  2511 8 
Y2 08/12/05 26/06/06  6065 36 
Y3a 18/08/06 03/05/06  5545
h 11 
Y3b 11/11/05,18/08/06 03/05/06  - 6 
Y4a 18/11/05 11/05/06  3238 13 
Y4b 07/02/06 11/05/06  3316 13 
Y5  03/11/05 11/07/06  2293 5 
Y6 07/12/05 14/06/06  5627 21 
Y7a   21/11/05,30/04/07 11/04/06  9397
I 
20 
Y7b 07/11/05 11/04/06  - 11 
Y8 28/11/05,17/12/07 26/06/06  1632 4 
Y9 11/11/05 26/06/06  3276 9 
Network overall 11/10/05 -  42900 157 
      
WEST MIDLANDS      
WM1 19/05/09 01/11/09  5605 0 
WM2 19/05/09 01/10/09  2252 3 
WM3 19/05/09 01/01/11  5571 0 
Network overall 19/05/09 -  15284 3 
      
      
h. Hospitals Y3a and Y3b belong to the same Trust and these are the combined 
number of live births. 
i. Hospitals Y7a and Y7b belong to the same Trust and these are the combined 
number of live births. 
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5.4 Recruitment 
Overall, 458 children were recruited into the CDSS by hospitals in the target area.  The 
numbers recruited by each hospital and by each Neonatal Network are shown in Table 5-3.  
The numbers recruited into the CDSS from the start of the study are shown for each yearly 
quarter in Figure 5-1.  Quarterly recruitment initially increased during each quarter as 
expected as the number of participating hospitals increased.  Recruitment for the second 
quarter of 2007 was above 20 cases, and stayed above 20 for each quarter for the next three 
years.  Recruitment was less than 20 for the second and third quarters of 2010, but this is 
balanced by a particularly high recruitment of over 30 cases for the last quarter of 2010.  The 
cumulative recruitment is shown in Figure 5-2. 
 
Figure 5-1. Recruitment into the CDSS by quarter. 
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Figure 5-2. Cumulative recruitment into the CDSS.  
 
5.5 Case characteristics for the CDSS 
The case characteristics for children entered into the CDSS are summarised in Table 5-4.  Of 
the 479 children with newborn consent there were 234 (48.9%) with an eligible neonatal 
sample.  There is no significant difference in the mean birth weight or gestational age for 
those with an eligible neonatal sample, those with an ineligible neonatal sample or those 
with no neonatal sample.
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Table 5-4. Characteristics of the children entered in the CDSS. 
 
All cases 
with 
newborn 
consent 
Cases with an 
eligible 
neonatal 
sample 
Cases with an 
ineligible 
neonatal 
sample 
Cases with no 
neonatal 
sample 
Cases with 
a neonatal 
blood film 
Cases with a 
sample at 0-
3months  
Cases with a 
sample at 1
st
 
birthday 
Cases with a 
sample at 2
nd
 
birthday 
Cases with a 
sample at 3
rd
 
birthday  
Cases with a 
sample at 4
th
 
birthday 
Number 479 234 27 218 189 247 48 10 14 5 
Sex:       boys 
              girls 
          missing 
265 (55%) 
213 (44%) 
1 (<1%) 
125 (53%) 
109 (47%) 
 
17 (63%) 
10 (37%) 
 
123 (56%) 
94 (43%) 
 
95 (50%) 
94 (50%) 
 
134 (54%) 
113 (46%) 
 
24 (50%) 
24 (50%) 
 
7 (70%) 
3 (30%) 
 
12 (86%) 
2 (14%) 
 
3 (60%) 
2 (40%) 
 
Mean birth 
weight 
(grams)  
2881 2878 2983 2871 2918 n/a n/a n/a n/a n/a 
Mean 
gestation 
(weeks) 
37.6 37.6 38 37.6 37.6 n/a n/a n/a n/a n/a 
 
 
 Chapter 6 Results: haematological parameters in DS neonates.  
6.1 Introduction 
This chapter presents the results of the full blood count analysis for DS neonates in the 
CDSS.  Values are expressed as mean (95% CI) and range (5- 95% percentiles).  Where 
results are referred to as significant, this indicates that p<0.05. 
6.2 Case characteristics 
The case characteristics for neonates eligible for the analysis of haematological parameters 
are shown in Table 6-1.   
 
Table 6-1. Case characteristics for samples included in the neonatal full blood count analysis. 
 
 
Sampled within 28 
days of birth 
Sampled within 7 days 
of birth 
Number  % Number % 
Total 234 (100) 177 (100) 
      
Sex Male 125 (53) 94 (53) 
      Birth weight < 2500 57 (24) 35 (20) 
(grams) 2501 to 3499 116 (50) 92 (52) 
 > 3500 28 (12) 23 (13) 
 missing 33 (14) 27 (15) 
      
Gestational age  30 to 32  10 (4) 5 (3) 
(weeks) 33 to 37  77 (33) 51 (29) 
 
38 to 42  140 (60) 115 (65) 
 
missing 7 (3) 6 (3) 
      
Processing time  0-2 132 (56) 95 (54) 
(days) 3-7 102 (44) 82 (46) 
      
A total of 234 cases had a sample taken within 28 days of birth, and of these 177 samples 
were taken within 7 days of birth.  There was a slight male preponderance, as there is in the 
general population, with 53% cases being male.   
As described in the methods information about birth weight and gestational age was 
requested on the hospital referral form completed by the clinician recruiting the family, and 
also on the initial questionnaire sent out to families.  Information about birth weight was 
missing for 33 (14%) cases, and for gestational age for 7 (3%) cases.  Half of cases had a 
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birth weight between 2501 to 3499 grams, with 24% being under this, and 12% being over 
this.  The distribution remained very similar when only those with a sample taken within 7 
days of birth were considered.  Just over half of all samples were processed within 2 days of 
venepuncture, with the remainder of samples being processed within 7 days of venepuncture. 
Again, this distribution was similar when only those with a sample taken within 7 days of birth 
were considered.  Just over a third of cases were preterm, with 4% being born at 30-32 
weeks gestation, 33% being born at 33-37 weeks gestation and 60% being born at 38-42 
weeks gestation.  When those with samples taken within 7 days of birth were considered 
there was a slight increase in the proportion born at term, with 65% cases being born at 38-
42 weeks gestation.   
6.3 Results for samples taken within the first week of life 
This section considers samples taken within the first week of life only.   
6.3.1 Red blood cells 
These results are shown in Table 6-2.  The red blood cell values for all samples were as 
follows: red blood cell count 5.6 (4.3-6.6) x1012 cells/l; haemoglobin 21.1 (16.8-25.3) g/dl; 
mean cell haemoglobin 37.4 (33.8-41.3) pg; haematocrit 0.6 (0.51-0.76) %; mean cell volume 
115.5 (102.1-128.5) fl; and nucleated red blood cells 3.8 (0-20.3) x109 cells/l.  There was little 
difference when the sample set was restricted to only those processed within 2 days. The 
main changes were a slight fall in the haemoglobin to 20.9 (15.9-25.8) g/dl; and in the mean 
cell volume to 111.7 (98.2-123.4) fl. 
6.3.2 White blood cell parameters 
These results are shown in Table 6-3.  The white blood cell values for all samples were as 
follows: white cell count 12.9 (6.1-24.2) x109 cells/l; neutrophils 8 (1.9-16) x109 cells/l; 
lymphocytes 3.6 (1.5-7.5) x109 cells/l; basophils 0.2 (0-0.6) x109 cells/l; eosinophils 0.2 (0-0.4) 
x109 cells/l; and monocytes 1.0 (0.2-2.0) x109 cells/l.  There were no notable differences in 
these when the set was restricted to those processed within 2 days only. 
These white blood cell results are restricted to those counts where the machine produced a 
complete white blood cell differential.  In some cases the machine was not able to adequately 
assign a white blood cell subtype.  When this occurred the machine was most likely to omit to 
give a neutrophil or lymphocyte count.  In some of these cases a basophil count was the only 
white blood cell subtype to be obtained.  The results from samples where a full differential 
count was available were compared with those from samples where only a part of the white 
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blood cell differential was obtained.  This indicated that those with a full white blood cell 
differential were the most robust.  This consideration has some overlap with the time to 
processing, which is considered later in this chapter, but is not the same. 
6.3.3 Platelets 
These results are shown in Table 6-4.  The platelet count was 142 (35-255) x109 cells/l and 
mean platelet volume 12.1 (10.4-13.9) fl for all samples.  These only changed slightly when 
the set was restricted to those processed within 2 days, yielding a marginally higher platelet 
count of 149 (35-290) x109 cells/l and a lower mean platelet volume of 11.7 (9.8-13.5) fl. 
 
 
Table 6-2. Range and mean values for red blood count parameters in DS neonates in the first week of life and regression analysis of gestation and 
birth weight. 
 
  Range (5-95% 
percentile) 
 Mean count (95% 
CI) 
 
Regression Model Effects 
 N‡   Model 
N** 
Gestation (per added week) Birth weight (per 100g) 
     
PROCESSED WITHIN 2 DAYS     
Red Cell Count (x10
12
 cells/l) 95 4.09-6.62 5.6 (5.4, 5.7) 77 0.21 (0.1, 0.31) -0.02 (-0.06, 0.01585) 
Haemoglobin (g/dl) 95 15.9-25.8 20.9 (20.2, 21.5) 77 0.78 (0.38, 1.18) -0.11 (-0.25, 0.04) 
Mean Cell Haemoglobin (pg) 95 33.6-41.2 37.4 (36.9, 37.9) 77 0.04 (-0.3, 0.38) -0.05 (-0.17, 0.07) 
Haematocrit (%) 94 0.46-0.74 0.6 (0.6, 0.6) 76 0.02 (0.01, 0.03) -0.003 (-0.01, 0.001) 
Mean Cell Volume (fl)  95 98.2-123.4 111.7 (110.2, 113.2) 77 0.05 (-0.97, 1.07) -0.2 (-0.56, 0.16) 
Nucleated RBC (x10
9
 cells/l) 73 0-22.8 4.2 (2.1, 6.3) 57 0.06 (-1.5, 1.62) -0.29 (-0.83, 0.25) 
       
PROCESSED WITHIN 7 DAYS     
Red Cell Count (x10
12
 cells/l) 177 4.3-6.6 5.6 (5.5, 5.7) 150 0.15 (0.08, 0.22) -0.02 (-0.04, 0.004) 
Haemoglobin (g/dl) 177 16.8-25.3 21.1 (20.7, 21.5) 150 0.55 (0.29, 0.81) -0.08 (-0.17, 0.01) 
Mean Cell Haemoglobin (pg) 177 33.8-41.3 37.7 (37.3, 38) 150 -0.0024 (-0.24, 0.24) -0.01 (-0.09, 0.07) 
Haematocrit (%) 176 0.51-0.76 0.6 (0.6, 0.7) 149 0.02 (0.01, 0.02) -0.0017 (-0.004, 0.0008) 
Mean Cell Volume (fl)  177 102.1-128.5 115.5 (114.3, 116.6) 150 0.12 (-0.69, 0.93) 0.1 (-0.17, 0.37) 
Nucleated RBC (x10
9
 cells/l) 145 0-20.3 3.8 (2.5, 5.2) 122 0.18 (-0.79, 1.15) -0.12 (-0.44, 0.19) 
       
 
Blood parameters significantly (p<0.05) affected by gestation or birth weight are shown in bold. 
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Table 6-3. Range and mean values for white blood count parameters in DS neonates in the first week of life and regression analysis of gestation and 
birth weight. 
 
Parameter  Range (5-95% 
percentile) 
 Mean count (95% 
CI) 
 
Regression Model Effects 
 N‡   Model 
N** 
Gestation (per added week) Birth weight (per 100g) 
     
PROCESSED WITHIN 2 DAYS: FULL DIFFERENTIAL COUNT AVAILABLE   
White Cell Count (x10
9
 cells/l) 68 6.1-24.2 13.0 (11.2, 14.9) 56 0.47 (-0.71, 1.65) 0.1 (-0.34, 0.54) 
Neutrophils (x10
9
 cells/l)  68 1.9-18.5 8.1 (6.6, 9.5) 56 0.69 (-0.21, 1.58) -0.01 (-0.35, 0.32) 
Lymphocytes (x10
9
 cells/l)  68 1.5-7.5 3.6 (3.1, 4.1) 56 -0.09 (-0.43, 0.25) 0.07 (-0.05, 0.2) 
Basophils (x10
9
 cells/l)  68 0-0.6 0.2 (0.1, 0.3) 56 -0.0033 (-0.03, 0.02) 0.00421 (-0.01, 0.01) 
Eosinophils (x10
9
 cells/l)  68 0-0.5 0.2 (0.1, 0.2) 56 0.0039 (-0.02, 0.03) -0.002(-0.01, 0.006) 
Monocytes (x10
9
 cells/l)  68 0.3-2.1 1.0 (0.9, 1.2) 56 -0.023 (-0.11, 0.06) 0.02 (-0.01, 0.05) 
       
PROCESSED WITHIN 7 DAYS: FULL DIFFERENTIAL COUNT AVAILABLE  
White Cell Count (x10
9
 cells/l) 81 6.1-24.2 12.9 (11.3, 14.6) 67 0.39 (-0.597, 1.38) 0.04 (-0.33, 0.4) 
Neutrophils (x10
9
 cells/l)  81 1.9-16.0 8.0 (6.7, 9.3) 67 0.58 (-0.176, 1.33) -0.03 (-0.31, 0.25) 
Lymphocytes (x10
9
 cells/l)  81 1.5-7.5 3.6 (3.1, 4.1) 67 -0.05 (-0.337, 0.24) 0.04 (-0.06, 0.14) 
Basophils (x10
9
 cells/l)  81 0-0.6 0.2 (0.1, 0.2) 67 -0.005 (-0.027, 0.02) 0.002 (-0.01, 0.01) 
Eosinophils (x10
9
 cells/l)  81 0-0.4 0.2 (0.1, 0.2) 67 0.01 (-0.011, 0.03) -0.003 (-0.01, 0.004) 
Monocytes (x10
9
 cells/l)  81 0.3-2.0 1.0 (0.9, 1.1) 67 -0.03 (-0.111, 0.05) 0.01 (-0.02, 0.04) 
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Table 6-4. Range and mean values for platelet parameters in DS neonates in the first week of life and regression analysis of gestation and birth 
weight for samples. 
 
  
Range (5-95% 
percentile) 
 Mean count (95% 
CI) 
Regression Model Effects 
 N‡   
Model 
N** 
Gestation (per added week) Birth weight (per 100g) 
     
PROCESSED WITHIN 2 DAYS   
Platelet Count (x10
9
 cells/l)  93 35-290 149 (133.2, 164.2) 76 -30.91 (-40.06, -21.75) 6.53 (3.31, 9.75) 
Mean Platelet Volume (fl)  27 9.8-13.5 11.7 (11.3, 12.2) 24 0.3 (-0.0007, 0.59) -0.12 (-0.24, 0.01) 
       
PROCESSED WITHIN 7 DAYS  
Platelet Count (x10
9
 cells/l)  172 35-255 142 (131.9, 152.1) 146 -20.85 (-27.18, -14.53) 3.8 (1.67, 5.92) 
Mean Platelet Volume (fl)  50 10.4-13.9 12.1 (11.8, 12.4) 45 0.22 (0.02, 0.42) -0.06 (-0.14, 0.02) 
       
 
Blood parameters significantly (p<0.05) affected by gestation or birth weight are shown in bold.
 
 
6.4 Association with birth weight 
As this is likely to be most relevant to samples taken closer to birth this was examined in 
cases with samples taken within the first 7 days of life.  The results for all red blood cell, white 
blood cell and platelet parameters are shown in Table 6-2, Table 6-3 and Table 6-4 
respectively.  Where there is a significant result this is highlighted in bold. 
Red blood cells 
Despite the association between birth weight and gestational age, there were no significant 
association between birth weight and red blood cell parameters.   
White blood cells 
There was no significant association between birth weight and white blood cell parameters.   
Platelets 
Regression analysis showed that there was a small increase in the platelet count with 
increasing birth weight.  This remained significant (p<0.05) and the association became larger 
when the set was restricted to those processed within 2 days, with an increase in platelet 
count of 6.5 (3.3, 9.8) x109 cells/l for each 100g increase in birth weight. This is shown in 
Figure 6-1. 
 
 
Figure 6-1. The association between birth weight and platelet count for neonates with DS 
sampled within the first seven days of life.   
 
Predicted values (+/- 95% CI) from linear regression models fitted to the data are shown.  Age at 
sampling and gestational age were set to 2 days of age and 38 weeks, respectively, to generate 
the predictions.  All measures were based on samples processed within seven days of 
sampling.  
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6.5 Association with gestational age  
Again this was examined in cases with samples taken within the first 7 days of life.  The 
results for all red blood cell, white blood cell and platelet parameters are shown in Table 6-2, 
Table 6-3 and Table 6-4 respectively.  Where there is a significant result this is highlighted in 
bold. 
Red blood cells 
Increasing gestational age was significantly associated (p<0.05) with an increase in 
haemoglobin, red cell count and haematocrit.  This association remained and became slightly 
more pronounced when only those processed within 2 days were considered.  In this set 
there was an increase in the haemoglobin of 0.78 g/dl, in the red cell count of 0.21 x1012 
cells/l, and in the haematocrit of 0.02% for each added week of gestation.  This is shown in 
Figure 6-2.   
White blood cells 
There was no significant association between gestational age and white blood cell 
parameters.   
Platelets 
Regression analysis showed that the platelet count fell with increasing gestational age.  This 
remained significant (p<0.05) and the association became larger when the set was restricted 
to those processed within 2 days, with a fall in platelet count of 30.9 (40.1, 21.8) x109 cells/l 
for each added week of gestational age.  This is shown in Figure 6-3.  When samples 
processed within 7 days of sampling were considered the mean platelet volume appeared to 
increase with increasing gestational age.  This association disappeared when the set was 
restricted to samples processed within 2 days only.   
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Figure 6-2. The association between gestational age and haemoglobin, haematocrit and red 
blood cell count in neonates with DS sampled within the first seven days of life.  
 
Predicted values (+/- 95% CI) from linear regression models fitted to the data are shown in blue.  
Age at sampling and birth weight were set to 2 days of age and 3000 grams, respectively.  
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Figure 6-3. The association between gestational age and platelet count in neonates with DS 
sampled within the first seven days of life.  
 
Predicted values (+/- 95% CI) from linear regression models fitted to the data are shown in blue.  
Age at sampling and birth weight were set to 2 days of age and 3000 grams, respectively. 
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6.6 Association with sampling to processing interval 
This is the interval between taking the sample and sample processing, given in whole days.  
Data from all 234 children sampled with 28 days of birth were included in this analysis.  All 
samples were processed within 7 days of venepuncture.  The distribution was skewed so that 
more children had samples processed with a shorter interval than with a longer interval.  Over 
half (56%) of samples were processed within 2 days of venepuncture.  This is illustrated in 
Figure 6-4.  
 
Figure 6-4. Number of samples at each sampling to processing interval. 
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6.6.1 Red blood cells 
Irrespective of interval length, nearly all samples had a complete set of red cell 
measurements.  The only exception was in the nucleated red blood cell count, which was 
missing in 34 cases.  There was no apparent trend in the number of samples which had a 
missing nucleated red blood cell result with interval length.   
The results are shown in Table 6-5.  The mean red blood cell count, the haemoglobin, the 
mean cell haemoglobin and the nucleated red blood cell count did not vary significantly with 
increasing sampling to processing interval.   The haematocrit and the mean cell volume both 
increased significantly (p<0.05) as the sampling to processing interval increased.  The 
haematocrit increased by 0.013 % with each additional day interval between sampling and 
processing, and the mean cell volume increased by 2.117 fl for each additional day.  This is 
shown graphically in Figure 6-5 and Figure 6-6.  It can be seen that there is a trend for the 
mean values at each day interval to increase for the haematocrit and the mean cell volume.  
In contrast, the other lines are approximately linear.   
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Table 6-5. Association between the number of days between sampling and processing on all 
of the blood parameters from children sampled within 28 days of life.   
 
Number of 
children 
Effect estimate  
(per day) 
(95% CI) p-value
 
     
RED BLOOD CELL PARAMETERS 
Red Cell Count (x10
12
 
cells/l) 
234 0.008 (-0.048, 0.065) 0.77 
Haemoglobin (g/dl) 234 0.106 (-0.118, 0.33) 0.36 
Mean Cell Haemoglobin 
(pg) 
234 0.151 (-0.02, 0.322) 0.08 
Haematocrit (%) 231 0.013 (0.007, 0.02) 6.00x10
-5
 
Mean Cell Volume (fl)  234 2.117 (1.614, 2.621) 1.79 x10
-16
 
Nucleated RBC (x10
9
 
cells/l) 
188 -0.388 (-0.951, 0.176) 0.18 
     
WHITE BLOOD CELL PARAMETERS: ALL SAMPLES PROCESSED WITHIN 7 DAYS 
White Cell Count (x10
9
 
cells/l) 
234 0.036 (-0.536, 0.609) 0.90 
Neutrophils (x10
9
 cells/l)  125 -0.722 (-1.335, -0.109) 2.10E-02 
Lymphocytes (x10
9
 cells/l)  126 -0.197 (-0.474, 0.08) 0.16 
Basophils (x10
9
 cells/l)  203 0.005 (-0.009, 0.019) 0.50 
Eosinophils (x10
9
 cells/l)  137 -0.008 (-0.023, 0.007) 0.29 
Monocytes (x10
9
 cells/l) 137 -0.09 (-0.144, -0.035) 0.00 
     
WHITE BLOOD CELL PARAMETERS: FULL DIFFERENTIAL; PROCESSED WITHIN 7 DAYS 
White Cell Count (x10
9
 
cells/l) 
125 -0.926 (-1.735, -0.117) 0.02 
Neutrophils (x10
9
 cells/l)  125 -0.722 (-1.335, -0.109) 2.10E-02 
Lymphocytes (x10
9
 cells/l)  125 -0.152 (-0.438, 0.134) 2.96E-01 
Basophils (x10
9
 cells/l)  125 -0.003 (-0.025, 0.019) 7.97E-01 
Eosinophils (x10
9
 cells/l)  125 -0.005 (-0.021, 0.011) 5.21E-01 
Monocytes (x10
9
 cells/l)  125 -0.075 (-0.136, -0.014) 1.62E-02 
     
WHITE BLOOD CELL PARAMETERS: FULL DIFFERENTIAL;  PROCESSED WITHIN 2 DAYS 
White Cell Count (x10
9
 
cells/l) 
101 -2.769 (-4.58, -0.958) 2.73E-03 
Neutrophils (x10
9
 cells/l)  101 -2.127 (-3.525, -0.729) 2.86E-03 
Lymphocytes (x10
9
 cells/l)  101 -0.544 (-1.162, 0.074) 8.45E-02 
Basophils (x10
9
 cells/l)  101 0.021 (-0.03, 0.073) 4.19E-01 
Eosinophils (x10
9
 cells/l)  101 0.016 (-0.02, 0.051) 3.90E-01 
Monocytes (x10
9
 cells/l) 101 0.084 (-0.052, 0.22) 2.25E-01 
     
PLATELET PARAMETERS     
Platelet Count (x10
9
 cells/l)  227 -4.937 (-11.069, 1.194) 0.11 
Mean Platelet Volume (fl)  79 0.195 (0.058, 0.332) 5.32 x10
-3
 
 
Blood parameters significantly (P<0.05) affected by the number of days between sampling and 
processing are shown in bold. 
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Figure 6-5. Stability of haemoglobin, haematocrit and red cell count with increasing sampling to 
processing interval. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.  
An increasing trend is apparent for haematocrit; the other lines are approximately linear. 
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Figure 6-6. Stability of mean cell haemoglobin, mean cell volume and nucleated red cell count 
with increasing sampling to processing interval. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.  
An increasing trend is apparent for mean cell volume; the other lines are approximately linear. 
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6.6.2 White blood cells 
The total white cell count was reported for all cases, regardless of interval length.  However, a 
differential white cell count was not reported for all of these.  A sample was less likely to have 
a differential white cell count with each increase in interval time.  Once the sampling to 
processing interval reached ≥3 days fewer than 50% of the samples had a differential white 
cell count. 
In order to examine the effect of interval length more closely the white blood cell data was 
considered in three sets: all samples; samples processed within 7 days and with a complete 
differential white blood cell count; and samples processed within 2 days and with a complete 
differential white blood cell count.  These results are shown in Table 6-5. 
In all three sets the neutrophil count fell with increasing interval length.  The neutrophil count 
accounts for the majority of the total white cell count.  The total white blood cell count fell with 
increasing sampling to processing interval length in the two sets which were restricted to 
those samples with a complete white blood cell differential.  However, this effect is lost in the 
set that included all samples.  Taken together the data indicates that the total white cell count 
and the neutrophil count both decrease with increasing interval length.  The monocyte count 
also fell with increasing interval length.   
The change in white blood cell parameters with increasing sampling to processing interval is 
shown graphically in Figure 6-7 and Figure 6-8.  When the set is restricted to samples 
processed within 2 days only then the lines between the means for lymphocytes, monocytes, 
basophils and eosinophils are all approximately linear.  However, the mean neutrophil count 
clearly falls after a sampling to processing interval of one day indicating that this parameter is 
the least stable and also showing that this drives the results for total white cell count stability.    
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Figure 6-7. Stability of white blood cell, neutrophil and lymphocyte counts with increasing 
sampling to processing interval.  
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.  
When a 2 day cut-off is used it can be seen that the lymphocyte results are approximately 
linear.  However, the neutrophil count clearly falls in the first 24 hour interval. 
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Figure 6-8. Stability of monocyte, basophil and eosinophil counts with increasing sampling to 
processing interval.  
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.  
When a 2 day cut-off is used it can be seen that the monocyte, basophil and eosinophil results 
are approximately linear.   
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6.6.3 Platelets 
A platelet count was recorded in 227/234 samples.  In some cases it was not possible to 
obtain a platelet count as there was a clot in the sample.  There was no apparent relationship 
between the likelihood of having either a platelet count or mean platelet volume reported and 
sampling to processing interval length.  Mean platelet volume was reported in a minority of 
the samples.   
The results of the regression analysis for the stability with increasing sampling to processing 
interval are provided in Table 6-5.  Mean platelet volume increased by 0.195 fl with each 
additional day between sampling and processing.  There was only one observation at seven 
days post-sampling which may have influenced the fit of the model.  The change in platelet 
parameters with increasing sampling to processing interval is illustrated in Figure 6-9.  There 
is an upward trend in the mean result for mean platelet volume after a sampling to processing 
interval of 5 days, although there are fewer data points with higher sampling to processing 
intervals which may distort this.  When a cut-off of 4 days is used it can be seen that the line 
becomes approximately linear. 
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Figure 6-9. Stability of platelet parameters with increasing sampling to processing interval.  
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.  
An increasing trend is apparent for the mean platelet volume (B), although the sharp increase 
between 6 and 7 days is likely to be exaggerated as there is only one result for day 7. When a 
cut-off of 4 days is used the line is approximately linear. 
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6.6.4 Determining the best cut-off for reliability 
Overall, there were six parameters that varied significantly (p<0.05) with an increasing 
sampling to processing interval length within the 7 day period: haematocrit; mean red blood 
cell volume; white blood cell count; neutrophil count; monocyte count; and mean platelet 
volume.  The model used to examine this had compared results with a sampling to 
processing interval of 0 (ie processed on the day of sampling) with those from samples with a 
sampling to processing interval of ≤7 days.  The analysis showed that results for these six 
parameters derived from samples with a sampling to processing interval of ≤7 days were 
significantly (p<0.05) different from those just taken from samples processed on the day of 
sampling.  However, for all other parameters there was no significant difference in results with 
the sampling to processing interval and the parameters are demonstrated to be stable. 
In order to determine when the sampling to processing interval became important for each of 
these six parameters further regression analysis models were created for each of the six 
parameters.  In these models the results from samples processed on the day of sampling 
were compared with results from all samples with a sampling to processing interval of ≤1 day, 
≤2 days, ≤3 days, ≤4 days, ≤5 days and ≤6 days.  The longest sampling to processing interval 
for which there was no significant (p<0.05) trend compared with the results from samples 
processed on the day of sampling was identified for each of the parameters.  The data could 
then be restricted appropriately.   
For all of the parameters apart from the six that varied with sampling a cut-off of 7 days could 
be used.  The trend in mean platelet volume was removed with a cut-off point of 4 days 
indicating that results were acceptable up to and including those with a sampling to 
processing interval of ≤4 days.   The trend in haematocrit, mean red blood cell volume and 
monocyte count disappeared when the cut-off point for these was reduced to ≤2 days 
indicating that results were acceptable up to and including those with a sampling to 
processing interval of ≤2 days.  This is shown graphically in Figure 6-5, Figure 6-6 and Figure 
6-8. 
However, even when a cut-off of 2 days was used for the neutrophil count the regression 
model showed a significant difference between results from samples processed on the day of 
sampling and those processed ≤2 days from sampling.  This is shown in Figure 6-7.  
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6.7 Association with postnatal age 
The association with postnatal age was examined in all of the 234 samples taken during the 
first 28 days of life.  In addition, the mean value and 95% CI for each haematological 
parameter was calculated for each week of life during the neonatal period.  These results are 
shown in Table 6-6, Table 6-7 and Table 6-8. 
Table 6-6. Association with postnatal age and blood parameters for children with DS sampled 
within 28 days of life.   
 
Blood parameter 
Number of 
children 
Effect estimate  
(per day) 
(95% CI) 
    
RED BLOOD CELL PARAMETERS 
Red Cell Count (x10
12
 cells/l) 234 -0.0391 (-0.0642, -0.014) 
Haemoglobin (g/dl) 234 -0.29 (-0.34, -0.23) 
Mean Cell Haemoglobin (pg) 234 -0.12 (-0.17, -0.07) 
Haematocrit (%)
a 
130 -0.0081 (-0.0106, -0.0056) 
Mean Cell Volume (fl)
a
  132 -0.15 (-0.37, 0.06) 
Nucleated RBC (x10
9
 cells/l) 200 -0.59 (-0.84, -0.34) 
    
WHITE BLOOD CELL PARAMETERS
a 
White Cell Count (x10
9
 cells/l) 101 -0.57937 (-0.89, -0.26) 
Neutrophils (x10
9
 cells/l) 101 -0.61 (-0.84, -0.39) 
Lymphocytes (x10
9
 cells/l)  101 0.018 (-0.053, 0.089) 
Basophils (x10
9
 cells/l)  101 -0.0047 (-0.0105, 0.0011) 
Eosinophils (x10
9
 cells/l)  101 0.0003 (-0.0038, 0.0043) 
Monocytes (x10
9
 cells/l) 101 0.0034 (-0.0121, 0.0189) 
    
PLATELET PARAMETERS    
Platelet Count (x10
9
 cells/l)  227 7.39 (5.86, 8.92) 
Mean Platelet Volume (fl)
b
  70 0.05 (0.00228, 0.09) 
    
    
 
a. data restricted to samples processed within 2 days of venepuncture 
b. data restricted to samples processed within 4 days of venepuncture 
 
Blood parameters with a significant (p<0.05) association with postnatal age are  
shown in bold.  
  
 
 
Table 6-7. Mean values for haematological parameters in children with DS sampled within 28 days of life shown for each week of life. 
 
 0-7 days 8-14 days 15-21 days 22-28 days 
 
Parameter 
 
N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) 
    
RED BLOOD CELL PARAMETERS         
Red Cell Count (x10
12
 cells/l) 177 5.6 (5.5, 5.7) 12 5.4 (5.2, 5.6) 10 4.9 (4.5, 5.2) 35 4.1 (3.7, 4.5) 
Haemoglobin (g/dl) 177 21.1 (20.7, 21.5) 12 19.8 (19.1, 20.5) 10 17.0 (15.8, 18.2) 35 14.5 (13.2, 15.9) 
Mean Cell Haemoglobin (pg) 177 37.7 (37.3, 38.0) 12 36.8 (36.3, 37.4) 10 34.9 (34.0, 35.9) 35 34.8 (33.6, 36.0) 
Haematocrit (%) 176 0.6 (0.6,0.7) 12 0.61 (0.59, 0.63) 8 0.53 (0.49, 0.57) 35 0.46 (0.41, 0.51) 
Mean Cell Volume (fl)  177 115.5 (114.3, 116.6) 12 113.3 (111.4, 115.2) 10 108.3 (104.8, 111.8) 35 109.9 (105.0, 114.7) 
Nucleated RBC (x10
9
 cells/l) 145 3.8 (2.5, 5.2) 12 0.68 (0.12, 1.24) 8 0.04 (0, 0.1) 35 0.13 (0, 0.39) 
         
WHITE BLOOD CELL PARAMETERS         
White Cell Count (x10
9
 cells/l) 81 12.9 (11.3, 14.6) 8 9.9 (8.0, 11.7) 8 11.0 (8.2, 13.9) 28 9.7 (8.1, 11.2) 
Neutrophils (x10
9
 cells/l)  81 8.0 (6.7, 9.3) 8 4.6 (3.6, 5.5) 8 4.5 (3.4, 5.7) 28 3.6 (2.7, 4.5) 
Lymphocytes (x10
9
 cells/l)  81 3.6 (3.1, 4.1) 8 3.9 (2.9, 4.8) 8 4.1 (3.4, 4.8) 28 4.2 (3.5, 5.0) 
Basophils (x10
9
 cells/l)  81 0.2 (0.1, 0.2) 8 0.16 (0.13, 0.19) 8 0.15 (0.07, 0.24) 28 0.14 (0.1, 0.18) 
Eosinophils (x10
9
 cells/l)  81 0.2 (0.1, 0.2) 8 0.16 (0.12, 0.20) 8 0.16 (0.09, 0.20) 28 0.14 (0.11, 0.33) 
Monocytes (x10
9
 cells/l)  81 1.0 (0.9, 1.1) 8 1.0 (0.9, 1.2) 8 1.0 (0.8, 1.3) 28 1.3 (0.6, 1.9) 
         
PLATELET PARAMETERS         
Platelet Count (x10
9
 cells/l) 172 142 (131.9, 152.1) 11 164 (145, 184) 9 237 (196, 278) 35 264 (215, 312) 
Mean Platelet Volume (fl)  50 12.1 (11.8, 12.4) 4 12.4 (11.8, 13.0) 7 12.3 (11.4, 13.1) 18 11.6 (10.9, 12.3) 
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Table 6-8. Ranges for haematological parameters in children with DS sampled within 28 days of life shown for each week of life. 
 
 0-7 days 8-14 days 15-21 days 22-28 days 
Parameter N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
    
RED BLOOD CELL PARAMETERS         
Red Cell Count (x10
12
 cells/l) 177 4.3-6.6 12 3.1-6.2 10 3.3-4.8 35 3.7-6.7 
Haemoglobin (g/dl) 177 16.8-25.3 12 9.5-19.6 10 11.6-17.6 35 13.2-23.2 
Mean Cell Haemoglobin (pg) 177 33.8-41.3 12 28.6-39.5 10 31.7-39.6 35 32.9-39.5 
Haematocrit (%) 176 0.51-0.76 12 0.3-0.69 8 0.36-0.58 35 0.4-0.71 
Mean Cell Volume (fl)  177 102.1-128.5 12 84.6-127.1 10 97.3-127.2 35 95.1-123.5 
Nucleated RBC (x10
9
 cells/l) 145 0-20.3 12 0 8 0-0.2 35 0-0.2 
         
WHITE BLOOD CELL PARAMETERS         
White Cell Count (x10
9
 cells/l) 81 6.1-24.2 8 8.1-10.7 8 4.3-12.3 28 5.7-22.0 
Neutrophils (x10
9
 cells/l)  81 1.9-16.0 8 2.2-4.8 8 1.2-6.0 28 1.6-11.1 
Lymphocytes (x10
9
 cells/l)  81 1.5-7.5 8 3.4-4.9 8 1.5-5.5 28 1.2-7.4 
Basophils (x10
9
 cells/l)  81 0-0.6 8 0.08-0.19 8 0-0.11 28 0.02-0.38 
Eosinophils (x10
9
 cells/l)  81 0-0.4 8 0.01-0.31 8 0.09-0.2 28 0.01-0.5 
Monocytes (x10
9
 cells/l)  81 0.3-2.0 8 0.6-2.7 8 0.1-1.1 28 0.5-2.1 
         
PLATELET PARAMETERS         
Platelet Count (x10
9
 cells/l) 172 35-255 11 102-463 9 167-451 35 61-333 
Mean Platelet Volume (fl)  50 10.4-13.9 4 10.2-12.6 7 10.5-12.9 18 10.9-14.3 
         
 
 
Red blood cells 
The haemoglobin, red blood cell count, haematocrit, mean cell haemoglobin and the 
nucleated red blood cell count all fell significantly (p<0.05) during the neonatal period with 
increasing postnatal age.  The haemoglobin fell by 0.0391 g/dl; the red blood cell count fell by 
0.29 x1012 cells/l; the haematocrit fell by 0.0081%; the mean cell haemoglobin fell by 0.12 pg; 
and the nucleated red blood cell count fell by 0.59 x109 cells/l with each postnatal day.  The 
nucleated red blood cell count fell to zero so that there were no nucleated red blood cells 
reported on samples ≥ 9 postnatal days old at sampling.  The mean red blood cell volume 
remained fairly stable throughout the neonatal period.  The pattern of change of the red blood 
cell parameters with postnatal age is illustrated in Figure 6-10 and Figure 6-11. 
Children were considered polycythaemic if either the total haemoglobin was greater than 22 
g/dl or the haematocrit was greater than 0.65.  In the first week of life 95 (54%) of the 176 
cases were polycythaemic.  This fell rapidly so that there were no cases of polycythaemia by 
the fourth week of life.  Details are shown in Table 6-9. 
 
Age at Sampling 
(days) 
Polycythaemic (n) Thrombocytopenic (n) 
0-7 54 (176) 61 (172) 
8-14 20 (35) 26 (35) 
15-21 17 (12) 18 (11) 
22-28 0 (8) 0 (9) 
 
Table 6-9. Percentage of children who were polycythaemic or thrombocytopenic by age for each 
postnatal week.  
 
Polycythaemia was defined as total haemoglobin >22 g/dl or haematocrit>0.65. 
Thrombocytopenia was defined as platelet count<150x109 cells/l. 
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Figure 6-10. The association between postnatal age and haemoglobin, haematocrit and red 
blood cell count in children with DS sampled within the first 28 days of life. 
 
The black line shows the mean value with the 95% CI shown in blue. 
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Figure 6-11. The association between postnatal age and mean cell haemoglobin, mean cell 
volume and nucleated red blood cell count in children with DS sampled within the first 28 days 
of life. 
 
The black line shows the mean value with the 95% CI shown in blue.  
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White blood cells 
The association between postnatal age and white blood cell parameters is shown inTable 
6-6.  The white blood cell count fell by 1.026 x109 cells/l; and the neutrophil count fell by 0.61 
x109 cells/l with each postnatal day.  The pattern of this fall is illustrated in Figure 6-12.. This 
shows that both the white blood cell count and the neutrophil count fall most rapidly during 
the first 2 weeks of life and are fairly stable thereafter.  In the graphic model the count 
appears to rise towards the end of the neonatal period, but there are fewer data points at this 
end.  The effect on the total white blood cell count is largely driven by the pattern of change of 
the neutrophil count.  The only other white blood cell type to vary during the neonatal period 
is the basophil count which appears to fall throughout the neonatal period, but in a more 
linear fashion.  This did not reach significance.  The pattern of change of the lymphocyte, 
monocyte, basophil and eosinophil counts with increasing postnatal age is illustrated in 
Figure 6-12 and Figure 6-13. 
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Figure 6-12. The association between postnatal age and total white cell, neutrophil and 
lymphocyte  count in children with DS sampled within the first 28 days of life. 
 
The black line shows the mean value with the 95% CI shown in blue. 
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Figure 6-13. The association between postnatal age and monocyte, basophil and eosinophil 
count in children with DS sampled within the first 28 days of life. 
 
The black line shows the mean value with the 95% CI shown in blue. 
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Platelets 
The association between postnatal age and white blood cell parameters is shown in Table 
6-6 and in Figure 6-14.  In contrast to the red and white blood cell parameters the platelet 
count increases in a linear manner throughout the neonatal period.  The platelet count 
increased by 7.39 x109 cells/l with each postnatal day.  There was also an initial increase in 
the mean platelet volume, but this appeared to peak around the middle of the neonatal period 
and then decrease.   
A child is considered to be thrombocytopenic if their platelet count is less than 150 x109 
cells/l.  In the first week of life 105 (61%) of the 172 cases were thrombocytopenic.  This fell 
rapidly so that there were no cases of thrombocytopenia by the fourth week of life.  Details 
are shown in Table 6-9. 
 
Figure 6-14. The association between postnatal age and platelet count and mean platelet volume 
in children with DS sampled within the first 28 days of life. 
 
The black line shows the mean value with the 95% CI shown in blue. 
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 Chapter 7 Results: the blood cell morphology of neonates with DS  
7.1 Introduction 
This chapter presents the results of the neonatal blood cell morphology review for DS 
neonates within the CDSS using the morphology review tool developed for this research. 
7.2 Case characteristics 
The case characteristics are provided in Table 7-1. 
Table 7-1. Case characteristics for samples included in the neonatal morphology analysis.  
     
 All  Suitable for full 
morphology 
review 
Suitable for 
limited 
morphology 
review 
Unsuitable 
Total 189  51  72  66  
          
Sex 
(number; %) 
Male 95 (50) 28 (55) 36 (50) 31 (47) 
 Female 94 (50) 23 (45) 36 (50) 35 (53) 
          
Blood source  Capillary 32 (17) 10 (20) 13 (18) 19 (29) 
(number; %) Venous 113 (60) 22 (43) 54 (75) 37 (56) 
 Unknown 44 (23) 19 (37) 5 (7) 10 (15) 
          
Mean birth 
weight 
(grams) 
 
  2918  2796  2939  2982  
Mean 
gestational age 
(weeks) 
 37.6  36.9  37.6  38.3  
          
Age at sampling 
(days) 
 6.0  9.2  4.9  4.8  
          
   
A stained slide was available for review in 189 cases.  Of these, 51 (27%) met the criteria for 
a full morphology review according to the morphology review tool (Appendix 9) while 72 
(38%) were suitable for a partial morphology review.  A further 66 (35%) slides were not 
suitable for morphology review as a result of degenerative change as a consequence of the 
delay between sampling and processing.  There were equal numbers of males and females.  
Most of the samples (60%) came from venepuncture.  Just under a fifth (17%) were capillary 
samples and the blood source was unknown in just under a quarter (23%) of cases.  When 
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this was broken down according to the suitability of the slide the proportion of capillary 
samples appears to increase in those with unsuitable samples. 
There were no significant (p<0.05) differences in birth weight or gestational age between the 
groups with slides that were suitable for a full review, suitable for a partial review or 
unsuitable for morphological review.   The mean birth weight for all cases in this analysis was 
2918 grams.  The mean birth weight was lower in the group with slides that were suitable for 
assessment, in keeping with the lower gestational age in this group.  The mean gestational 
age for all cases in this analysis was 37.6 weeks.  The mean age at sampling was 6 days.  
The mean age in the group with suitable samples was higher at 9.2 days, while the mean 
ages at sampling in the groups with either a partially or an unsuitable slide were similar at 4.9 
and 4.8 days respectively. 
7.3 Red blood cell morphology 
There were 123 slides suitable for assessment of the red blood cell morphology.  The most 
commonly noted red blood cell feature was the presence of nucleated red blood cells, which 
were seen in  68/123 (55.3%) slides.  Spherocytes were seen in 52/123 (42.3%) slides; 
Howell-Jolly bodies were seen in 44/123 (35.8%) slides; and target cells were seen in 
(34.1%) slides.  Basophilic stippling was uncommon, being noted in 14/123 slides (11.4%).  
The frequency of the different red blood cell features is shown in Figure 7-1. 
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Figure 7-1. The frequency of specific red blood cell features in blood films from neonates with 
DS. 
 
 
 
 
Figure 7-2. The frequency of specific neutrophil features in blood films from neonates with DS. 
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7.4 Neutrophil morphology 
There were 49 slides which were suitable for assessment of the neutrophil morphology.  The 
most common finding was of hypogranular neutrophils which were noted in 46/49 (93.9%) 
slides.  Vacuolated neutrophils were seen in 38/49 (77.6%) slides and Pelgeroid neutrophils 
in 26/49 (53.1%) slides.  Agranular and hypersegmented neutrophils were present in 7/49 
(14.3%) slides.  This is shown in Figure 7-2. 
As each cell was individually scored, it was also possible to calculate the percentage of cells 
with each feature.  Hypogranularity was present in 40% neutrophils and neutrophil 
vacuolation in 24.3% neutrophils whereas Pelgeroid, agranular and hypersegmented 
neutrophils were present in fewer than 10% of cells.  This is shown in  
Table 7-2.  
 
 
Total slides 
reviewed 
Slides with specific feature 
present 
Overall percentage of 
cells with the specific 
feature %   number % 
     
Hypogranular neutrophils 49 46 93.9 40.0 
Neutrophil vacuolation 49 38  77.6 24.3 
Pelgeroid neutrophils 49 26  53.1 9.6 
Agranular neutrophils 49 7  14.3 6.8 
Hypersegmented 
neutrophils 
49 7  14.3 0.5 
     
 
Table 7-2. The frequency of neutrophil abnormalities in neonatal blood films from children with 
DS. 
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Figure 7-3. Photographs of specific morphological features in neonates with DS. 
 
A.  
 
B.  
 
C.  
 
A. Megakaryocyte at the edge of a film from a neonate with TMD; B. Micro megakaryocyte at 
the edge of a film from a neonate without TMD; C. Megakaryocyte fragment.  
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D.  
 
E.  
 
F.  
 
D. Megakaryocyte fragment in the centre, with giant platelets and nucleated red blood cells; 
E. Giant platelet with blast cells and a nucleated red blood cell; F. Giant platelet with pallor, 
blast, nucleated red blood cell and neutrophil with poor nuclear lobation. 
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G.  
 
H.  
 
I.   
 
G and H. Hypogranular neutrophils with Pelgeroid nuclei. I. Eosinophil with Pelgeroid 
nucleus. 
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7.5 Blast cells 
There were 51 slides which were suitable for a white blood cell differential count, and blasts 
were present in 29 (57%) these.  In the majority of cases a blast type was not ascribed.  
However, myeloblasts were reported in 5/29 (17%) cases with blasts and lymphoblasts in 
1/29 (3%) cases.  Cytoplasmic blebbing was not common, being reported in 3/29 (10%) 
cases only.  A morphological diagnosis of TMD was made on 8/189 (4.2%) films. 
During the review process it was evident that although there were slides where the 
morphology had degenerated so that a white blood cell differential might not be performed 
accurately, it was still possible to identify blasts in many of these slides.  This led to a repeat 
review of all the slides deemed only partially suitable and of those deemed unsuitable for 
review to identify those where blasts were clearly present.  At this second review the 
presence or absence of nucleated red blood cells was also ascertained.  The results of this 
second review are given in Table 7-3.   
Table 7-3. Results of second review to determine only presence of blasts and nucleated red 
blood cells. 
     
 
 
All 
 
 
Suitable for full 
morphology 
review 
 
Suitable for 
limited 
morphology 
review 
 
Unsuitable 
         
Total 189  51 
 
72 
 
66  
          
Blasts present 
(number; %) 
 92 (48.7) 29 (56.9) 38 (52.8) 25 (37.9) 
          
Nucleated red 
blood cells 
present 
(number; %) 
 111 (58.7) 25 (49) 43 (59.7) 43 (65.2) 
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7.6 Comparison of manual and automated methods for identifying blasts 
As well as generating numerical parameters the automated analyser is able to identify when 
abnormal cells are present and generates appropriate flags, which are given as text 
comments on the report.  The ability of the analyser to identify samples with blasts was 
examined.  If the two flags which specifically suggested blasts were present then just over 
half of the samples had blasts on manual review, so that a blast flag had a sensitivity of 72% 
and a specificity of 43%.  If three further flags which highlighted a more general white blood 
cell abnormality, such as the presence of immature granulocytes, were also included then the 
sensitivity improved to 90%, but the specificity dropped to 17%.  This is shown in Table 7-4. 
When the sensitivity for identifying blasts in films which were subsequently given a 
morphological diagnosis of TMD were considered the sensitivity with the two blast flags was 
50%, and when the three abnormal white cell flags were also added in this improved to 75%.   
 
  Blasts on manual review 
  absent present 
    
Automated blast flag absent 38/164 (23%) 21/164 (13%) 
present 50/164 (30%) 55/164 (34%) 
    
Automated blast or 
abnormal white cell flag 
absent 15/164 (9%) 8/164 (5%) 
present 72/164 (44%) 69/164 (42%) 
    
 
Table 7-4. Comparison of manual and automated methods for identifying blasts 
 
 
7.7 Platelet morphology 
There were 123 slides suitable for assessment of the platelet morphology.  Giant platelets 
and/or megakaryocyte fragments were seen in 107/123 (87%) slides.  The platelet colour 
appeared abnormal in 81 (65.9%), and in all of these cases platelets were considered pale. 
Photographs of these features are provided in   
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Figure 7-3.   
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 Chapter 8 Results: haematological values beyond the neonatal 
stage  
8.1 Introduction 
This chapter presents the results of the full blood count analysis for children in the CDSS 
beyond the neonatal period.  Values are expressed as the mean (95% CI) and range (5- 95% 
percentiles).  Where results are referred to as significant, this indicates that p<0.05. 
8.2 Case characteristics 
These are provided in Table 8-1. 
 
 Cases with a 
sample at 0-
3months  
Cases with a 
sample at 1
st
 
birthday 
Cases with a 
sample at 2
nd
 
birthday 
Cases with a 
sample at 3
rd
 
birthday  
Cases with a 
sample at 4
th
 
birthday 
Number 247 48 10 14 5 
Sex:       boys 
              girls 
134 (54%) 
113 (46%) 
 
24 (50%) 
24 (50%) 
 
7 (70%) 
3 (30%) 
 
12 (86%) 
2 (14%) 
 
3 (60%) 
2 (40%) 
 
 
Table 8-1. Case characteristics for children with samples in the analysis of haematological 
parameters beyond the neonatal stage.  
 
8.3 Red blood cells 
The striking finding for all the red blood parameters is the difference between the results at 
birth compared with the results at 1 year and the subsequent similarity between the results at 
1, 2, 3 and 4 years.  Moreover, there is no overlap between the 95% CI for the mean values 
of red blood cell parameters at birth compared with results at 1, 2, 3 and 4 years (p<0.05). 
Considering the changes in the values between birth and 1 year, the red cell count fell from 
5.4 (4.0-6.6) x1012 /l to 4.5 (3.9-5.1) x1012 /l; haemoglobin fell from 20.3 (13.8-24.8) g/dl to 
13.1 (10.8-14.6) g/dl; mean cell haemoglobin fell from 37.2 (32.9-41.1) pg to 28.8 (25.2-31.5) 
pg; haematocrit fell from 0.62 (0.45-0.75) to 0.42 (0.33-0.53); mean cell volume fell from 
114.5 (100.0-127.8) fl to 91.9 (80.6-111.0) fl; and the nucleated red blood cell count fell from 
2.68 (0-14.1) x 109 /l to 0.01 (0-0.04) x 109/l.  Nucleated red blood cells were absent after 1 
year of age.  The difference between the values at birth and the subsequent values at the 
other age points is particularly striking when the mean cell haemoglobin is considered.  Here, 
there is no overlap between the range at birth and the four subsequent ranges, all of which 
are similar to one another. These results are shown in Table 8-2, Figure 8-1 and Figure 8-2.  
 
 
Table 8-2. Mean values for red blood count parameters in children with DS up to and including their 4
th
 birthday. 
 
 Birth
a 
1 year
b 
2 years
b 
3 years
b 
4 years
b 
 N Mean (95% CI)  N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) 
           
Red cell count (x10
12
 cells/l) 245 5.4  (5.3, 5.5) 48 4.5 (4.4, 4.7) 10 4.5 (4.2, 4.8)  14 4.6 (4.4, 4.8)  5 4.5 (4.3, 4.7) 
Haemoglobin (g/dl) 245 20.3 (19.9, 20.7) 48 13.1 (12.5, 13.6) 10 13.0 (12.6, 13.4) 14 13.5 (12.7, 14.3) 5 13.4 (13.0, 13.8) 
Mean cell haemoglobin (pg) 245 37.2 (36.9, 37.6) 48 28.8 (28.1, 29.4) 10 29.0 (27.9, 30.1) 14 29.2 (28.5, 30.0) 5 30.0 (28.9, 31.0) 
Haematocrit (%) 242 0.62 (0.62, 0.63) 48 0.42 (0.40, 0.44) 10 0.43 (0.41, 0.45) 14 0.44 (0.40, 0.48) 5 0.40 (0.39, 0.41) 
Mean cell volume (fl)  244 114.5 (113.4, 115.6) 48 91.9 (89.3, 94.4) 10 96.0 (90.4, 100.5) 14 95.4 (90.4, 100.5) 5 89.4 (85.1, 93.6) 
Nucleated RBC (x10
9
 cells/l) 208 2.68 (1.7, 3.66) 47 0.01 (0, 0.04) 9 0 13 0 4 0 
           
 
a. birth - 3 months 
b. birthday  + 3 months
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Table 8-3. Range of values for red blood count parameters in children with DS up to and including their 4
th
 birthday. 
 
 Birth
a 
1 year
b 
2 years
b 
3 years
b 
4 years
b 
 N 
Range (95% 
percentile)  
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
           
Red cell count (x10
12
 cells/l) 245 4.0-6.6 48 3.9-5.1 10 3.8-5.0 14 3.9-5.6 5 4.2-4.7 
Haemoglobin (g/dl) 245 13.8-24.8 48 10.8-14.6 10 12-14 14 12-17.1 5 12.9-14 
Mean cell haemoglobin (pg) 245 32.9-41.1 48 25.2-31.5 10 26.9-31.6 14 26.5-32 5 29.1-31.7 
Haematocrit (%) 242 0.45-0.75 48 0.33-0.53 10 0.37-0.47 14 0.34-0.62 5 0.39-0.42 
Mean cell volume (fl)  244 100.0-127.8 48 80.6-111.0 10 83.6-105.9 14 82.2-110.6 5 83.2-95.5 
Nucleated RBC (x10
9
 cells/l) 208 0-14.1 47 0-0.04 9 0 13 0 4 0 
           
 
a. birth - 3 months 
b. birthday  ± 3 months 
 
 
 
 
Figure 8-1. Mean values for haemoglobin, haematocrit and red cell count for children with DS 
from birth up to and including their 4
th
 birthday. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.   
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Figure 8-2. Mean values for mean cell haemoglobin, mean cell volume and nucleated red cell 
count for children with DS from birth up to and including their 4
th
 birthday. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.   
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8.4 White blood cell parameters 
Again, there appears to be a marked difference in the total white cell count, and in all the 
white blood cell subtypes, between birth and the results at 1 year and a subsequent similarity 
between the results at 1, 2, 3 and 4 years.  Again, there is no overlap between the 95% CI for 
mean values of white blood cell parameters at birth compared with results at 1, 2, 3 and 4 
years indicating that this is a significant (p<0.05).  The exception to this is the eosinophil 
count where there is the same trend, but where there is overlap between the 95% CI. 
Considering the changes in the values between birth and 1 year, the total white blood cell 
count fell from 11.7 (5.9-23.8) x 109/l to 6.8 (4.2-9.9) x 109/l; the neutrophil count fell from 6.6 
(1.9-15.8) x 109/l to 3.2 (1.5-7.4) x 109/l; the lymphocyte count fell from 3.7 (1.5-7.4) x 109/l to 
2.8 (1.5-4.5) x 109/l; the monocyte count fell from 1.0 (0.3-2.0) x 109/l to 0.6 (0.3-1.3) x 109/l; 
the basophil count fell from 0.17 (0-0.52) x 109/l to 0.09 (0.02-0.21) x 109/l; and the eosinophil 
count fell from 0.17 (0-0.47) x 109/l to 0.14 (0-0.30) x 109/l. 
The ranges tend to become narrower from the 1st birthday onwards. Moreover, this occurs 
because the upper limit decreases while the lower limit remains relatively constant.  These 
results are shown in Table 8-4, Table 8-5, Figure 8-2, Figure 8-3 and Figure 8-4. 
  
 
 
Table 8-4. Mean values for white blood count parameters in children with DS up to and including their 4
th
 birthday. 
 
 Birth
a 
1 year
b
 2 years
b 
3 years
b 
4 years
b
 
 N Mean (95% CI)  
 
N Mean (95% CI)   N Mean (95% CI) 
 
N Mean (95% CI) 
 
N Mean (95% CI) 
 
           
White cell count (x10
9
 cells/l) 130 11.7 (10.5, 12.9) 45 6.8 (6.2, 7.4) 10 5.4 (4.1, 6.7) 13 6.3 (5.9, 6.7) 5 7.0 (5.3, 8.7) 
Neutrophils (x10
9
 cells/l)  130 6.6 (5.7, 7.5) 45 3.2 (2.7, 3.7) 10 2.4 (1.6, 3.3) 13 3.5 (3.1, 3.9) 5 4.1 (2.6, 5.5) 
Lymphocytes (x10
9
 cells/l)  130 3.7 (3.3, 4.1) 45 2.8 (2.5, 3.1) 10 2.3 (1.9, 2.6) 13 2.1 (1.8, 2.3) 5 2. 2(1.9, 2.6) 
Basophils (x10
9
 cells/l)  130 0.17 (0.14, 0.21) 45 0.09 (0.07, 0.11) 10 0.11 (0.07, 0.14) 13 0.08 (0.05, 0.10) 5 0.08 (0.05, 0.11) 
Eosinophils (x10
9
 cells/l)  130 0.17 (0.14, 0.19) 45 0.14 (0.09, 0.19) 10 0.13 (0.07, 0.19) 13 0.1 (0.06, 0.15) 5 0.15 (0.05, 0.25) 
Monocytes (x10
9
 cells/l)  130 1.0 (0.9, 1.1) 45 0.6 (0.5, 0.6) 10 0.4 (0.2, 0.7) 13 0.5 (0.4, 0.7) 5 0.5 (0.3, 0.6) 
           
 
a. birth - 3 months 
b. birthday  + 3 months 
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Table 8-5. Range of values for white blood count parameters in children with DS up to and including their 4
th
 birthday. 
 
 Birth
a 
 1 year
b 
2 years
b 
 3 years
b 
 4 years
b 
 N Range (95% 
percentile)  
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
           
           
White cell count (x10
9
 
cells/l) 
130 5.9-23.8 45 4.2-9.9 10 3.4-10.7 13 4.7-7.4 5 4.6-10.0 
Neutrophils (x10
9
 cells/l)  130 1.9-15.8 45 1.5-7.4 10 1.1-6 13 2.3-4.6 5 1.9-6.6 
Lymphocytes (x10
9
 cells/l)  130 1.5-7.4 45 1.5-4.5 10 1.3-3.0 13 1.3-2.7 5 1.7-2.6 
Basophils (x10
9
 cells/l)  130 0-0.52 45 0.02-0.21 10 0.04-0.19 13 0.02-0.2 5 0.05-0.13 
Eosinophils (x10
9
 cells/l)  130 0-0.47 45 0.01-0.3 10 0.04-0.34 13 0.03-0.33 5 0.07-0.34 
Monocytes (x10
9
 cells/l)  130 0.3-2.0 45 0.3-1.3 10 0.1-1.3 13 0.2-1.1 5 0.3-0.7 
           
 
a. birth - 3 months 
b. birthday  ± 3 months
 
 
 
 
Figure 8-3. Mean values for white cell, neutrophil and lymphocyte count for children with DS 
from birth up to and including their 4
th
 birthday. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.   
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Figure 8-4. Mean values for monocyte, basophil and eosinophil count for children with DS from 
birth up to and including their 4
th
 birthday. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.   
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8.5 Platelets 
Again, there appears to be a marked difference in the platelet count and the mean platelet 
volume between birth and the results at 1 year and a subsequent similarity between the 
results at 1, 2, 3 and 4 years.  Again, there is no overlap between the 95% CI for mean 
values for the platelet parameters at birth compared with results at 1, 2, 3 and 4 years 
indicating that this is a significant difference.   
The mean platelet count increases between birth and 1 year rising from 160 (38-317) x 109/l 
to 308 (152-483) x 109/l.  The mean value for mean platelet volume decreases between birth 
and 1 year falling from 12.1 (10.5-13.9) fl to 10.3 (8.7-11.9) fl. 
It can be seen that both the upper and lower limits increase for the platelet count from birth to 
the 1st birthday and onwards.  This increase is most marked for the lower value which 
increases from 35 x 109/l at birth to 152 x109/l at 1 year.  In contrast, the upper and lower 
limits for the mean platelet volume both fall from birth to the 1st birthday and onwards.   These 
results are shown in Table 8-6, Table 8-7 and Figure 8-5.   
 
 
 
Table 8-6. Mean values for platelet parameters in children with DS up to and including their 4
th
 birthday. 
 
 Birth
a 
1 year
b 
2 years
b 
3 years
b 
4 years
b 
 N Mean (95% CI)  N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) N Mean (95% CI) 
           
Platelet count (x10
9
 cells/l) 238 160 (150, 170) 46 308 (279, 338) 10 280 (232, 327) 14 306 (268, 344) 14 278 (213, 342) 
Mean platelet volume (fl)  80 12.1 (11.9, 12.3) 39 10.3 (10.0, 10.6) 8 10.4 (9.8, 11.1) 10 10.5 (9.7, 11.2) 10 10.3 (9.8, 10.8) 
           
 
a. birth - 3 months 
b. birthday  + 3 months   
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Table 8-7. Range of values for platelet parameters in children with DS up to and including their 4
th
 birthday. 
 
  Birth
a 
 1 year
b 
2 years
b 
 3 years
b 
 4 years
b 
 N Range (95% 
percentile)  
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
N 
Range (95% 
percentile) 
           
Platelet count (x10
9
 cells/l) 238 38-317 46 152-483 10 160-387 14 169-389 5 195-363 
Mean platelet volume (fl)  80 10.5-13.9 39 8.7-11.9 8 8.8-11.9 10 8.5-12.9 5 9.6-11 
           
 
a. birth - 3 months 
b. birthday  + 3 months
 
 
 
 
Figure 8-5. Mean values for platelet count and mean platelet volume for children with DS from 
birth up to and including their 4
th
 birthday. 
 
Black squares indicate mean values (+/- standard error) of the parameter at each day interval.   
 
 
 
 
 
  
186 
 
 Chapter 9 Discussion 
The central hypothesis underpinning this research is that if characterised in as near a 
population based cohort as possible then the haematological profile of neonates with DS will 
prove to be distinct.  Accordingly, the primary aims of this work were: 
1. To describe the neonatal haematological ranges for children with DS with reference to 
the standard haematological parameters typically measured as part of full blood count 
analysis; 
2. To examine factors that may be associated with variations in the neonatal 
haematological profile of children with DS; 
3. To describe the features of neonatal blood cell morphology in children with DS; 
4. To describe the haematological parameters in children with DS beyond the neonatal 
stage. 
Each of these aims will be discussed in turn in this chapter and their outcome reviewed.   
9.1 Case characteristics 
This is the largest data set to date of full blood count parameters in neonates with DS, and 
this remains the case even when the set is restricted to those cases with a full blood count 
sample taken in the first week of life.  Moreover, it is the only prospective analysis considering 
haematological parameters throughout the neonatal period. 
In both the neonatal and in the first week of life analysis there is a male preponderance with 
53% of cases being male.  A male excess in DS births has been consistently noted 
elsewhere (Kovaleva, 2002; Bloemers et al, 2007).  
Just over a third (37%) births were preterm, this fell slightly to 32% for the first week of life 
analysis.  There are various possible reasons for the difference between the groups: families 
with a preterm newborn baby might be less likely to be approached about the study in the first 
week of life as the babies might be sicker; it might be perceived to be less urgent as they 
were likely to be in hospital for longer; and even if they were recruited within the first week of 
life venepuncture might be put off until they were larger.  In the CDSS the mean gestational 
age was lower than the general population – as noted by other groups.  The birth cohort 
reported by the Dutch Paediatric Surveillance Unit (DPSU) reported a mean gestational age 
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of 38 weeks, compared with 39.1 weeks for their control group (Weijerman et al, 2008).  The 
Intermountain Healthcare Hospitals study of haematological parameters within the first week 
in neonates with DS reported a mean gestational age of 37.4 +/1.9 weeks (Henry et al, 2007).  
In the CDSS just under a quarter of babies (24%) had a birth weight of <2500 grams.  This 
falls to a fifth (20%) for the first week of life analysis which may reflect the reduction in 
preterm births in that set.  Birth weight was taken from the initial hospital referral form, from 
the family questionnaire and from the obstetric note abstraction.  Not all cases have been 
abstracted so far, and not all families completed a family questionnaire, but all had a hospital 
referring form.  Despite this the weight was missing for just under a sixth of cases (14% for 
the neonatal analysis; 15% for the first week of life analysis).  The DPSU reported a mean 
birth weight of 3119 grams in boys compared with 3525 grams for controls, and 2901 grams 
in girls compared with 3389 grams for controls (Weijerman et al, 2008).  The Intermountain 
Healthcare Hospitals study reported a mean birth weight of 2894 +/ 618 grams (Henry et al, 
2007).   
The male excess observed in the neonatal haematology analysis was only observed in cases 
with slides suitable for full morphological analysis.  However, the earlier gestational age and 
lower birth weight were similar for cases in the neonatal haematology and neonatal 
morphology analyses.  
9.2 Haematological parameters in DS neonates 
The findings of the CDSS neonatal analysis: 
1. Support the hypothesis that neonates with DS have a distinct haematological profile; 
2. Have enabled the characterisation of haematological parameters throughout the neonatal 
period in a comprehensive manner with the production of charts giving mean and range 
values for the CDSS population - this has not been done before;   
3. Have demonstrated the association of the neonatal haematological parameters with birth 
weight, gestational age, sampling to processing interval and postnatal age, providing 
novel insight into the role of these variables. 
The findings are summarised in Table 9-1, and are then discussed below. 
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Table 9-1. Summary of the findings of the neonatal analysis of haematological parameters for the CDSS. 
 
 
Change 
compared with 
wider neonatal 
population  
Change with 
increasing 
birth weight 
Change with 
increasing 
gestational 
age 
Change with 
increasing 
postnatal age 
Cut-off 
for 
stability 
(days) 
      
RED BLOOD CELL PARAMETERS 
Haemoglobin ↑ → ↑ ↓ 7 
Haematocrit ↑ → ↑ ↓ 2 
Red blood cell 
count 
→ → ↑ ↓ 7 
Mean cell 
haemoglobin 
↑ → → ↓ 7 
Mean cell 
volume 
↑ → → ↓ 2 
Nucleated red 
blood cell count 
↑ → → → 7 
      
WHITE BLOOD CELL PARAMETERS 
White cell 
count 
→ → → ↓ - 
Neutrophils ↑ → → ↓ - 
Lymphocytes ↓ → → ↓ 7 
Monocytes → → → ↓ 2 
Eosinophils → / ↓ → → ↓ 7 
Basophils Insufficient data → → ↓ 7 
      
PLATELET PARAMETERS 
Platelet count ↓ ↑ ↓ ↑ 7 
Mean platelet 
volume 
↑  → → → 4 
      
Arrows in blue indicate a difference from the wider neonatal population. 
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9.2.1 First week of life analysis: red blood cells 
Samples taken within the first week of life were considered first as many of the comparable 
reports are limited to this period.  This is also the period in which any effects of gestational 
age or birth weight are likely to be most pronounced and so the regression analysis was 
performed on this data set. 
Haemoglobin 
The haemoglobin and haematocrit both appear higher than the reference values for 
neonates.  Here the haemoglobin was 21.1 (16.8-25.3) g/dl.  The mean for the general 
population of neonates age 3 days studied by the Intermountain group was 16.6 g/dl which is 
outside the CDSS range, while the mean for the CDSS group is higher than the upper limit of 
the range for the Intermountain group which was 20.9 g/dl (95% percentile value) (Jopling et 
al, 2009).  Similarly, the mean reported for neonates at 1 week is 17.5 g/dl, which is right at 
the bottom of the CDSS range (Orkin & Nathan 2009).   
There are five reports which consider the haemoglobin in DS neonates (Behrman, Sigler and 
Patchefsky, 1966; Thüring and Tönz, 1979; Lappalainen and Kouvalainen, 1972; Kivivuori, 
Rajantie and Siimes, 1996; Henry et al, 2007).  However, one of these consists of 3 case 
reports only (Behrman, Sigler and Patchefsky, 1966); one only considers the effect of 
haemoglobin on the platelet count (Thüring and Tönz, 1979); one does not give either figures 
or graphical illustration (Lappalainen and Kouvalainen, 1972); and in the small prospective 
study the data is presented graphically only over a 12 month period so that the numbers 
cannot be accurately extrapolated (Kivivuori, Rajantie and Siimes, 1996). The largest and 
most recent paper plots the individual data points against what it considers a reference range 
of 13-22 g/dl (Henry et al, 2007).  It can be seen on this graph that there are consistently 
more data points near and above the upper limit than the lower one, especially in the first 72 
hours of life.  Moreover, in the text of the paper the authors state that one third of 
haemoglobin results were above 22 g/dl, and 14 % of results above 23 g/dl.  This is 
consistent with the findings here that the haemoglobin in DS neonates appears increased. 
Haematocrit 
The haematocrit was 0.6 (0.51-0.76) compared with 0.49 (0.36-0.62) (mean; 95% percentile 
values) from the Intermountain group for neonates age 3 days (Jopling et al, 2009) so that the 
CDSS mean haematocrit is right at the upper limit of the range for the wider population while 
the mean for the wider population is below the lower limit of the range for the CDSS 
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population.  The mean reported for neonates at 1 week is 0.54, which, although higher than 
that reported by the Intermountain group, is still lower than the CDSS mean (Orkin and 
Nathan, 2009).   
Although polycythaemia was the first red blood cell abnormality to be described in children 
with DS (Weinberger and Oleinick, 1970), most of the papers do not give either mean values 
or reference ranges.  In the Intermountain paper on DS neonates the individual data points 
are plotted against an estimated reference range for haematocrit of 0.4-0.6 (Henry et al, 
2007).  Again, the results tended to be near and above the upper limit, with the haematocrit 
being greater than 0.65 and 0.7 in one third and 14 % cases respectively.  This is consistent 
with the findings here that the haematocrit in DS neonates appears increased.   
When the haemoglobin and haematocrit findings are considered together 95 (54%) of the 176 
cases were polycythaemic (total haemoglobin was greater than 22 g/dl or the haematocrit 
was greater than 0.65) in the first week of life.  The incidence of polycythaemia for all term 
neonates has been consistently reported as being between 2-5% (Wirth et al. 1979; 
Ramamurthy & Brans 1981; Reisner et al. 1983).  This work suggests that there is a ten to 
twenty fold increase in polycythaemia in DS.  The significance of neonatal polycythaemia is 
yet to be fully elucidated – whether or not this occurs in the context of DS.  It is known that 
cerebral blood flow is decreased in neonates with polycythaemia (Rosenkrantz and Oh, 
1982), and a number of studies have reported a variety of symptoms that have been 
observed in polycythaemic neonates (Gross, Hathaway and McGaughey, 1973; Ramamurthy 
and Brans, 1981; Black et al, 1982).  However, the frequency of these symptoms varies 
considerably between reports – for example, cyanosis is reported to occur in 89% and tremor 
or jitters in 67% in one study (Gross, Hathaway and McGaughey, 1973) compared with a 
frequency of 17% and 13% respectively in another study (Ramamurthy and Brans, 1981).  
The numbers in these studies are small, with even the largest only considering 111 infants 
(Black et al, 1982).   Moreover, the nature of the association is unclear and many of the 
symptoms described appear likely to be a consequence of the original insult that led to 
polycythaemia rather than a consequence of it.   
It is possible to lower the haematocrit with partial exchange transfusion (PET), but there is no 
evidence to support this in an asymptomatic infant.  Its benefit in symptomatic infants is 
unclear.  PET has been associated with an increase in necrotising enterocolitis (Black et al, 
1985a) and does not appear to be associated with a more rapid improvement in neurological 
symptoms (Goldberg et al, 1982).  A recent Cochrane review of the use of partial exchange 
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transfusion (PET) for neonatal polycythaemia to prevent neuro-disability concluded that there 
was no proven clinically significant short or long-term benefits of PET in polycythaemic 
newborn infants who were clinically well or who had only minor symptoms related to 
hyperviscosity (Ozek, Soll and Schimmel, 2010).  It also found an apparent increase in 
necrotizing enterocolitis in neonates treated with PET.  However, follow-up data were 
imprecise so that the true risks and benefits of PET are still unclear.  There have been a 
number of longitudinal studies of polycythaemic infants.  These agree that infants with 
polycythaemia are at increased risk of subsequent neurological sequelae and this risk does 
not appear to be modified by PET (Black et al, 1982; Black et al, 1985b; Delaney-Black et al, 
1989; Bada et al, 1992).  They conclude that there is an initial hypoxic event – which may be 
an adverse intrauterine environment, fetal hypoxia or asphyxia – which results in an adaptive, 
erythropoietin driven, polycythaemia coincident with neurological damage. 
Children with DS have typically been excluded from the above studies.  It is not yet known 
whether there is a similar association with neonatal polycythaemia and subsequent 
neurological sequelae, or whether there is any role for PET.  A study of erythropoietin levels 
in the umbilical cord blood of 18 neonates with DS and 36 control infants did demonstrate a 
significantly increased erythropoietin level in the DS group (Widness et al, 1994).  
Erythropoietin does not cross the placenta and so is assumed to be of fetal origin (Jacobson, 
Marks and Gaston, 1959).  Increased levels of fetal erythropoietin have previously been 
shown to be associated with intrauterine hypoxaemia and intrauterine growth retardation 
(Snijders et al, 1993).  Erythropoietin is a critical stimulator of erythropoiesis.  Hypoxia results 
in increased transcription of the erythropoietin gene, and increased erythropoietin levels, 
which in turn increases erythropoiesis (Wang and Semenza, 1995).   
Red blood cell count 
The red blood cell count is an often overlooked parameter.  The red blood cell count here of 
5.6 x1012 cells/l is only slightly higher than a mean of 5.1 x1012 cells/l reported for neonates at 
1 week in the wider population, and the mean for the wider population is well within the CDSS 
range of 4.3-6.6 x1012 cells/l suggesting that there is not a marked difference between the two 
groups (Orkin and Nathan, 2009).  It has not been reported for DS neonates before.   
Mean cell haemoglobin 
Given that the haemoglobin is notably higher but the red blood cell count only slightly higher 
than the general population values it is unsurprising that the mean cell haemoglobin also 
appears to be higher in the CDSS than the general population.  The mean cell haemoglobin 
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was 37.7 (33.8-41.3) pg compared with 36.6 (32.9-40.4) pg (weighted mean; 95% percentile 
values) for neonates aged 1 day (Christensen et al, 2008) or mean 34 pg for neonates at 1 
week (Orkin and Nathan, 2009).  Again, there are no comparable reports of the mean cell 
haemoglobin in DS neonates.  It is mentioned briefly in the prospective study of 25 neonates 
with DS (Kivivuori, Rajantie and Siimes, 1996).  Although no numbers are given, the authors 
note that the values are close to the upper range of reference values.     
Mean cell volume 
It has been recognised for a long time that the red blood cells of the fetus and neonates are 
larger than in later childhood or adults.  The red blood cells appear to be larger still in DS 
neonates.  The mean cell volume was 115.5 (102.1-128.5) fl compared with 107.8 (98-117.6) 
fl (weighted mean; 95% percentile values) for neonates aged 1 day (Christensen et al, 2008) 
or mean 107 fl for neonates at 1 week (Orkin and Nathan, 2009) or mean 110 fl at birth taken 
from the paper previously considered as standard reference (Matoth, Zaizov and Varsano, 
1971).  An increased mean cell volume is seen in premature compared with term neonates in 
the general population reflecting splenic immaturity (Diagne et al, 1995).  It is thought that the 
mean cell volume decreases with increasing gestational age as the spleen becomes more 
mature and is able to perform more effective remodelling of the red cell membrane (Orkin and 
Nathan, 2009).  The mean cell volume values for the CDSS population are comparable to 
those of neonates of 26-28 weeks gestation (Christensen et al, 2008) or to fetuses sampled 
at 29-30 weeks gestation (Forestier et al, 1991).  Macrocytosis has been recognised in adults 
and children with DS, but has only been reported in DS neonates more recently.  The small 
prospective study of DS neonates (Kivivuori, Rajantie and Siimes, 1996) give values for the 
mean red cell volume in the first week with values of 110 (79-124) fl (mean; 95% percentile 
values). This is similar to the larger retrospective study which quotes 110 ± 7 fl (mean; 2 
standard deviations) although the graph indicates that these values are higher in the first 48 
hours (Henry et al, 2007).  Our values were slightly higher than this which may reflect timing 
as most of the CDSS samples were taken within the first few days of life when the mean cell 
volume is highest.  
Nucleated red blood cells 
Nucleated red blood cells are expected to disappear from the peripheral circulation by the 4th 
day of life (Bain, 2002).  The mean nucleated red blood cell count of 3.8 (0-20.3) x109 cells/l 
for the first week of life in this group would appear to be higher than the value of 2.3  (0-6.4) 
x109 cells/l (mean; 25-75th percentile values) reported for the general population (Perrone et 
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al, 2005).  This parameter was reported graphically in the large retrospective study of 
neonates with DS although no numbers are given (Henry et al, 2007).  It can be seen from 
the graph that there are data points above zero beyond the fourth day of life and in the CDSS 
data nucleated red blood cells also persisted beyond the fourth day.   
An increased or persisting nucleated red blood cell count has been recognised as an 
important marker of perinatal brain damage since the 1990s (Green, Hendon and Mimouni, 
1995; Buonocore et al, 1999).  Subsequent reports have consistently found an association 
between nucleated red blood cell count and adverse perinatal outcomes.  A recent study 
which looked at over 35 000 results found a four-fold increase in intra-ventricular 
haemorrhage and in retinopathy of prematurity in cases where the nucleated red blood cell 
count was over 95% of the reference ranges determined for that population (Christensen et 
al, 2011).  The authors conclude that an increase in nucleated red blood cells is a marker of 
perinatal hypoxia occurring as a result of a hypoxia-driven increase in erythropoietin.  In 
support of this they note that an increase in erythropoietin levels has been demonstrated in 
many conditions associated with perinatal hypoxia.  Importantly, an increase in erythropoietin 
has also been demonstrated in the cord blood of neonates with DS (Widness et al, 1994).  
They also note that hepatic haematopoiesis is still making a significant contribution to 
haematopoiesis at birth, especially in preterm births, and suggest that nucleated red blood 
cells may lose their nucleus less readily on leaving the liver than the bone marrow.  This latter 
idea is hypothetical. 
Taken together this work suggests that the red blood cells of neonates with DS within the first 
week of life are similar in number, but larger and more haemoglobin rich with a consequent 
increase in haematocrit than in neonates without DS.  There is a concurrent increase in 
nucleated red blood cells which may be a marker of perinatal hypoxia.   
9.2.2 First week of life analysis: white blood cell parameters 
Total white blood cell count 
The total white cell count in the CDSS group appears very similar to values obtained for the 
wider population with a white cell count of 12.9 (6.1-24.2) x109 cells/l for the CDSS compared 
with a reference range of 12.2 (5.0-21.0) x109 cells/l (mean; 95% CI) for the first week of life 
in the general population (Orkin and Nathan, 2009).   
194 
 
Differential white blood cell count 
However, when the differential count is examined the story becomes more interesting as the 
neutrophil component appears increased with a relative lymphopenia in the CDSS.  The 
CDSS neutrophil count was 8 (1.9-16) x109 cells/l compared with 5.5 (1.5-10) x109 cells/l 
(mean; 95% CI) for the first week of life (Orkin and Nathan, 2009), or 5.4 (1.3-13) x109 cells/l 
(weighted mean; 95% percentile values) for neonates aged 3 days (Schmutz et al, 2008).  
This finding is consistent with the large retrospective study of neonates with DS which also 
found a relative neutrophilia, noting that 80% had a neutrophilia when compared with the 
Manroe ranges (Manroe et al, 1979) and also remarking that only 1/158 cases had a 
neutrophil count < 1.0 x109 cells/l (Henry et al, 2007). 
Determining the neutrophil count in DS neonates is important clinically as neonatal units may 
use the white cell count, or more specifically the neutrophil count, in algorithms to determine 
the likelihood of sepsis (Verani, McGee and Schrag, 2010).   However, although the 
neutrophil count appears to be similar, or even higher, in DS compared with the general 
population, it is not wise to infer that both populations will respond similarly to infection.  
Consequently, algorithms for neonatal sepsis which incorporate the neutrophil count need 
specific validation in neonates with DS.   
In contrast, the lymphocyte count in the CDSS neonates appears slightly lower than in the 
general population at 3.6 (1.5-7.5) x109 cells/l compared with 5.0 (2.0-17.0) x109 cells/l 
(mean; 95% CI) for the first week of life (Orkin and Nathan, 2009).  Although the actual 
lymphocyte count has not been reported before in DS neonates, it was referred to as being 
lower in a study of lymphocyte subpopulations in children with DS (de Hingh et al, 2005).  
The monocyte count in the CDSS neonates appears similar to that of the general population 
at 1.0 (0.3-2.0) x109 cells/l compared with mean 1.1 x109 cells/l for the first week of life (Orkin 
and Nathan, 2009), or 1.12 (0.21-2.55) (mean; 95% CI) at 3 days (Christensen et al, 2010).  
The eosinophil count also appears similar, or possibly lower, at 0.2 (0-0.4) x109 cells/l 
compared with mean 0.5 x109 cells/l for the first week of life (Orkin and Nathan, 2009), or 
0.47 (0.1-1.2) (mean; 95% CI) at 3 days (Christensen et al, 2010).  It is not possible to 
compare the basophil count as there are no reference values for the general population.  
Monocyte, eosinophil and basophil values have not been reported before in neonates with 
DS. 
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9.2.3 First week of life analysis: platelets 
The results here indicate that the platelets of neonates with DS are reduced in number and 
increased in size.  This relationship is important: historically, many discussions of platelets 
have focussed only on the platelet number.  However, it is now apparent that it is platelet 
mass, rather than simply platelet number, which affects platelet function (Thompson and 
Jakubowski, 1988).  An association between thrombocytopenia and increasing mean platelet 
volume has been demonstrated in the neonatal setting in the general population (Kipper and 
Sieger, 1982). 
The mean platelet count in the CDSS was low at 142 (35-255) x109 cells/l compared with the 
values reported for the general population of 271 (134-415) x109 cells/l (weighted mean; 95% 
percentile values) by the Intermountain group for neonates at 3 days – the mean for the 
CDSS is right at the bottom of the range for the wider population, while the mean for the 
wider population is actually above the upper limit of the CDSS range.  Similarly, the reported 
mean for neonates at 1 week is at the upper end of the CDSS range at 248 x109 cells/l (Orkin 
and Nathan, 2009).   
Thrombocytopenia was one of the earliest haematological abnormalities to be reported in DS 
(Behrman, Sigler and Patchefsky, 1966), and has been consistently reported in DS neonates 
since.  However, only a few studies actually report platelet values.  A study of 70 neonates in 
the first week of life found a platelet count of 91 (45-175) x109 cells/l (median; 90% 
percentiles) (Thüring and Tönz, 1979); while a sample of 25 neonates with samples taken at 
48 hours found values of 148 (41- 408) x109 cells/l (median, range) (Hord, Gay and Whitlock, 
1995).  The large retrospective study of DS neonates reports a range of 20- 490 x109 cells/l 
and states that 66% had a platelet count <150 x109 cells/l including 33% with a platelet count 
< 100 x109 cells/l and 6% with a platelet count < 50 x109 cells/l (Henry et al, 2007). 
The incidence of neonatal thrombocytopenia in the general population is reported to be 2-8% 
(Burrows and Kelton, 1990; Sainio et al, 2000) suggesting a seven to thirty fold increase in 
neonates with DS.  Thrombocytopenia in DS is early onset –present at birth - and tends to 
resolve.  The most common cause of early onset thrombocytopenia (defined as being present 
within 72 hours of birth) is chronic fetal hypoxia (Watts and Roberts, 1999).  The natural 
history of this is spontaneous resolution and there are rarely clinical sequelae.  The 
thrombocytopenia of DS appears to follow this pattern, and the association with chronic fetal 
hypoxia would be consistent with the red blood cell findings already discussed.  Correlation 
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with clinical features, both contemporaneous and subsequent behaviour, will be helpful and 
will be part of future work.  
In contrast the mean platelet volume here appeared higher than that of the general 
population.  The CDSS values were 12.1 (10.4-13.9) fl compared with 8.4 (6.9-10.7) fl 
(weighted mean; 95% percentile values) for neonates at 3 days.  The mean value for the 
CDSS is above the upper limit of the range for the wider population, and there is very little 
overlap at all between the ranges.  The values here are consistent with the large 
retrospective analysis which reported mean platelet volume at 9.15 ± 1.3 fl (mean ± SD) with 
24% values being >10 fl (Henry et al, 2007). 
Larger platelets are typically more active in terms of their haemostatic function (Thompson et 
al, 1983; Thompson and Jakubowski, 1988), and this may explain why bleeding problems 
have not been described in DS neonates despite their generally low platelet counts.  
Whereas reticulocytes are younger and larger red blood cells which become small with 
increasing maturity large platelets do not appear to be immature platelets.  Instead, their 
increased size appears to be a feature of bone marrow production factors and they remain 
large until the end of their life.  Interestingly, these papers suggest that they have an 
increased life span compared with their smaller counterparts. 
9.2.4 Association between birth weight and red blood cell parameters 
There are no previous reports which have considered the association between birth weight 
and haematological parameters in DS neonates.  
There have only been a few reports of the relationship between birth weight and red blood 
cell parameters in neonates.  Changes appear to be mild and to resolve rapidly (Ozyürek et 
al, 2006).  The lack of an association here would seem to be consistent with the wider 
neonatal population.  
9.2.5 Association between birth weight and white blood cell parameters 
There is no evidence that changes in birth weight are associated with changes in white blood 
cell parameters.  The lack of an association here would therefore seem to be consistent with 
the wider neonatal population. 
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9.2.6 Association between birth weight and platelet parameters 
The platelet count has been consistently shown to rise with increasing birth weight in the 
general population, with several studies comparing SGA with AGA babies (McIntosh, 
Kempson and Tyler, 1988; Ozyürek et al, 2006) and one comparing babies >2000 grams with 
those <2000 grams (Arad et al, 1986).  This finding was replicated here in the neonatal CDSS 
population.  
9.2.7 Association between gestational age and red blood cell parameters 
There are no previous reports which have considered the association between gestational 
age and haematological parameters in DS neonates.  
The association between increasing gestational age and an increase in haemoglobin, 
haematocrit and red cell count is consistent with that described in the general population – 
both in neonates (Jopling et al, 2009), and in fetuses sampled in utero (Forestier et al, 1986; 
Forestier et al, 1991).  
9.2.8 Association between gestational age and white blood cell parameters 
Although some studies have reported a lower neutrophil count in babies born preterm in the 
general population this effect has not been consistently reported (Lloyd and Oto, 1982; 
Mouzinho et al, 1992; Mouzinho et al, 1994).  No significant association was found between 
gestational age and white blood cell parameters in the CDSS analysis. 
9.2.9 Association between gestational age and platelet parameters 
The finding that the platelet count fell with increasing gestational age is significant and  the 
effect became larger when the set was restricted to those processed within 2 days, with a fall 
in platelet count of 30.9 (40.1, 21.8) x109 cells/l for each added week of gestational age.  
However, this is strikingly different to the relationship in the general population where studies 
have shown a stable platelet count with increasing gestational age in neonates (Sell and 
Corrigan, 1973) and in fetuses sampled in utero (Forestier et al, 1986; Forestier et al, 1991), 
while the largest dataset reported a small increase in the platelet count from 22 weeks 
gestation (Wiedmeier et al, 2009).   
9.2.10 Sampling to processing interval 
When the CDSS was set up it was not routine practice for children with DS to have a full 
blood count checked if they looked clinically well.  This meant that a new sample needed to 
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be taken for the study in many cases as there was no local record of the full blood count 
results.  Ideally a sample is processed in a local laboratory on the day that it is taken to 
minimise any artefacts introduced by a delay in processing.  However, processing does not 
always occur on the day a sample is taken – for example samples taken in the community 
may be subject to transport delays.  The CDSS was set up in over 60 hospitals and it was not 
logistically possible for the samples to be processed in each local laboratory before being 
sent to York for storage.  It was therefore set up so that samples would be posted directly to 
the central haematology laboratory used by the CDSS.  In order to try to minimise delays 
prepaid addressed padded bags were provided along with instructions for these to go directly 
in the post, rather than, for example, being first logged in to the local laboratory. 
It was evident that this pathway would incur a delay in processing for all but those with 
samples taken in the same hospital as the analyser.  One of the important aspects of this 
analysis was therefore to examine the stability of the haematological parameters with an 
increasing sampling to processing interval. 
9.2.11 Stability of red blood cell parameters  
The increase in the haematocrit and the mean cell volume with increasing sampling to 
processing interval is consistent with results from performance evaluation studies of the 
Sysmex XE-2100 which examined stability over a 68 hour period (Walters and Garrity, 2000).  
This found no significant variation in the haemoglobin or red blood cell count, but the 
haematocrit and mean cell volume were affected.   
There was no evidence of a change in the stability of the nucleated red blood cell results with 
time.  There were a number of samples for which a nucleated red blood cell count was not 
reported.  However, the samples processed at the start of the study were analysed on an 
Advia 2120, which was not set to report the nucleated red blood cell count.  The Sysmex XE-
2100 was set to report the nucleated red blood cell count, but would not do so if the results 
indicated that a valid result would not be obtained.  Most of the samples with a missing 
nucleated red blood cell count had been processed on the Advia 2120 and the random 
pattern of interval length in those samples was therefore to be expected as it reflected on the 
analyser and not the sample characteristics.   
199 
 
9.2.12 Stability of white blood cell parameters  
Although the white blood cell count was reported on all samples, including those with a 7 day 
sampling to processing interval, the number with an available white blood cell differential 
count fell off rapidly with increasing interval time.  The stability of the differential count is 
known to be subject to change with age, and the performance evaluation studies of the 
Sysmex XE-2100 reported that the differential count was stable to ~36 hours if refrigerated 
and to ~24 hours at room temperature (Walters and Garrity, 2000).  In our set, which was a 
much larger sample than that used in the performance evaluation, similar results were 
obtained.  Interestingly, the lymphocyte, eosinophil and basophil counts remained stable 
throughout the period examined although in practice this was 3 days for most results as the 
machine rarely yielded a differential count beyond this time. 
9.2.13 Stability of the platelet parameters  
The stability of the platelet count with increasing sampling to processing interval is consistent 
with the findings from the performance evaluation study (Walters and Garrity, 2000).  The 
increase in mean platelet volume with increasing sampling to processing interval is consistent 
with a number of other studies (Jackson and Carter, 1993; Wynn et al, 1995).   
9.2.14 Determining the cut-off for reliability 
The upward trend in the mean platelet volume only became significant after 4 days, and the 
trends in the haematocrit, mean red blood cell volume and monocyte count after 2 days.  The 
data was therefore restricted accordingly.  The neutrophil count was the least stable with age 
and the effect, although small, persisted even in the set restricted to 2 days – as did the effect 
on the total white cell count as the biggest contribution to this is from the neutrophil count.  
Overall, given the necessary logistical restrictions when the study was set up, the findings of 
the stability analysis were better than expected and indicated that the results could be 
interpreted with confidence.  
9.2.15 Association between postnatal age and red blood cell parameters 
Although postnatal age is recognised as an important factor affecting haematological 
parameters in the general population, there are no previous reports of the effect of postnatal 
age on the haematological parameters in DS within the neonatal period.  The large 
retrospective study only considered samples taken in the first week of life (Henry et al, 2007), 
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while the small prospective study examined samples from the first week of life, but did not 
take further samples until 6 weeks of age (Kivivuori, Rajantie and Siimes, 1996). 
The association between increasing postnatal age and a decrease in haemoglobin, red blood 
cell count, haematocrit, mean cell haemoglobin and the nucleated red blood cell observed in 
this population of DS neonates is the same as that seen in the wider neonatal population 
(Vahlquist, 1941; Gairdner, Marks and Roscoe, 1951; Matoth, Zaizov and Varsano, 1971; 
Stockman and Oski, 1980; Perrone et al, 2005; Jopling et al, 2009; Christensen et al, 2011).  
Importantly, with regard to polycythaemia the fall in haemoglobin and haematocrit with 
increasing postnatal age meant that none met the criteria for polycythaemia by the fourth 
week of life.  
The only red blood cell parameter not to show a significant change with increasing postnatal 
age was the mean red blood cell volume which remained fairly stable throughout the neonatal 
period.  Studies in the general neonatal population have indicated a fall in the mean red blood 
cell volume with increasing age (Gairdner, Marks and Roscoe, 1951; Matoth, Zaizov and 
Varsano, 1971; Stockman and Oski, 1980).  The small prospective study of DS neonates 
indicated that the mean red blood cell volume did fall from birth to 6 weeks and continued to 
do so until around 6 months of age.  It may be that this was not evident in the CDSS as most 
samples were taken early in the postnatal period, or because the association becomes 
important after the neonatal period. 
9.2.16 Association between postnatal age and white blood cell parameters 
The pattern of change in the white blood cell count described here – a fall over the first two 
weeks and then a plateau – is again driven by that seen in the neutrophil component, and 
mirrors that seen in the wider neonatal population where it has been well documented (Kato, 
1935; Xanthou, 1970; Manroe et al, 1979; Schmutz et al, 2008).  The only other white blood 
cell type to vary during the neonatal period is the basophil count which appears to fall 
throughout the neonatal period, but in a more linear fashion.  Although, little has been 
published on the basophil count in this period there are some data indicating that the basophil 
count rises initially and then falls (Xanthou, 1970).  Most of the literature on lymphocytes, 
monocytes and eosinophils suggests that the predominant pattern is for these to remain 
stable (Xanthou, 1970; Weinberg et al, 1985; Christensen et al, 2010), as seen in the CDSS 
population.   
201 
 
9.2.17 Association between postnatal age and platelet parameters 
Again, the increase in platelet count seen throughout the neonatal period mirrors that 
consistently described in the wider neonatal population (Ablin et al, 1961; Aballi, Puapondh 
and Desposito, 1968; Appleyard and Brinton, 1971; Arad et al, 1986; Kayiran et al, 2003; 
Ozyürek et al, 2006; Wiedmeier et al, 2009).  This pattern is particularly important in the DS 
population who have a markedly lower platelet count at birth, with over 60% meeting 
conventional criteria for thrombocytopenia (platelet < 150 x 109/l).  However, by the fourth 
week there were no cases meeting these criteria.   
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9.2.18 Summary of the neonatal analysis 
The main findings of the neonatal CDSS analysis are of increased haemoglobin, haematocrit 
and mean red blood cell volume without an increase in the red cell count, an increase in and 
persistence of nucleated red blood cells, and thrombocytopenia with increased mean platelet 
volume.  The effects of gestational age, birth weight and postnatal age are all similar to those 
described in the wider neonatal population with the striking exception of the relationship 
between gestational age and platelet count.   
Some of these features are similar to those seen in fetal rather than neonatal 
haematopoiesis.  In view of this and given the extraordinary occurrence of transient 
myeloproliferative syndrome in neonates with DS, which is thought to occur in a 
haematopoietic progenitor cell with a hepatic ontogeny, it is reasonable to hypothesise that 
the switch from hepatic to marrow haematopoiesis may be delayed in DS.  However, taken 
together, the findings here are also consistent with the features of chronic fetal hypoxia.  This 
idea is supported by the lower birth weight and earlier mean gestational age found in this 
population – and in other studies of DS neonates (Myrelid et al, 2002; Henry et al, 2007; 
Weijerman et al, 2008) - which are consistent with adverse intrauterine conditions and 
particularly with chronic fetal hypoxia.  This is a different proposition altogether as this would 
appear to implicate an external factor – placental insufficiency - in contrast to the theory of 
delayed switching which may be considered as factor intrinsic to the fetus with DS.  However, 
given that this is occurring in a neonatal population with DS a theory involving placental 
insufficiency would need to explain how the presence of DS affected the placenta in this way.  
There are two main possibilities: either there is a common maternal factor which is associated 
with placental insufficiency and DS; or, the presence of somatic trisomy 21 adversely affects 
the development or long term health of the placenta.  Finally, it is possible that chronic fetal 
hypoxia may itself then lead to delayed switching from hepatic to marrow haematopoiesis. 
Untangling the reasons for the haematological changes seen is important.  If the changes 
relate entirely to intrinsic factors consequent on the presence of trisomy 21 then these will 
deepen our understanding of haematopoiesis.  If there is also an extrinsic factor then the 
possibility of beneficial intervention becomes more realistic. 
Historically it had been assumed that cerebral hypoxic-ischaemic injury in the neonatal 
population was primarily a consequence of acute peri-partum asphyxia.  However, more 
recently it has become apparent that only a minority of cases have markers associated with 
acute asphyxia.  Studies of children with cerebral palsy indicate that 10-20% only have 
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clinical or biological markers of acute perinatal or early neonatal asphyxia (Palmer et al, 1995; 
Hankins and Speer, 2003), and chronic fetal hypoxaemia is now thought to be causative in 
the majority.  This has generated study into possible markers of chronic fetal hypoxaemia and 
an elevated nucleated red blood cell count has emerged as an important candidate.   
In addition to its value as a potential marker of chronic intrauterine hypoxaemia, the nucleated 
red blood cell count may also be informative with regard to the timing of hypoxaemia.  A study 
of the cord nucleated red blood cell counts of 153 neurologically impaired neonates were 
compared with those from 83 apparently healthy neonates (Korst et al, 1996).  Clinical 
information was used to determine the likely timing of the hypoxic injury.  The nucleated cell 
count was higher in those with neurological impairment.  Importantly, within this group those 
with a history suggestive of chronic hypoxaemia had a higher nucleated red blood cell count, 
and these took longer to clear when compared with those who had a history suggestive of 
acute asphyxia.  This finding is also consistent with a subsequent retrospective study of the 
full blood count results of 47 infants with asphyxia sufficient to cause subsequent neurological 
impairment (Phelan et al, 2007).  The infants were grouped according to their clinical history.  
Those with apparent chronic intrauterine hypoxia appeared to have an elevated nucleated red 
blood cell count ≥26/100 WBC and/ or a platelet count <100 within the first 5 days of life - in 
contrast to those with a history consistent with acute birth hypoxia. 
A study of the nucleated red blood cell count in term and AGA infants compared 29 infants 
with polycythaemia with a control group of 37 infants (Mandel et al, 2003).  The haematocrit, 
red blood cell count and nucleated red blood cell count were all significantly higher and the 
platelet count was significantly lower in those with polycythaemia.  The authors concluded 
that these features reflected intrauterine hypoxia.  
Abnormal Doppler studies of the umbilical vein and artery are associated with adverse 
intrauterine conditions and intrauterine growth restriction.  The relationship between abnormal 
Doppler studies of the umbilical artery, middle cerebral artery and umbilical vein, and 
nucleated red blood cell count was studied in 84 fetuses (Baschat et al, 1999).  Increasing 
abnormalities of the Doppler studies were associated with an increasing nucleated red blood 
cell count and a longer time to clearance was seen in those with the most abnormal Doppler 
results.  Similar results were observed in a study examining the effect of intrauterine hypoxia 
on the neonatal red blood cell count in 134 singleton pregnancies using Doppler studies of 
the fetoplacental circulation as a proxy of intrauterine hypoxaemia (Axt-Fliedner et al, 2001).  
Increasing abnormalities of the Doppler studies was associated with an increase in the 
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neonatal nucleated red blood cell count.  This finding has also been replicated in SGA 
neonates (Bernstein, Minior and Divon, 1997). 
It is clear that the constellation of polycythaemia, an elevated nucleated red cell count and its 
persistence in the peripheral circulation in the neonatal period, and thrombocytopenia are all 
consistent with chronic intrauterine hypoxia.  The next consideration is to review evidence for 
a pathological mechanism to explain how and why this might occur in DS.     
In the early development of the human placenta the trophoblast differentiates along two 
critical pathways: one to form the cytotrophoblast; one to form the syncytiotrophoblast.  One 
of the essential functions of the latter is the synthesis of progesterone and human chorionic 
gonadotrophin (hCG).  Although the literature on placental development in DS is limited, 
abnormal syncytiotrophoblast formation has been reported in DS (Frendo et al, 2001; Massin 
et al, 2001; Malassiné, Frendo and Evain-Brion, 2010; Pidoux et al, 2012).  At least one of the 
underlying reasons for this would appear to be overexpression of SOD-1, which is located on 
chromosome 21, as overexpression has been demonstrated to lead to impairment of 
trophoblast fusion and differentiation (Frendo et al, 2000). Interestingly, in a recent paper, 
treatment with synthetic hCG has been shown to reverse abnormal trophoblast fusion and 
differentiation in vitro in a trisomy 21 affected trophoblast cell culture (Malassiné, Frendo and 
Evain-Brion, 2010). 
There are various clinical features of placental insufficiency that may be picked up on routine 
ultrasonography.  These include alterations in the fetal heart rate, a reduction in placental 
volume and absent or reversed end-diastolic flow – all of which have been reported in 
association with DS (Kariniemi and Aula, 1982; Metzenbauer et al, 2002; Wong and Levine, 
2005).  However, these do not appear to have been looked for in a systematic manner and 
the planned abstraction of the obstetric records associated with this population of DS 
neonates affords an opportunity for this to be done. 
The second key finding here is of the altered relationship between gestational age and 
platelet count, namely a fall in platelet count with increasing gestational age in contrast to the 
relatively stable relationship described in the wider neonatal population.  At first, this might 
suggest that there is a global increase in megakaryopoiesis in DS in utero which resolves 
towards term.  However, this would not seem to be backed up by the platelet count which is 
demonstrably low.  It does, though, appear to be a feature of an in utero process as the 
platelet count behaves after birth in the same way as in the wider population, increasing 
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throughout the neonatal period.  This process may be driven by chronic hypoxia - discussed 
above as a possible cause for the distinct haematological profile of DS neonates.  If there is 
indeed placental insufficiency then this would be expected to have an increasing impact with 
increasing gestational age and thrombocytopenia is a recognised feature of chronic 
intrauterine hypoxia.  The haemoglobin, haematocrit and red blood cell count all increase with 
increasing gestational age as they might be expected to if their production is also being 
driven by hypoxia, but as this is also the direction of change in the general population it does 
not stand out.    
Finally, in addition to elucidating further the mechanisms underlying the changes seen one of 
the next steps is to correlate the haematological findings in DS neonates with their clinical 
features to determine the clinical significance.  In this regard there are three specific areas of 
immediate interest relating to polycythaemia, neutrophilia and thrombocytopenia.  These are 
considered further in the final section on future work. 
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9.3 Blood cell morphology in DS neonates 
This is the first report of the blood cell morphology of a prospective cohort of DS neonates 
using a validated morphology tool.  Leading from the central hypothesis was the supposition 
that neonates with DS would have a distinct morphological profile, and that this might yield 
additional information that was not evident from the numerical parameters alone. 
9.3.1 Development of a validated tool morphological analysis 
One of the unique attributes of a haematologist is the continuity of care provided as both 
clinician and pathologist.  In addition to their clinical duties, the haematologist is responsible 
for the interpretation of the numerical results and morphological appearances of blood and 
bone marrow samples.  Although there is still progress to be made on understanding the 
significance of numerical parameters, particularly in children and in specific populations, 
these parameters are at least readily quantifiable.  Morphological assessment, that is the 
study of the appearance or shape of blood cells, is far more qualitative.  Indeed, for many the 
attraction and enjoyment of morphology is found in practising an art requiring skill, experience 
and a visual appreciation of subtle changes in colour or form. 
The ability to interpret morphological appearance is largely taught by individuals to individuals 
and is further validated by the rigorous professional examinations that all haematologists are 
required to sit before being allowed to practice as a consultant.  Recent research found there 
were 850 haematology consultants in the United Kingdom of whom fewer than 50 were 
paediatric haematologists (The British Society for Haematology and The Royal College of 
Pathologists, 2008).  Consequently, expertise in haematological morphology is rare, with 
paediatric morphology an even rarer skill.  
The attempt to standardise the morphology review was time consuming, and the failure of the 
initial proforma highlighted how qualitative morphology may be.  The particular challenge of 
trying to standardise neonatal morphology reporting was described in a study designed to 
assess inter-reader variability in identification of segmented and immature neutrophils in 94 
neonates (Schelonka et al, 1994).  This concluded that ‘the clinical utility of the manual 
differential leukocyte count in the evaluation of neonates is limited’ because of the lack of 
agreement.  In contrast, a comprehensive comparison of manual and automated results for 
neonates using the CellaVision DM automated microscope concluded that conventional 
microscopy remained essential when analysing neonatal samples (Billard et al. 2010).   
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The CellaVision is designed to determine a white blood cell differential by analysing the visual 
appearance of individual cells in far higher numbers than would be possible manually.  It is 
also able to recognise a range of red blood cell abnormalities in the same way.  The 
morphology reporting tool developed here was designed without any awareness of the 
CellaVision system, but is based on the same idea that each cell needs to be analysed and 
described.  The validation exercise for the morphology reporting tool developed here 
indicated that there was good intra and inter-operator consistency, without which reassurance 
analysis would have been fruitless. 
The results of the slides from the unselected neonatal population which were used in the 
morphology tool validation cannot be taken as reference data as the neonates were not 
healthy.  Given the ethical difficulties in obtaining blood samples from healthy neonates who 
do not require venepuncture it will be difficult for reference data to be collected.  Babies in the 
UK do have a heel prick test at day 5 for Guthrie spot testing and it might be possible to set 
up a study which involved a blood slide being made at the initial heel prick.  It would 
potentially be possible for a large number of samples to be obtained in this way, but this was 
outside the scope of this present work.   
9.3.2 Neonatal red blood cell morphology 
The overall incidence of nucleated red blood cells was 59%.  This increased from 49% for 
slides which were fully suitable to 60% for partially suitable and 65% for unsuitable slides.  
The fully suitable slides were taken at a mean age of 9.2 days, which was older than either of 
the other two groups.  As the nucleated red blood cell count falls with increasing postnatal 
age the proportion would be expected to be lowest in the fully suitable group – as found here.  
Given that nucleated red blood cells should have disappeared by the fourth postnatal day, 
their persistence is striking and is consistent with the automated findings.  
Spherocytes were present in just under half of all cases.  Red blood cells are typically 
biconcave discs, in contrast spherocytes are spheroidal red blood cells which consequently 
lack an area of central pallor and are smaller in diameter with denser staining.  They are 
associated with haemolytic states including hereditary spherocytosis, autoimmune and 
alloimmune haemolytic anaemia and hyposplenism. Howell-Jolly bodies are dark purple 
spheroidal or oblong inclusions, which are 1-2 µm across. They are nuclear remnants and are 
seen in any process causing erythroid hyperproliferation, including megaloblastic anaemia, 
thalassaemia and hyposplenism.  Spherocytes and Howell-Jolly bodies are recognised as 
features of neonatal blood films, where it is assumed that they are a feature of hyposplenism 
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(De Alarcón and Werner, 2004).  Given the lack of reference data it is not possible to say 
whether their presence here simply reflects that of a neonatal population, or whether there is 
an increased erythropoietic drive. 
Target cells were present in a third of cases.   Target cells are associated with 
haemoglobinopathies, thalassaemia, iron deficiency, liver disease and hyposplenism.  
However, they may also be seen as an artefact of rapid drying when the haemoglobin tends 
to ‘puddle’ in the centre of large cells and so their presence has to be interpreted with caution. 
Although basophilic stippling was uncommon, occurring in around 10% cases, this was still 
thought to be higher than expected.   Basophilic stippling refers to the presence of fine blue 
grey stipples which represent clustered ribosomes in immature red blood cells.  They are a 
marker of ineffective erythropoiesis and are seen in many erythropoietic disorders with the 
exception of iron deficiency anaemia.  They are increased in thalassaemia, megaloblastic 
anaemia, unstable haemoglobins, haemolytic anaemia, dyserythropoietic states, liver 
disease, heavy metal poisoning and pyrimidine 5’-nucleotidase deficiency.   
Taken together, the main findings here are of persistent nucleated red blood cells, which may 
reflect intrauterine hypoxia (as discussed in section 9.2.18) and a constellation of red blood 
cell features associated with hyposplenism and increased erythropoiesis. 
9.3.3 Neonatal neutrophil features 
The additional information contributed by the individual cell analysis was very helpful in 
indicating how common a feature was when it was present.  For example, both agranular 
neutrophils and hypersegmented neutrophils were present in 7/49 (14%) slides.  However, 
~7% neutrophils were agranular while only 0.5% neutrophil were hypersegmented indicating 
that even when the latter were present they were rare.  Hypersegmented neutrophils occur 
when there are five or more nuclear lobes and are an indication of megaloblastic anaemia or 
of a severe haemolytic anaemia.  They are occasionally features of chronic infection, chronic 
myeloid leukaemia, myeloproliferative disorders and of cytotoxic or anti-metabolite therapy.  
The frequency here does not appear remarkable. 
In contrast, the finding of agranular neutrophils does appear to be significant, especially when 
the very high frequency of hypogranular neutrophils is taken into account.  These were seen 
in almost all slides.  Overall, just under half of all neutrophils had reduced granularity - 40% 
being hypogranular and 7% agranular.  Hypogranular neutrophils lack the small pink granules 
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usually seen in mature neutrophils, or the coarse purple primary granules seen in toxic 
granulation, and are a feature of myelodysplasia (Widell et al, 1995; Germing et al, 2012).   
Neutrophil vacuolation was common, being seen in just over three quarters of slides and a 
quarter of neutrophils.  Vacuolation may be associated with metabolic disorders – both in 
those with the disease and occasionally in heterozygotes.  It is postulated that it occurs as a 
result of dissolution of abnormal inclusions.  Vacuolation is also seen in infection, ethanol 
ingestion, Jordan’s anomaly where the vacuoles contain lipid (Rozenszajn et al, 1966).  
Neutrophil vacuolation has also been described in grey platelet syndrome (White and 
Brunning, 2004).  
Pelgeroid neutrophils were also common, being present in just over half of slides, and around 
10% of neutrophils.  Pelgeroid neutrophils are described when there is a bilobed nucleus and 
coarsely clumped chromatin.  This combination is referred to as the Pelger-Huët anomaly, 
having been first described by Pelger in 1928 and the familial nature recognised by Huët in 
1931 (Cunningham et al, 2009).  The anomaly may be acquired in acute or chronic myeloid 
leukaemia, myelodysplasia or after cytotoxic chemotherapy.  In comparison with the 
constitutional form in pseudo Pelger-Huët anomaly the bilobed cells are a minority, as here.  
Pelgeroid neutrophils can be seen when there is a delay in processing, as can vacuolation 
(Anderson et al, 2005), and although this may account for some of the incidences it should 
not account for all as only those with intact morphology were selected. 
9.3.4 Neonatal platelet morphology 
Giant platelets and/or megakaryocyte fragments were ubiquitous.  Giant platelets are 
platelets with a diameter similar to that of a red blood cell or small lymphocyte.  Aside from 
rare congenital syndromes, they are often a feature of increased turnover, and are seen in 
immune thrombocytopenia, thrombotic thrombocytopenia, disseminated intravascular 
coagulation, myeloproliferative disorders (including acute megakaryoblastic leukaemia), 
myelodysplasia, hyposplenism and megaloblastic anaemia.  There is no formal definition of a 
megakaryocyte fragment, and so the following advice was followed: “It is rather arbitrary how 
you draw a dividing line between a giant platelet and a megakaryocyte fragment. If a giant 
platelet has a normal structure, i.e. a central granulomere and a peripheral hyalomere, I am 
happy to call it a giant platelet regardless of its size. If it is structurally abnormal and really 
enormous I think one could reasonably use the term ‘megakaryocyte fragment’. I think one 
sees such things in myeloproliferative neoplasms in accelerated phase.” (Barbara Bain; 
personal communication).   
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In addition to the increase in platelet size, the platelet colour was abnormal, being pale in 
around two thirds of cases.  Platelet colour is mainly due to small azurophilic alpha granules.  
If these are reduced or absent then the platelet appears pale blue or grey as in grey platelet 
syndrome where there is loss of alpha granules during megakaryocyte maturation with 
consequent poor aggregation and a bleeding diathesis.  In contrast platelet colour may also 
appear pale where there have been granules, but where these have been released either in 
vivo or in vitro.  The former may occur after cardiopulmonary bypass and the latter after 
difficult venepuncture when the platelets may also be clumped.  Agranular platelets are also 
seen in myelodysplasia.  There is no reason to suppose that venepuncture was especially 
difficult and the pale colour was not associated with platelet clumps. 
Megakaryocytes and bare nuclei were also seen, but as discussed in section 2.2.3 these are 
recognised features of neonatal films. 
Taken together, both the increase in platelet size and the pallor may indicate an underlying 
myeloproliferative/myelodysplastic process. 
9.3.5  Blast cells in the neonatal films 
Overall, blasts were present in around half of all the neonatal blood films.  When this is 
broken down by suitability of the slide the proportion of slides with blasts identified falls from 
56.9% for those with suitable slides, to 52.8% for those with only partially suitable slides and 
then to 37.9% for those with the poorest quality slides.  This apparent fall is likely to be 
because the blast cell morphology becomes harder to recognise as the morphology 
deteriorates and so is under-reported in those classed as ‘unsuitable’.  When there is a delay 
in processing a blood sample artefactual changes may appear which can mimic blasts as the 
nucleoli become more pronounced and the grainy appearance of the nucleus becomes 
smoother and glassy.  There had to be at least 3 cells with an unequivocal appearance of a 
blast for blasts to be deemed present.  It was encouraging that the suitability status did not 
change on re-review for any of the slides.   
The best evidence suggests that the incidence of TMD in neonates with DS is probably 
around 4% (Pine et al, 2007).  It is therefore clear that the presence of blasts alone does not 
indicate TMD.  However, there are distinct morphological features which suggest TMD – 
particularly the appearance and number of blasts.  In the CDSS analysis a diagnosis of TMD, 
based on morphological appearances, was made in 8/189 (4.2%) cases and this incidence 
would be consistent with other work.    
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9.3.6 Comparison of manual and automated methods for identifying blasts 
One of the questions being addressed here is whether manual examination of a blood film is 
required to identify TMD.  It is clear from the above that blasts are common and that review of 
all films with blasts is required to differentiate those with the appearances of TMD.  The next 
question is whether the automated analysis was able to identify accurately which samples 
had blasts – in which case it could be argued that films only needed to be made on these.  In 
fact, when the blast flags only were considered the sensitivity was only 72%, and although 
this improved to 90% when all abnormal white blood cell flags were used this is still 
inadequate.  Moreover, the sensitivity was lower when the ability of the machine to identify 
blast in films with TMD was considered, and even when all abnormal white cell flags were 
considered 25% samples with TMD had no flags. 
The relatively low sensitivity and specificity are at first surprising, but are actually quite similar 
to results obtained in a performance evaluation of the Sysmex XE-2100 which looked at the 
immature granulocyte flag (Briggs et al, 1999).  This evaluation did not consider the blast flag.   
9.3.7 Summary of neonatal morphology findings 
The morphology review of neonatal blood films in the CDSS demonstrated that blood films 
from neonates in the CDSS appear to have distinct features.  In particular, there were 
features of: 
1. Hyposplenism and increased erythropoiesis - spherocytes, Howell-Jolly bodies, target 
cells, basophilic stippling and nucleated red blood cells; 
2. chronic placental insufficiency - persistence of nucleated red blood cells with giant 
platelets;  
3. myelodysplasia/myeloproliferation - hypogranular neutrophils, Pelgeroid neutrophils, 
giant platelet and platelet pallor.  
Moreover, comparison of the automated analysis and manual reviews indicated that the 
former was unable to identify all samples with blasts and given the clinical imperative to 
identify TMD this research suggests that morphological review of a blood film is indicated in 
all neonates with DS. 
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9.4 Haematological values beyond the neonatal stage  
9.4.1 Introduction 
This section considers the results of the analysis of haematological parameters in children 
with DS beyond the neonatal period. 
Considerable thought was given to the best way to present this data.  When children were 
beyond the neonatal period, samples tended to arrive at any point in the year with no specific 
relationship to their birthday.  It would have been possible to create simple scatter graphs 
with each result plotted and these can be useful ways to consider change with time.  
However, one of the driving forces of this work has been the desire to produce results in a 
way that might be clinically useful.  It was therefore decided to consider results around each 
birthday, accepting that samples taken 3-9 months after a birthday would be lost from the 
analysis.   This meant that the mean values for each year could be developed.  Although 
some groups have included multiple results for the same child this was not done here in order 
to avoid bias.   
9.4.2 Red blood cells 
One of the key findings is that there is a distinct change in the haematological profile in this 
population between birth and 1 year.  The haematological parameters are then fairly stable 
throughout the period examined, although there appears to be a slight trend upwards in the 
haemoglobin and mean cell haemoglobin.  There are several previous studies of children with 
Down syndrome which have considered red cell parameters.  However, none of these 
included neonates and so the change in parameters over the first year of life has not been 
described in the same population before.  The second important finding is that children with 
DS appear to have a distinct haematological profile with an increase in haemoglobin, mean 
cell haemoglobin, haematocrit and mean cell volume. 
Red blood cell count 
The mean red cell count in the 1-4 year old children was 4.5 (4.4, 4.7) x1012 /l.  There are two 
previous reports of red cell count in children with DS, both of which reported similar values.  
The first looked at 63 children aged 3 months to 7 years and reported a red cell count of 4.4 ± 
0.4 x1012 /l (mean ± SD) in those aged 3 months to 2 years and  4.3 ± 0.1 x1012 /l (mean ± 
SD) in those aged between 2-7 years (Starc, 1992).  The second considered 17 children 
aged between 2-5 years old and reported a red cell count of 4.7 ± 0.3 x1012 /l (mean ± SD) 
(David et al, 1996).   
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When the values obtained here for children with DS are compared with two sets of reference 
data for the wider paediatric population they also appear to be similar.  The first dataset is 
compiled from several sources and is provided in the most recent edition of a classic 
paediatric haematology reference book (Orkin and Nathan, 2009) and the second is the “in 
house” paediatric reference range developed by the York Hospital haematology laboratory 
(Martin Howard and Martin Skelton, personal communication).  These give a red cell count of 
4.5 ± 0.8 x1012 /l (mean ± 2SD) for children 6 months to 2 years and of 4.6 ± 0.7 x1012 /l 
(mean ± 2SD) for children aged 2 to 6 years, or a red cell count range of 3.9-5.3 x1012 /l for 
children aged 2-6 years respectively.  The values for children with DS in the CDSS are 
consistent with these.  Moreover, the two studies which reported the red cell count in DS also 
included age matched control groups (Starc, 1992; David et al, 1996).  There was no 
difference in the red cell count in children with DS compared with controls in these reports, 
consistent with these findings.   
Haemoglobin 
However, although the haemoglobin falls after birth it still appears to be higher than in the 
wider paediatric population.  There are three studies which report the haemoglobin in children 
with DS – the two above which considered red cell count (Starc, 1992; David et al, 1996), and 
a recent paper designed to investigate the prevalence of iron deficiency in DS (Dixon et al, 
2010).  Although the age range of children studied in the latter paper was 1 to 19.7 years, the 
median age was only 4.7 years and so it is a comparable population.    These studies 
reported a haemoglobin of 12.8 ± 1 g/dl (mean ± SD) in those aged 3 months to 2 years and  
12.9 ± 0.8 g/dl (mean ± SD) in those aged between 2-7 years (Starc, 1992); 13.5 ± 1.3 g/dl 
(mean ± SD) in children 2-5 years old (David et al, 1996); and 13.1 ± 1.1 g/dl (mean ± SD) in 
those aged 12 to 36 months and  13.8 ± 1 g/dl (mean ± SD) in those over 36 months (Dixon 
et al, 2010).  These are all similar to the values obtained in the CDSS population.  Moreover, 
there appears to be a slight trend upwards in the haemoglobin count after 2 years of age 
which is consistent with the findings of the most recent study.  This appears to be driven by 
an increase in mean cell haemoglobin as the red cell count is stable. 
The two reference datasets used here give a haemoglobin of 12 ± 1.5 g/dl (mean ± 2SD) in 
those aged 6 months to 2 years and  12.5 ± 1 g/dl (mean ± 2SD) in those 2 to 6 years old or a 
range of 11.5-13.5 g/dl.  Although there is some overlap with the values obtained in the 
CDSS, it is evident that the values for the DS population are higher - for example, the mean 
haemoglobin for children with DS aged 3 years was 13.5 g/dl which would be right at the top 
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of both the textbook and the hospital range.  Further the upper limit of the range for 
haemoglobin values in the CDSS for children at their 1st birthday and beyond is ≥ 14 g/dl 
which is above the upper limit of the reference range.  The two papers which included age 
matched control groups (Starc, 1992; David et al, 1996) found a significant increase in the 
haemoglobin in DS compared with controls, consistent with these findings.   
Mean cell haemoglobin 
Mean cell haemoglobin has been reported in children with DS in the same three studies 
which considered haemoglobin (Starc, 1992; David et al, 1996; Dixon et al, 2010).  These 
reported a mean cell haemoglobin of 29.5 ± 2 pg (mean ± SD) in those aged 3 months to 2 
years and  29.9 ± 1.5 pg  (mean ± SD) in those aged between 2-7 years (Starc, 1992); 29.1 ± 
1.6 pg (mean ± SD) in children 2-5 years old (David et al, 1996); and 29.2 ± 1.5 pg (mean ± 
SD) in those aged 12 to 36 months and  30.7 ± 1.8 pg(mean ± SD) in those over 36 months 
(Dixon et al, 2010).  These are all similar to the values obtained in the CDSS population.  
Moreover, there again appears to be a slight trend upwards in the mean cell haemoglobin 
count after 2 years of age which is consistent with the findings of the most recent study which 
leads to an apparent increase in haemoglobin. 
The only reference values indicate a mean cell haemoglobin of 27 ± 4 pg (mean ± 2SD) in 
those aged 6 months to 2 years and  27 ± 3 pg (mean ± 2SD) in those 2 to 6 years old (Orkin 
and Nathan, 2009).  Although there is some overlap with these values and the CDSS results, 
the SD for the wider paediatric population is fairly large.  When the mean values are 
considered the mean cell haemoglobin in DS appears higher, and again it can be seen that 
the upper limit of the range for mean cell haemoglobin at and beyond the 1st birthday is ≥ 31.5 
pg, which is above the upper limit for the reference population.  The two papers which 
included age matched control groups also found a significant increase in the mean cell 
haemoglobin in DS compared with controls (Starc, 1992; David et al, 1996).   
Haematocrit 
Haematocrit has been reported in children with DS in four studies (Roizen and Amarose, 
1993; Starc, 1992; Bartelik, 1995; David et al, 1996).  These reported a haematocrit of  39.1 
% (range 35.8-41.8) in those aged 2-6 years (Roizen and Amarose, 1993); 38.4 ± 3.2 % 
(mean ± SD) in those aged 3 months to 2 years and 38.8 ± 1.7 % (mean ± SD) in those aged 
between 2-7 years (Starc, 1992); and 40.2 ± 2.6 % (mean ± SD) in children 2-5 years old 
(David et al, 1996).  These are all similar to the values obtained in the CDSS population.  
Although there is an increased incidence of congenital cardiac defects in DS these are not 
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usually cyanotic.  The NDSP reported an incidence of major cardiac defects in 44% neonates 
with DS, with ventricular septal defect in 43%, secundum atrial septal defect in 42%, 
atrioventricular septal defect in 39% and tetralogy of Fallot in 6% (Freeman et al, 2008).  Only 
the latter is cause of cyanotic heart disease and so is unlikely to account for the increase 
seen in haematocrit. 
The reference values give a haematocrit of 36 ± 3 % (mean ± 2SD) in those aged 6 months to 
2 years and  37 ± 3 % (mean ± 2SD) in those 2 to 6 years old (Orkin and Nathan, 2009); or a 
local hospital range of 34-40 %.  There is no overlap with the mean values for DS obtained 
here for children aged 1, 2 or 3 years old consistent with a significant difference.  For those 
aged 4 years old the mean haematocrit was 40 (39, 41) % (mean; 95% CI).  Again the upper 
limit of the range for haematocrit in the CDSS at and beyond the 1st birthday was ≥ 42% 
which was above the range for the wider paediatric population.  This is in agreement with 
three case-controlled studies which found that haematocrit was significantly increased in 
children with DS (Roizen and Amarose, 1993; Starc, 1992; David et al, 1996). 
Mean cell volume 
Mean cell volume has been reported in children with DS in five studies (Roizen and Amarose, 
1993; Akin, 1988; Starc, 1992; Bartelik, 1995; David et al, 1996).  These reported a mean cell 
volume of  86.9 (81.8, 97.8) fl in those aged 2-6 years (Roizen and Amarose, 1993); mean 90 
fl in 7 children whose age was not reported (Akin, 1988); 87.9 ± 6 fl (mean ± SD) in those 
aged 3 months to 2 years and 89.6 ± 3.4 fl (mean ± SD) in those aged between 2-7 years 
(Starc, 1992); and 86.5 ± 4.6 fl (mean ± SD) in children 2-5 years old (David et al, 1996).  
These all overlap the values obtained in the CDSS population, although the values obtained 
in the CDSS appear slightly higher.   
The reference values give a mean cell volume of 78 ± 8 fl (mean ± 2SD) in those aged 6 
months to 2 years and  81 ± 6 fl (mean ± 2SD) in those 2 to 6 years old (Orkin and Nathan, 
2009); or a local hospital range of 75-87 fl.  There is no overlap with the mean values for DS 
obtained here for children aged 1, 2 or 3 years old consistent with a significant difference.  
For those aged 4 years old the mean cell volume was 89.4 (85.1, 93.6) % (mean; 95% CI).  
The mean value for mean red cell volume in DS is outside the ranges for the wider paediatric 
population.   The upper limits of ranges for the children in the CDSS appear to fall with 
increasing age, but even at the 4th birthday point the upper limit is 95.5 fl which is 
considerably higher than that of the reference population.  This is in agreement with three 
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studies which were case-controlled studies which found that mean cell volume was 
significantly increased in children with DS (Starc, 1992; David et al, 1996).  
The persistence of an increased mean cell volume has important clinical implications.  A child 
with DS and iron deficiency might have a mean red cell volume which appeared normal when 
compared to standard reference charts.  The iron deficiency might be missed and remain 
untreated with adverse health consequences.  This concern has recently been substantiated 
by a study of 114 children with Down’s syndrome which set out to determine the prevalence 
of iron deficiency in this population (Dixon et al, 2010).  It found that 13/15 children who were 
diagnosed with iron deficiency or iron deficiency anaemia would have been missed if red 
blood cell indices alone had been used as a means of screening as a result of the elevated 
mean red cell volume in this group.  Alternatively, unnecessary blood samples might be taken 
to investigate an apparently high mean red cell volume, when it was actually within the 
normal range for DS.   
Nucleated red blood cells 
Nucleated red blood cells are expected to disappear from the blood after four days, although 
it has already been noted in the neonatal analysis that there is a tendency for them to persist 
in neonates with DS.  The finding that nucleated red blood cells are present in the peripheral 
blood at 1 year in the CDSS population is in stark contrast to the wider paediatric population 
where they would not be expected in healthy children.  They are seen when there is an 
increase in erythropoiesis or in association with bone marrow infiltration.  There are many 
potential causes of increased erythropoiesis, one of which is iron deficiency.  The prevalence 
of iron deficiency in DS has been reported as 10% (Dixon et al, 2010), which is broadly 
similar to prevalence estimates in the wider paediatric population (Rodd and Blankenstein, 
1995; Cogswell et al, 2009) suggesting that this does not wholly account for the presence of 
nucleated red blood cells in the 1 year old group which appears to be a feature of DS.  
Interestingly, the prevalence appears to be almost twice as high in those 12-36 months 
compared with those > 36 months old (Dixon et al, 2010), or in those 1-2 year old compared 
with those 3-5 years old (Cogswell et al, 2009).  Given that nucleated red blood cells were 
only seen in those at 1 year, and not a 2, 3 or 4 years, when iron deficiency is less likely to 
occur, it may have a role in their presence.    
In summary, it appears that the haemoglobin, mean cell haemoglobin, haematocrit and mean 
cell volume are higher in children with DS while the red cell count is similar to that of the 
general paediatric population.   
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9.4.3 White blood cell parameters 
Analysis of the white blood cell parameters again indicates that there is a marked change 
between parameters at birth and those taken around subsequent anniversaries, which appear 
to be fairly similar.  Moreover, the white blood cell count appears to be lower when compared 
with the wider paediatric population and this is driven particularly by a lower lymphocyte 
count. 
Total white blood cell count 
A low white blood cell count in apparently healthy children with DS was reported in a 
longitudinal study of 8 children being followed up to determine the effects of growth hormone 
in this group (Ridler and Shapiro, 1959).  A preliminary study of 7 children with DS reported a 
mean white cell count of 6.2 x109/l which it compared with an expected range of 7-13 x109/l 
(Akin, 1988).  A subsequent case controlled study looking at 18 children aged 2-6 years 
reported the white cell count in 14/18 (Roizen and Amarose, 1993). Although the mean white 
cell count was lower in the children with DS at 6.6 (3.3-10) x109/l (mean; range) compared 
with the controls at 8.2 (5.4-15.1) x109/l (mean; range) this was not significant.  Following this 
there have been three further case controlled studies.  A study of 62 children with DS aged 3 
months to 10 years, along with a control group of 25 children, reported a lower white cell 
count in those with DS (Bartelik, 1995).  A study of 17 children with DS aged 2-5 years found 
a lower white cell count in those with DS at 6.8 ± 2.4 x109/l (mean ± SD) compared with 8 ± 
1.4 x109/l (mean ± SD) in 23 age-matched controls (David et al, 1996).   The most recent 
study looked at 41 children with DS and again reported a lower white cell count compared 
with 41 age matched controls (Bloemers et al, 2010a).  The mean white cell counts in all 
these studies are similar to those reported here for the CDSS population where it ranged 
between 3.4-10.7 x109/l for those aged 1-4 years. 
The reference values give a mean white cell count of 10.6 (6-17) x109/l (mean; 95% CI) in 2 
year olds and  9.1 (5.5-15.5) x109/l (mean; 95% CI) in 4 year olds (Orkin and Nathan, 2009); 
or a local hospital range of 5-17 x109/l for 2-6 year olds.  Although most of the mean values 
obtained for the children with DS overlap with these, they are all at the lower end of the 
reference ranges, and the mean white cell count for DS children at 2 years is outside the 
reference range.  Moreover, it can be seen that the lower end of the ranges for the CDSS 
population at and beyond the 1st birthday is lower with a minimum value of 3.4 x 109/l, while 
the upper end is lower than the wider paediatric population with a maximum value of 10.7 x 
109/l.   
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White blood cell differential count 
Only a few studies have also looked at the white blood cell differential in children with DS.  
These were all case controlled and all agreed that there appears to be a lower lymphocyte 
count (Bartelik, 1995; David et al, 1996; Bloemers et al, 2010a).  Bloemers, who used flow 
cytometry, also reported lower absolute neutrophil and monocyte counts, but with a 1.5 fold 
increase in CD14(dim)CD16(+) monocytes. These are proinflammatory and they speculate 
that they may play a role in the many chronic inflammatory conditions associated with DS. 
Separately, an increase in ALL and early infections are both associated with DS.  However, 
although population-based studies have identified an increased morbidity and mortality due to 
infection (Hill et al, 2003), there are no detailed reports of the infection pattern of a cohort of 
DS children – although a recent prospective cohort study did demonstrate that DS is a risk 
factor for respiratory syncitial virus related bronchiolitis (Bloemers et al, 2007).  However, 
although studies have suggested that there is an altered lymphocyte profile in DS, the basis 
of any immune defect remains unclear (Hill et al, 2003; Ram and Chinen, 2011; Joshi et al, 
2011).  Co-existent physical problems may also exacerbate a susceptibility to infection – for 
example, congenital cardiac defects predisposing to endocarditis (these may require surgery 
with an increased risk of nosocomial infection); narrowing of the Eustachian tube 
predisposing to persistent otitis media with effusion (glue ear); feeding difficulties with an 
increased risk of aspiration and consequent respiratory problems; and an increase in mouth 
breathing in DS predisposing to respiratory infection.  The pattern of infections in children with 
DS merits further investigation, and may shed light on the apparent predisposition to infection 
to help target further immunological evaluation of this population. 
When the ranges for the differential counts are considered it becomes apparent that the lower 
limit changes relatively little even from the values at birth, while the upper limit falls in the 
period from birth to the 1st birthday and then stays relatively stable thereafter.  
The mean neutrophil counts in the CDSS at 2 and 4 years are 2.4 x 109/l and 4.1 x 109/l 
respectively which appear similar to the reference values of 3.5 x 109/l and 3.8 x 109/l at the 
same ages (Orkin and Nathan, 2009).  The mean lymphocyte counts at 2 and 4 years were 
2.3 x 109/l and 2.2 x 109/l which appear lower than the reference values of 6.3 x 109/l and 4.5 
x 109/l at the same ages (Orkin and Nathan, 2009).  The mean monocyte counts at 2 and 4 
years were 0.4 x 109/l and 0.5 x 109/l which appear similar to reference values of 0.5 x 109/l 
and 0.5 x 109/l at the same ages (Orkin and Nathan, 2009).    The mean eosinophil counts at 
2 and 4 years were 0.13 x 109/l and 0.15 x 109/l which appear similar to reference values of 
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0.3 x 109/l and 0.3 x 109/l at the same ages (Orkin and Nathan, 2009).    There are no 
appropriate reference values for basophil counts in children. 
Overall, it appears that the white cell count and the lymphocyte count are lower in children 
with DS compared with the wider paediatric population.   
9.4.4 Platelets 
Although thrombocytopenia is a feature of DS during the neonatal period the platelet count 
has been shown to rise with postnatal age.  It appears that the platelet count is similar to that 
of the wider paediatric population during the four years studies here.   
There is just one case controlled study of the platelet count in children with DS (David et al, 
1996).  This reported a mean platelet count of 326 ± 54 x 109/l (mean ± SD) in children aged 
2-5 years with DS compared with 324 ± 69 x 109/l (mean ± SD) in age matched controls.  
There was no significant difference between these.  The values obtained in the CDSS 
population, with means of 278-308 x 109/l, also appear similar. 
There is little reference data for platelet counts in the wider paediatric population.  There is 
some data from a study intended to generate reference thrombopoietin values for children 
(Ishiguro et al, 1999)  These give values of 314 ± 78 x 109/l (mean ± SD) and 304 ± 66 (mean 
± SD) at 1-2 years and 3-4 years which are similar to the values obtained in the DS children 
here. 
There is also little data on the mean platelet volume in children.  The same case controlled 
study mentioned above did look at this parameter and found no significant difference between 
cases and controls with mean platelet volume 7.3 ± 0.8 fl (mean ± SD) in children aged 2-5 
years with DS compared with 8 ± 1.1 fl (mean ± SD) (David et al, 1996).  Although the mean 
platelet volume fell between birth and 1 year, with stable values thereafter, the mean values 
obtained in the CDSS appear to be higher than either the children with DS or the wider 
paediatric population with means of 10.3-10.5 fl during the 4 years studied.  
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9.4.5 Summary of the haematological analysis beyond the neonatal stage 
The analysis of haematological parameters in children in the CDSS beyond the neonatal 
period shows that although there is a marked change between birth and the 1st birthday, with 
most parameters being fairly stable thereafter, they do not “normalise” and children with DS 
appear to have a distinct haematological profile throughout their early years.  Children in the 
CDSS had higher haemoglobin, mean cell haemoglobin, haematocrit and mean cell volume, 
but a lower white blood cell count, when compared with accepted reference values.  The 
lower white cell count appears to reflect a lower lymphocyte count.  In contrast to the 
differences seen in the neonatal period, the platelet count was similar to that of the wider 
paediatric population.   
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9.5 Establishment of the cohort 
9.5.1 Points arising from the consultation process 
The consultations conducted as part of the scoping work confirmed that there was a 
willingness to participate – both from clinicians and families - and this lent momentum to the 
development of the study.  It did however reveal a striking variety of practice, which needed 
to be accommodated within the study design.  In particular, there were several points of 
practice which emerged from the consultation phase and which were important in shaping the 
study.  
Taking a full blood count in the neonatal period 
It became evident that it was not routine practice to check a full blood count in all neonates 
with DS.  This was unexpected for several reasons: anecdotally, the paediatric 
haematologists consulted thought that they were often asked to review and full blood count 
results from DS neonates, and also, they believed it was good practice to check a full blood 
count in DS neonates.   
As described already, children with DS are at an increased risk of ALL and AML.  In children 
with DS and a history of TMD the risk of acute leukaemia, is even higher.  Although fatal if 
untreated, ML-DS has an excellent response to treatment, and occurs within a relatively short 
period of time – the first five years of life.  In the local Regional Centre for Paediatric 
Haematology it has been considered good practice therefore to monitor children with a 
diagnosis of TMD during this period of increased risk.  The monitoring would typically consist 
of three monthly full blood counts during the first two years and then six monthly full blood 
counts, all with morphology review, up to five years of age.  In addition, the diagnosis of TMD 
would be recorded in the medical notes.  If a child who is known to have had TMD develops a 
cytopenia then the child is investigated promptly given the particularly high risk of early acute 
leukaemia.   
Once it was realised that there was a discrepancy between what was perceived to be good 
practice and what was actually happening wider consultations were initiated.  These involved 
paediatric haematologists in other centres.  There was a consensus amongst those 
questioned that current understanding of the relationship between neonatal TMD and 
subsequent ML-DS had developed such that it should now be considered good practice to 
check full blood counts routinely in all neonates with DS.  In fact, this was already 
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recommended practice in other countries (Van Cleve and Cohen, 2006; Henry et al, 2007) .  
The situation was then reviewed with the clinicians on the Stakeholder Committee, and with 
neonatologists in the YNN.  It was then agreed that a new service would be offered by the 
Regional Centre for Paediatric Haematology to hospitals within the region: if clinicians wished 
to have a full blood count and morphology reviewed by a paediatric haematologist then they 
could send a sample directly to Regional Centre for Paediatric Haematology.  This was a new 
clinical service developed in response to this perceived need, independent of the study.   
Taking blood tests during the early years 
It became clear that the recommended annual blood tests were done less frequently in actual 
practice.  This meant that there were fewer samples from beyond the postnatal period.  
Relationship with stakeholders  
The relationships with the DSA and the DSMIG were foundational in the study development 
process.  The contact with both was initially to seek advice, but in both cases then developed 
in one of active support from the organisation for the CDSS.  The DSA invited the CDSS to 
submit an article about the study for publication in the quarterly journal it produces for 
members (Appendix 10).  They also volunteered to include information about the CDSS in the 
packs sent out to all new members of the DSA.  The latter offer was not taken up, largely 
because of the resource implications.  
9.5.2 Hospital participation 
One of the concerns of the CDSS was to recruit a population that was generalisable to the 
wider population of neonates with DS.  Consequently, all hospitals within the target area with 
a maternity unit were approached, whether they were large teaching hospitals with a high 
birth rate or smaller units in more rural locations with low birth rates.  All hospitals agreed to 
participate and almost all recruited into the CDSS.  Recruitment was highest from the 
Yorkshire Neonatal Network where the study was piloted and where there were already links 
established with clinicians. 
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 Chapter 10 Conclusion 
10.1 Main findings 
The main aim of this work was to describe the haematological profile of neonates with DS 
and to examine factors that might be associated with variability.  It has been demonstrated 
that neonates with DS have an increased haemoglobin, haematocrit and mean red cell 
volume, without a marked increase in the red blood cell count, an increase in and persistence 
of nucleated red blood cells, and thrombocytopenia with increased mean platelet volume.  
Taken together these features are consistent with chronic intrauterine hypoxia.  Recent 
research on trophoblast formation in trisomy 21 supports this suggestion.    
The effects of gestational age, birth weight and postnatal age on haematological parameters 
are all similar to those described in the wider neonatal population with the striking exception 
of the relationship between gestational age and platelet count.  In the wider population the 
platelet count remains stable with increasing gestational age.  In contrast, in the CDSS the 
platelet count fell with increasing gestational age.   
The analysis of the morphology of neonates with DS demonstrated features consistent with 
chronic intrauterine hypoxia, hyposplenism as well as increased, and possibly ineffective, 
erythropoiesis.  Further, some features are consistent with a 
myeloproliferative/myelodysplastic process.  Moreover, this work demonstrated that 
automated analysis was not sufficient to identify blasts and manual review of a film is 
indicated to look for evidence of TMD. 
Analysis of the haematological parameters in children beyond the neonatal period and up to 
their 4th birthday demonstrated a change in parameters between birth and the 1st birthday with 
most parameters being fairly stable thereafter.  It was also demonstrated that the 
haematological profile continues to differ from that of the wider population with increase in 
haemoglobin, mean cell haemoglobin, haematocrit and mean cell volume. In contrast, the 
white blood cell count appears to be lower, largely as a consequence of a lower lymphocyte 
count.  The platelet count appeared to be similar to that of the wider paediatric population 
during the four years studied.   
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10.2 Significant outcomes 
Establishment of the CDSS 
One of the most significant outcomes of this work is the successful establishment of a cohort 
of neonates with DS.  This was developed from scratch, involving considerable time and 
effort.   
Most large cohort studies are voluntary and consequently true population based studies are 
rare.  The CDSS relied on the voluntary participation of hospitals, clinicians and families and 
thus is not truly population based although it is the closest to a population based birth cohort 
of children with DS that there has been.  The aim here was to develop a cohort within which 
the haematological parameters of neonates particularly could be examined, and this has 
been done.   
One of the accepted limitations of the study is that there is little information on those who did 
not take part.  The British Paediatric Surveillance Unit (BPSU), which comes under the 
auspices of the Royal College of Paediatrics and Child Health, requires clinicians to notify the 
BPSU at regular intervals every time certain named diagnoses are made.  However, this list 
does not include a diagnosis of DS.  Data on diagnoses of DS is available from the National 
Down Syndrome Cytogenetic Registry (NDSCR).  Regional cytogenetic laboratories 
voluntarily notify the NDSCR when they make a diagnosis of DS.  The majority of these are 
prenatal diagnoses.  The NDSCR estimates their ascertainment at ~94% and the live birth 
rate for DS has consistently been at 1.1: 1000 live births during the study period.  However, 
as the purpose of the NDSCR is to describe trends in the numbers of Down’s syndrome live 
births and antenatal diagnoses in England and Wales it records very few identifying details.  
There is therefore no complete register of children born with DS in the UK.  Further research 
in this area would undoubtedly be facilitated by the establishment of a National Registry such 
as exist for cancer, which was able to record more complete demographic information.  
Moreover, in the UK the number of children born with DS has remained relatively stable over 
the last twenty years, at just over one in every 1000 live-births.  Any fall in births that might be 
expected from an expanded antenatal screening programme appears to have been offset by 
a rise in maternal age (Morris and Alberman, 2009).  Therefore the needs of this population 
remain as important as they have always been. 
The important question for the CDSS is whether the fact that it was voluntary and not 
population based has significantly influenced the results.  As discussed in section 9.1 the 
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case characteristics for the CDSS are comparable to what would be expected and this 
suggests that the results are generalisable.    
Dissemination of information 
During this process information about the CDSS was disseminated in a number of ways – 
primarily through direct contact with clinicians across the north of England, but also through 
the website (www.cdss.org.uk), oral and poster presentations to the DSMIG, national and 
international scientific meetings, and through publications in the Journal of the DSA and in 
peer reviewed journals (James et al, 2008; James and Kinsey, 2009).  Further details of 
these are provided in Appendices 10-19.   
Change in clinical practice 
When this work was begun it was not routine practice to take a full blood count in neonates 
with DS.  This practice changed during the course of the study as awareness of the 
significance of TMD increased - often as direct outcome of presentations and discussions 
about the CDSS.  For example, the Leeds Teaching Hospitals NHS Trust guidelines for the 
management of a neonate with DS were revised to recommend that all neonates with DS 
have a full blood count and film (available on the Leeds Teaching Hospitals Trust intranet: 
nww.lhp.leedsth.nhs.uk).  In addition, the national recommendations of the DSMIG have 
changed following presentations at national meetings (Charleton, Dennis and Marder, 2010) 
and revised  guidelines are due to be published next year. 
Characterisation of the neonatal haematological profile in DS 
This work has all been carried out with clinical management in mind and it is hoped that the 
description of mean and range values for neonates, and older children, with DS will be a 
useful tool for clinicians. 
Development of a validated morphology review tool 
The initial morphology review highlighted a number of different problems with traditional ways 
of reporting morphology and required the development of a new tool for morphology 
reporting.  This has been validated and successfully used in the context of the CDSS - 
enabling the description of distinctive features of blood cell morphology in neonates with DS.  
However, the future of morphology merits further discussion.  While it may be very 
interesting, it is very time consuming, and the role of newer technologies such as the 
CellaVision DM automated microscope should be explored.  If these are able to provide at 
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least as much information as manual microscopy yields, and if they can do so accurately and 
reliably, but in a more timely manner, then this would be a considerable advantage over 
manual review alone. 
10.3 Ongoing and future work 
There is considerable interest in TMD, and as discussed, there is uncertainty about basic 
questions such as the incidence of GATA1s mutations at birth.  Further work is now 
underway to extract DNA from the neonatal samples to determine the incidence of GATA1s 
mutations in the CDSS population.  This can then be correlated with the automated and 
manual analysis already completed on these samples.  It is already clear that blasts are a 
frequent finding in blood films from DS neonates and the haematological parameters of a 
single full blood count in a child with TMD that is already regressing may be unremarkable.  
This suggests that GATA1 mutation analysis may be required if all cases of TMD are to be 
identified.  GATA1 mutation analysis is costly, time-consuming and not freely accessible – a 
national strategy is therefore required.  This work will inform that discussion by demonstrating 
whether or not automated and manual analysis was sufficient in identifying those with TMD.   
One of the strengths of the CDSS is the potential for correlation with clinical data.  Once the 
obstetric and neonatal abstraction is completed it will be possible to correlate the neonatal 
results with the clinical findings.  This will enable specific questions to be addressed in the 
future, including: 
1. Did any of the neonates receive treatment for polycythaemia?   
2. Can algorithms currently in use for the management of suspected neonatal sepsis 
which include the neutrophil count be validated in DS? 
3. Did any of the neonates have bleeding problems? 
4. Did any of the neonates receive platelet transfusions? 
5. Do maternal obstetric factors have any effect on the haematology parameters? 
It will also be possible to look at the incidence and associations with other congenital 
abnormalities associated with DS.  Later on it will also be possible to obtain clinical data from 
older children in the cohort, which would enable further questions to addressed, including: 
1.  What is the clinical significance of neonatal polycythaemia beyond the neonatal 
period?  In particular, is there any effect of neonatal polycythaemia on subsequent 
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development, neurological sequelae or the development of secondary 
polycythaemia in children with congenital cyanotic cardiac disease? 
2. What is the clinical significance of leucopenia? 
3. Can algorithms for the management of suspected neonatal sepsis which include the 
neutrophil count be validated in DS? 
4. What is the pattern of infectious episodes throughout the early years?  Is it possible 
to identify those most at risk of serious or frequent infection?  Is there a relationship 
between the pattern of infections and leucopenia? 
Although the initial impetus for the CDSS came from a desire to study the haematology of 
children with DS, its scope rapidly enlarged to include all aspects of health with the aim of 
developing a cohort that also would be useful to the wider medical community.  At present 
three collaborations are nested within the study: 
1. Investigating the prevalence of autism spectrum disorder in children with Down 
syndrome; 
2. Examining early communication skills in children with Down syndrome; 
3. Investigating the relationship between health and development in children with Down 
syndrome. 
Further information about these is found in the study protocol (Appendix 11).  
There are many other questions thrown up by this research which lie outside the current 
scope of the CDSS.  In particular, these include: 
1. Given the frequent hypogranularity of neutrophils, are there any differences in 
neutrophil function in DS? 
2. Given the frequent pallor of platelets, are there any differences in platelet function in 
DS? 
3. What are the reference haematology values for a cohort of UK neonates? 
4. What are the morphological appearances of blood cells in healthy UK neonates – 
when reviewed in the manner described here?  
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10.4 Overall conclusion 
The research supports the hypothesis that neonates with DS have a distinct haematological 
profile, and this has been characterised in what is the largest report of DS neonates to date.   
The pattern of these changes is consistent with chronic intrauterine hypoxia.   
For the first time factors affecting the neonatal full blood count in DS neonates have been 
examined, and the morphological appearances of the blood films in this population have been 
described.   
It has been demonstrated that automated analysis is insufficient to identify TMD, and manual 
assessment of the blood cell morphology is indicated in all neonates with DS.   
Importantly, it has also been shown that the children in the CDSS continue to have a distinct 
haematological profile throughout their early years – and this will need to be confirmed in 
other series. 
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Appendices 
Appendix 1.  Calculation of red blood cell indices. 
1. HB is determined by measuring the optical density of a solution of haemoglobin or a 
derivative, such as cyanmethaemoglobin, at a particular wavelength.  HB is expressed as g/dl 
(mass concentration) or as mmol/l (molar concentration). 
2. PCV is defined as the proportion of a column of centrifuged blood that is occupied by 
RBC expressed as a decimal fraction indicating the l/l amount.  PCV was initially synonymous 
with the haematocrit (HCT).  However, the term PCV is now reserved for values obtained 
using manual techniques, whilst haematocrit (HCT) indicates a value determined using an 
automated method.  Modern analysers may measure a microhaematocrit using 
centrifugation, although this is affected by many factors such as duration and force of 
centrifugation, size of capillary tube, amount of anti-coagulant and presence of red cell 
changes like spherocytosis or sickle cell disease.  Alternatively, they may determine the HCT 
by measuring the number and size of RBC passing through a sensor deriving the HCT using 
the formula:  
  HCT  =  RCC (x 1012/l) x MCV (fl)     
    100 
3. RCC is measured directly using an electrical impedance method: as individual blood 
cells pass through a narrow aperture they temporarily impede the flow of current between two 
electrodes.  Each interruption corresponds to an individual cell.  Although, white blood cells 
(WBC) will be included in the count this is considered acceptable as they are usually present 
100-fold less often than RBC.  RBC are expressed x 1012/l. 
4. MCV is a measure of the average size of a circulating RBC.  It may be measured 
directly using laser optics or an aperture-impedance method as the magnitude of the drop 
reflects the volume of the cell, expressed in femtolitres (fl).  Alternatively, it may be calculated 
using the RCC and HCT, although the HCT should be corrected to account for the plasma 
trapped between the RBC to avoid over-estimating the MCV: 
  MCV (fl) = HCT (x1000) 
    RCC x (1012/l) 
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5. The MCHC is a measure of the HB concentration in an average circulating RBC.  
Most modern analysers measure the HB and use a calculated value for the HCT to give the 
MCHC using the following: 
  MCHC (g/dl) = HB (g/dl)  
    HCT 
6. The MCH is a measure of the average amount of HB in a circulating RBC.  This may 
be calculated using directly measured values for the HB and RCC:  
  MCH (pg) = HB (g/dl) 
     RCC (x 1012/l) 
7. Red blood cell distribution width (RDW) is a quantitative measure of variation in RBC 
size, expressed as either the standard deviation (SD) or the coefficient of variation (CV) of 
individual measurements of RBC volume; 
8. Nucleated red blood cells (NRBC), being nucleated, are often mistakenly included in 
the automated white blood cell count (WBC).  More sophisticated analysers are now able to 
differentiate NRBC from WBC using cluster analysis based on differences in fluorescence 
intensity and forward light scatter.  This enables them to be counted (so that an accurate 
WBC can also be calculated by subtracting the NRBC from the total nucleated cell count 
(TNCC). 
9. Reticulocytes are young RBC recently released from the bone marrow, and still 
containing ribosomal RNA which may be directly stained or labelled with fluorochromes.  
Reticulocytes may then be detected by light scatter or light absorbance and are expressed as 
either an absolute count or as a percentage of total RCC.  The amount of RNA required for a 
reticulocyte to be counted varies from machine to machine and so reference ranges are 
specific to each instrument type. 
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Appendix 2.  United Kingdom Accreditation Service and Clinical Pathology 
Accreditation Ltd. 
Within the UK there are two laboratory accreditation bodies, operating in complementary fields: 
the United Kingdom Accreditation Service (UKAS) and Clinical Pathology Accreditation UK Ltd 
(CPA).  These operate as a partnership which enables the two organisations to co-operate on 
the development of accreditation policy and facilitates the exchange of best practice.  The 
partnership is aimed at strengthening the authority and reputation of accreditation both in the 
UK and internationally by bringing together two organisations with established reputations in 
their respective fields. It is also a means of reducing the risk of fragmenting accreditation and 
avoiding proliferation of accreditation standards for laboratories. UKAS and CPA also work 
together to develop international recognition of accreditation.  UKAS is recognised by 
Government as the national accreditation body and is the signatory of international mutual 
recognition agreements on behalf of the UK. It is intended that the partnership between UKAS 
and CPA will, in due course, be incorporated into these agreements.  
The partnership is the culmination of discussions, which started with a joint statement of intent 
in 1998 to co-operate in areas of mutual interest and benefit. The introduction of international 
standards for laboratory accreditation [ISO 17025 & ISO 15189] set a benchmark so that UKAS 
and CPA could agree on common criteria making a partnership possible as well as desirable to 
prevent duplication.  At present, each organisation aims to maintain their corporate identity and 
to retain respective control over professional [technical] decisions and standards.  A Council, 
set up to oversee the development of the partnership, meets regularly to discuss the 
development and activities of the partnership. A number of policies have been agreed to 
facilitate the partnership, including exchange of information, confidentiality, and competition. 
Details of these can be found on the websites together with more information on both 
organisations: www.ukas.com  and www.cpa-uk.co.uk. 
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Appendix 3.  UK National External Quality Assessment Scheme for 
Haematology. 
The aim of the UK National External Quality Assessment Scheme for Haematology is to help  
to improve and maintain performance of laboratory haematology at a high level of proficiency.  
External quality assessment for haematology in the UK was first introduced in 1968 by the 
British Committee for Standardization in Haematology (BCSH). The project was financed by a 
modest grant from the Nuffield Provincial Hospitals Trust. The results of the early trials were 
reported by S M Lewis and B J Burgess in the British Medical Journal, 1969, 4:253-256. From 
this developed the UK National External Quality Assessment Scheme for Haematology (UK 
NEQAS(H)) which currently has about 650 participants. This scheme is concerned with 
general haematology. There are also complementary national schemes for blood coagulation 
testing, blood transfusion laboratory practice, haematinic assays, leucocyte 
immunophenotyping and feto-maternal haemorrhage. 
Two specimens are used for analysis of the full blood count. These whole blood specimens 
are pooled human donations (collected into CPD-A1 anticoagulant) and partially fixed. Blood 
is dispensed into vials aseptically, using a special mixing-dispenser unit to ensure identical 
aliquots. The shelf life of the partially fixed human product is at least four weeks at 4oC. Red 
cell concentration may be varied by removal or addition of plasma. White cell and platelet 
concentration may be varied by removal or addition of cells (using appropriate filters and/or 
centrifugation) or by addition of buffy coat and/or platelet concentrates. 
Full blood count surveys are distributed 12 times a year. 
The lack of internationally recognised standards, except for haemoglobin, necessitates the 
use of a consensus target value to establish acceptable limits of performance. As the many 
different analysers available use a variety of technologies and diluents, they may respond in 
different ways to the stabilised material used in UK NEQAS (H) surveys. Performance is 
therefore assessed within instrument groups against the consensus target value.   
Further information may be found on the UK NEQAS websites: www.ukneqas.org.uk and 
www.ukneqas-haem.org.uk.   
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Appendix 4.  Study protocol 
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Appendix 5.  DSMIG schedule for health checks in children with DS. 
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Appendix 6.  Paperwork needed for the newborn entry pack. 
Each newborn pack contained the following: 
i. Alert card 
ii. Newborn entry pack cover sheet 
iii. Parent information leaflet - newborn 
iv. Parent consent form - newborn 
v. Information sheet for health professional 
vi. Referring hospital form 
vii. Haematology laboratory blood form 
i. Alert card  
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ii. Newborn entry pack cover sheet 
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iii. Parent information leaflet - newborn 
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iv. Parent consent form - newborn 
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v. Information sheet for health professional
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vi. Referring hospital form 
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vii. Haematology laboratory blood form 
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Appendix 7.  Standard operating procedure for processing the blood samples 
in the haematology laboratory.   
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Appendix 8.  Triggers for referral to the Regional Centre for Paediatric 
Haematology. 
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Appendix 9.  Morphology reporting tool. 
Standard morphology review procedure 
 
1. Confirm that the identification codes on the slide and on the reporting sheet are the 
same. 
2. Examine the slide under x4 magnification, beginning at the peripheries. Ensure that 
these have been fully viewed before moving on. 
3. Examine the slide under x40 using an oil immersion lens.   
4. A white blood cell differential count should then be performed if it is possible to identify 
>75% of all white blood cells.  If there are many disrupted cells then a differential 
count cannot accurately be performed and should not be attempted. 
5. In order to complete the differential white blood cell count 100 consecutive identifiable 
white blood cells should be counted taking an area of the film where the red blood 
cells are one cell thick – that is where they do not overlie one another and are 
approximately adjacent. 
6. Pause at each white blood cell to identify its type. 
7. Once the type has been identified, consider the appearance of the cell and note 
whether it has any of the features being considered on the form for that cell type. 
8. Once this has been done, move on to the next white blood cell. 
9. At the same time as the white blood cell differential is being completed please record 
the number of nucleated red blood cells seen in order to calculate the nucleated red 
blood cell count per 100 white blood cells. 
10. Once the white blood cell differential has been completed complete the answers to the 
questions on nuclear/cytoplasmic asynchrony and on blasts. 
11. Now, consider the red blood cells.  At least twenty fields should be viewed before 
concluding that the abnormal red cell features being sought are absent. 
12. Finally, consider the platelets.  Again view at least twenty fields before concluding that 
the abnormal platelet features being sought are absent. 
13. Review the form to check that all the questions have been completed.   
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Appendix 10.  Article about the CDSS published in the quarterly DSA Journal. 
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Appendix 11.  Acute leukaemia in children with Down syndrome.  The 
importance of population based study.   
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Appendix 12.  Haematological disorders in children with Down syndrome. 
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Appendix 13.  Oral presentation at the 2008 Royal College of Paediatrics and 
Child Health Spring Meeting. 
Abstract reference: RCPCH/SM08/18556 
The Children with Down’s Syndrome Study (CDSS):  a robust evidence base for the 
management of children with Down’s syndrome 
Aim: To establish a population-based cohort of children with Down Syndrome (DS) and follow 
them from birth onwards to investigate their health.    
Methods: The study is a collaborative venture between clinicians, epidemiologists, laboratory 
scientists, the Down’s Syndrome Medical Interest Group, and the Down’s Syndrome 
Association. Following the identification of these key stakeholders, a two-stage wide ranging 
consultation process was initiated.  In the first stage, the emphasis was on understanding 
clinical practice in relation to the care of children with DS in their early years.  In the second 
stage families of children with DS were visited and their views sought.  The target population 
is covered by six Neonatal Network Regions (~175 000 births per annum) in the North of 
England.  After obtaining ethics approval and conducting a successful pilot in one Neonatal 
Network area, the study has been extended across the five adjacent Neonatal Networks.  All 
families with a baby with DS born since 1st May 2006 are eligible.  The information collected 
at birth includes a new-born blood sample, as well permission to contact the parents later and 
to access their medical records.  Follow-up includes the completion of annual health 
questionnaires and the collection of buccal swabs from family members and blood samples 
from the child. 
Results: To date, the study is recruiting in 52 hospitals across the six Networks, and 120 
families have been recruited.  Comparison with data from the National Down’s Syndrome 
Cytogenetic Registry for 2006 indicates an initial ascertainment of almost 75%.  This will 
improve as the study becomes established and the remaining 11 hospitals come on-board. 
We anticipate ~500 families will be enrolled by the end of 2009.  Initial analysis will focus on 
describing haematological parameters and illness patterns.   
Conclusion: The CDSS will be the largest population-based cohort of children with DS 
anywhere in the world.  It is a significant resource with the potential to develop an evidenced-
based approach to the understanding and management of the health and care of children 
with DS.    
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Appendix 14.  Poster presentation 130 at the Perinatal Medicine 2008 Meeting. 
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Appendix 15.  Poster presentation 132 at the Perinatal Medicine 2008 Meeting. 
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Appendix 16.  Oral presentation at the 2010 American Society of Haematology 
Annual Meeting; abstract 79. 
Haematological Reference Ranges for Neonates with Down Syndrome In the UK: A 
Report From the Children with Down's Syndrome Study 
Rebecca James1*, Tom Johnston1*, Tracy Lightfoot1*, Dan Painter1*, Pat Ansell1*, Eve 
Roman1* and Sally Kinsey2 
1Epidemiology&Genetics Unit, Department of Health Sciences, University of York, York, 
United Kingdom 
2St. James' Univ. Hospital, Leeds, United Kingdom 
Introduction: The Children with Down’s Syndrome Study (CDSS; http://www.cdss.org.uk/) is 
a unique observational study following a population-based cohort of children with Down’s 
syndrome (DS) from birth onwards.    Here we present the initial set of neonatal full blood 
count results - demonstrating that haematological values in DS neonates differ markedly from 
those of the general neonatal population; and providing, for the first time, DS specific 
reference ranges for haematological parameters for immediate clinical use.   
Methods:  Recruitment to the population based CDSS opened in May 2006 and is 
ongoing.  At entry, a blood sample taken in EDTA is sent to a designated laboratory with full 
CPA (UK) accreditation and processed using a Sysmex XE2100 or Advia 2120 according to a 
standard operating procedure.  Clinical and demographic details, including date of birth, 
gestational age and birth weight are collected routinely.  Of the 229 children recruited with 
appropriate samples, 197 are included in the analysis presented here:  32 were excluded 
because the sample was after 28 days of age; had a delay in processing; or had no 
result.  Regression analyses considered effects of age at sampling, days until processing, 
sex, and source of sample.  Gestational age and birth weight were examined in children 
sampled within 3 days of birth.   
Results:   There were 109 boys and 88 girls.  Median age at sampling was 3 days (IQR: 1-
7).  Median gestational age was 39 weeks (IQR: 37-39) and median birth weight was 3.0 kg 
(IQR: 2.4-3.4).  The DS neonates had a similar RCC, but higher HB, HCT and MCV, when 
compared with standards for the general neonatal population: RCC 5.4 ± 0.82 x1012/l; HB 
20.0 ± 3.3 g/dl with HCT 0.62 ± 0.1%, and MCV 115.5 ± 9.0 fl.  By conventional standards, 
43% of DS neonates would be considered to be polycythaemic (HCT>65%), and 76% 
macrocytic (MCV>110 fl).  WCC was 13.9 ± 8.4 x109/l with differential analysis (on a subset of 
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100 children with suitable samples) showing neutrophils 6.4 ± 5.3 x109/l; lymphocytes 3.4 ± 
2.0 x109/l; monocytes 0.97 ± 0.55 x109/l; eosinophils 0.22 ± 0.32 x109/l; and basophils 0.20 ± 
0.19 x109/l.  In 41% cases monocytes were >1.0 x109/l.  The overall mean platelet count was 
161 ± 89 x109/l.  Thrombocytopenia was most common in the first week of life: 63% having 
platelets < 150 x109/l.  Only 8% of children sampled in their fourth week of life had a platelet 
count < 150 x109/l.   Mean MPV was 11.8 ± 1.0 fl which is greater than the 95th percentile 
MPV for a general neonatal population.  HB, RCC, HCT, MCV, RDW-CV, nucleated red blood 
cells, WCC, neutrophils and lymphocytes all fell with each increasing day of age.  These 
parameters did not vary with sex or source of sample.  Platelet and monocyte number both 
increased slightly with increasing birth weight, while HB and RCC fell.  HB, HCT, RCC and 
neutrophils increased with each week of increasing gestational age, while the platelet count 
fell.   
Conclusions: The haematological profile of DS neonates appears to be distinct from that of 
the general neonatal population reflecting altered trilineage haematopoiesis.  The most 
striking features are the increased HB, HCT and MCV - with a preserved RCC; monocytosis; 
and thrombocytopenia with increased MPV.  These features, particularly large haemoglobin-
rich erythrocytes and thrombocytopenia, are associated with fetal haematopoiesis, 
suggesting that the switch to adult haematopoiesis may be delayed in DS.  For example, the 
mean MCV here is comparable with that at 30 weeks gestation for the general 
population.  Interestingly, the neutrophil count appears lower than the general population, 
although it follows a similar postnatal pattern: falling rapidly over the first few days before 
plateauing from day 10. Many neonatal units incorporate the neutrophil count in algorithms to 
indicate the likelihood of sepsis; these may need to be revised for DS neonates.  Fetal 
thrombocytopenia has been described previously in DS.  It is clear from this work that the 
platelet count increases with advancing postnatal age, so that in contrast to other causes of 
neonatal thrombocytopenia, a well DS neonate with thrombocytopenia does not require 
additional investigation.  This work provides a much needed evidence-base for clinical 
practice: the predictive percentile charts indicating the expected range by age for the 
neonatal period and illustrating the natural history.   
Disclosures: No relevant conflicts of interest to declare.  
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Appendix 17.  Oral presentation at the 2010 American Society of Haematology 
Annual Meeting; abstract 80. 
A Comprehensive Report of Blood Cell Morphology for Neonates with Down’s 
Syndrome In the UK: A Report From the Children with Down’s Syndrome Study  
Rebecca James1*, Tom Johnston1*, Tracy Lightfoot1*, Dan Painter1*, Pat Ansell1*, Eve 
Roman1* and Sally Kinsey2 
1Epidemiology&Genetics Unit, University of York, York, United Kingdom 
2St. James' Univ. Hospital, Leeds, United Kingdom 
Introduction: The Children with Down’s Syndrome Study (CDSS; http://www.cdss.org.uk/) is 
a unique observational study following a population-based cohort of children with Down’s 
syndrome (DS) from birth onwards.    Although haematological abnormalities are well 
recognised in DS neonates blood morphology is less well described.  This is the first 
prospective report of blood cell morphology in DS neonates.   
Methods: Recruitment to the population based CDSS opened in May 2006 and is 
ongoing.   At entry, a blood sample taken in EDTA is sent to a designated laboratory with full 
CPA (UK) accreditation.  Blood films were reviewed by two Paediatric Haematologists 
following a specific proforma developed after a series of pilot studies which had identified the 
range of morphological abnormalities seen in DS neonates.  Reporting was subsequently 
standardised so that inter and intra-operator variability were minimised.  Critically, abnormal 
features were recorded for each individual white cell.  All slides reported on here were taken 
within 28 days of birth and had to be of adequate quality with regard to stain, spread and 
EDTA change.  These were considered independently for cell type.  
Results: Microscopic review was performed in slides from 154 DS neonates; 88 of these met 
the quality criteria for at least one cell type.  The most consistent abnormalities were of 
platelets: giant platelets were present in 78/88 (89%); pale, hypogranular platelets in 61/88 
(69%) and megakaryocyte fragments in 30/88 (34%).  The most common red blood cell 
changes were macrocytosis and polychromasia, occurring in ≥5% all red cells in 48/68 (71%) 
and 33/68 (49%) respectively.  Nucleated red blood cells were seen in 34/71 (48%); 
spherocytes in 28/68 (41%); target cells in 27/68 (40%); Howell Jolly bodies in 26/68 (38%) 
and basophilic stippling in 9/69 (13%).  The neutrophils tended to be hypogranular 35/36 
(97%) and/or agranular 6/36 (17%).  None were hypergranular.  Neutrophil vacuolation was 
common, occurring in 29/36 (81%) whilst Pelgeroid neutrophils occurred in 12/36 (33%) and 
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hypersegmentation in 7/36 (19%).  Granulocytic nuclear/cytoplasmic dysynchrony was noted 
in 25/36 (69%) with the nucleus appearing relatively immature and with the granules often 
clustering in one area leaving an area of agranular bluish cytoplasm.  Lymphocyte 
morphology was unremarkable.  Monocytes were typically vacuolated and often had stellate 
or elongated nuclei: these features occurred in 30/36 (83%); 27/36 (75%) and 6/36 (17%) 
slides respectively; no azurophilic granules were seen.  Both eosinophils and basophils 
tended to be dysplastic with abnormal hypogranulation in 18/36 (50%) and 20/36 (56%) 
respectively.  Blasts were seen in 19/36 (53%), but cytoplasmic blebbing was rare 2/36 
(6%).  In the majority the blast type could not be ascribed.   
Conclusions:  The blood cell morphology of DS neonates described above is distinctive and 
resembles that typically seen in the fetus.  An unusual feature of DS neonates is the 
spontaneous regression of transient myeloproliferative disorder (TMD).  This work suggests 
that fetal, ie hepatic, haematopoiesis is still significant in DS neonates and supports the idea 
that TMD arises from a fetal progenitor and regresses as the cellular context changes to turn 
off hepatic haematopoiesis.  Myeloid leukaemia later develops in ~20% who have had 
TMD.  This might occur if a GATA1 mutated fetal progenitor was able to seed and 
successfully populate the bone marrow.  Importantly, although blasts were present in 53%, 
not all of these had TMD.  There is a clear clinical imperative for identifying TMD as it occurs 
in ~4-6% DS neonates and defines a group at high risk of developing a highly treatable 
leukaemia within a limited time-frame.  This work suggests that full blood count and film 
review alone are insufficient to identify TMD, and that GATA1 mutation analysis is 
needed.  Such expensive, time consuming and specialized analysis would require a national 
approach.  An important lesson of this work is also the need to standardise morphology 
reporting: to quantify what is an inherently qualitative and subjective process.  The proforma 
developed here provides a template for others to use in this group and in the general 
population.   
Disclosures: No relevant conflicts of interest to declare.  
276 
 
Appendix 18.  Oral presentations made to other national and regional meetings. 
Interest in the Children with Down Syndrome Study has also led to invitations to present at 
the following meetings: 
08/05/08 Yorkshire Academic Paediatrics Group: Establishing a truly population based cohort 
- The Children with Down Syndrome Study; 
05/06/08 Down Syndrome Medical Interest Group one day symposium and members’ 
meeting: Research update; 
10/11/08 Yorkshire branch of the British Society for Community Child Health Autumn 
Combined Community and General Paediatric Meeting: The Children with Down Syndrome 
study;  
01/04/09 Guest lecture at the 2009 Royal College of Paediatrics and Child Health Spring 
Meeting.  
20/10/09 Yorkshire Neonatal Network Forum: The Children with Down Syndrome Study; 
27/11/09 Down Syndrome Medical Interest Group one day symposium and members’ 
meeting: Haematology update; 
26/11/10 Down Syndrome Medical Interest Group one day symposium and members’ 
meeting: Haematological reference ranges for babies with Down syndrome; 
24/03/11  Yorkshire Neonatal Network: Haematological reference ranges for babies with 
Down syndrome 
In addition I have regularly been invited to present at in-house meetings both at the University 
of York and within the Leeds Teaching Hospitals. 
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List of Abbreviations 
 
AGA   appropriate for gestational age 
ALL   acute lymphoblastic leukaemia 
AMKL   acute megakaryoblastic leukaemia 
AML   acute myeloid leukaemia 
CDSS   Children with Down Syndrome Study 
CI   confidence intervals 
CLRN   comprehensive local research network 
CPA   Clinical Pathology Accreditation 
DGH   district general hospital 
DS   Down syndrome 
DSA   Down Syndrome Association 
DSMIG   Down Syndrome Medical Interest Group 
EDTA   ethylene diamine tetraacetic acid 
ECSG   Epidemiology and Cancer Statistics Group 
FBC   full blood count 
FEP   free erythrocytic protoporphyrin 
GATA1   globin transcription factor 1 
GATA1s  short form of globin transcription factor 1 
GP   general practitioner 
HB   haemoglobin 
HbA1   haemoglobin A1 
HbA2   haemoglobin A2 
HbF   fetal haemoglobin 
hCG   human chorionic gonadotrophin 
HCT    haematocrit 
HIV   human immunodeficiency virus 
IHH   Intermountain Healthcare Hospitals 
ISLH   International Society for Laboratory Haematology 
I:T   immature to total neutrophil ratio 
JAK2   janus kinase 2 
LBW   low birth weight 
MCH   mean cell haemoglobin 
MCHC   mean cell haemoglobin concentration  
MCV   mean red blood cell volume 
MDS   myelodysplasia 
ML-DS   myeloid leukaemia of Down’s syndrome 
MPV   mean platelet volume 
MRC   Medical Research Council 
NDSCR   National Down Syndrome Cytogenetic Registry 
NDSP   National Down Syndrome Project 
NEQAS   National External Quality Assessment Scheme 
NHS   National Health Service 
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NRBC   nucleated red blood cells 
PCHR   personal child health record 
PCV   packed cell volume 
PET   partial exchange transfusion 
PLT   platelet 
RBC   red blood cell 
RCC   red blood cell count  
RDW    red blood cell distribution width 
SD   standard deviation 
SGA   small for gestational age 
SJUH   St James’ University Hospital  
SOD1   superoxide dismutase 
TMD   transient myeloproliferative disorder 
TS   transferrin saturation 
UKAS   United Kingdom Accreditation Service 
UKCRN   United Kingdom Clinical Research Network 
VLBW   very low birth weight 
WBC   white blood cell 
WHO   World Health Organisation 
YH    York Hospital 
YNN   Yorkshire Neonatal Network  
ZCP   zinc complex protoporphyrin 
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